Journal Article
. 2016 Dec; 389(10066):255-265.
doi: 10.1016/S0140-6736(16)32517-X.

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer 1 Fabrice Barlesi 2 Daniel Waterkamp 3 Keunchil Park 4 Fortunato Ciardiello 5 Joachim von Pawel 6 Shirish M Gadgeel 7 Toyoaki Hida 8 Dariusz M Kowalski 9 Manuel Cobo Dols 10 Diego L Cortinovis 11 Joseph Leach 12 Jonathan Polikoff 13 Carlos Barrios 14 Fairooz Kabbinavar 15 Osvaldo Arén Frontera 16 Filippo De Marinis 17 Hande Turna 18 Jong-Seok Lee 19 Marcus Ballinger 3 Marcin Kowanetz 3 Pei He 3 Daniel S Chen 3 Alan Sandler 3 David R Gandara 20 OAK Study Group  
Affiliations
  • PMID: 27979383
  •     19 References
  •     1601 citations

Abstract

Background: Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer.

Methods: We did a randomised, open-label, phase 3 trial (OAK) in 194 academic or community oncology centres in 31 countries. We enrolled patients who had squamous or non-squamous non-small-cell lung cancer, were 18 years or older, had measurable disease per Response Evaluation Criteria in Solid Tumors, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer. Patients with a history of autoimmune disease and those who had received previous treatments with docetaxel, CD137 agonists, anti-CTLA4, or therapies targeting the PD-L1 and PD-1 pathway were excluded. Patients were randomly assigned (1:1) to intravenously receive either atezolizumab 1200 mg or docetaxel 75 mg/m2 every 3 weeks by permuted block randomisation (block size of eight) via an interactive voice or web response system. Coprimary endpoints were overall survival in the intention-to-treat (ITT) and PD-L1-expression population TC1/2/3 or IC1/2/3 (≥1% PD-L1 on tumour cells or tumour-infiltrating immune cells). The primary efficacy analysis was done in the first 850 of 1225 enrolled patients. This study is registered with ClinicalTrials.gov, number NCT02008227.

Findings: Between March 11, 2014, and April 29, 2015, 1225 patients were recruited. In the primary population, 425 patients were randomly assigned to receive atezolizumab and 425 patients were assigned to receive docetaxel. Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations. In the ITT population, overall survival was improved with atezolizumab compared with docetaxel (median overall survival was 13·8 months [95% CI 11·8-15·7] vs 9·6 months [8·6-11·2]; hazard ratio [HR] 0·73 [95% CI 0·62-0·87], p=0·0003). Overall survival in the TC1/2/3 or IC1/2/3 population was improved with atezolizumab (n=241) compared with docetaxel (n=222; median overall survival was 15·7 months [95% CI 12·6-18·0] with atezolizumab vs 10·3 months [8·8-12·0] with docetaxel; HR 0·74 [95% CI 0·58-0·93]; p=0·0102). Patients in the PD-L1 low or undetectable subgroup (TC0 and IC0) also had improved survival with atezolizumab (median overall survival 12·6 months vs 8·9 months; HR 0·75 [95% CI 0·59-0·96]). Overall survival improvement was similar in patients with squamous (HR 0·73 [95% CI 0·54-0·98]; n=112 in the atezolizumab group and n=110 in the docetaxel group) or non-squamous (0·73 [0·60-0·89]; n=313 and n=315) histology. Fewer patients had treatment-related grade 3 or 4 adverse events with atezolizumab (90 [15%] of 609 patients) versus docetaxel (247 [43%] of 578 patients). One treatment-related death from a respiratory tract infection was reported in the docetaxel group.

Interpretation: To our knowledge, OAK is the first randomised phase 3 study to report results of a PD-L1-targeted therapy, with atezolizumab treatment resulting in a clinically relevant improvement of overall survival versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expression or histology, with a favourable safety profile.

Funding: F. Hoffmann-La Roche Ltd, Genentech, Inc.

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, +16 authors, Edward B Garon.
Lancet, 2015 Dec 30; 387(10027). PMID: 26712084
Highly Cited.
Considerations for second-line therapy of non-small cell lung cancer.
Thomas E Stinchcombe, Mark A Socinski.
Oncologist, 2008 Mar 08; 13 Suppl 1. PMID: 18263772
Review.
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo.
Jun Yang, Leonardo V Riella, +14 authors, Mohamed H Sayegh.
J Immunol, 2011 Jun 24; 187(3). PMID: 21697455    Free PMC article.
PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.
O Akbari, P Stock, +6 authors, R H Dekruyff.
Mucosal Immunol, 2009 Sep 11; 3(1). PMID: 19741598    Free PMC article.
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
J M Kim, D S Chen.
Ann Oncol, 2016 May 22; 27(8). PMID: 27207108
Highly Cited. Review.
Postprogression Prolongation of Survival in EGFR-Mutated Lung Cancer: Reconciling the ASPIRATION and IMPRESS Trials.
David R Gandara, Mary Redman, Fred R Hirsch.
JAMA Oncol, 2016 Jan 01; 2(3). PMID: 26720042
Inhibitory B7-family molecules in the tumour microenvironment.
Weiping Zou, Lieping Chen.
Nat Rev Immunol, 2008 May 27; 8(6). PMID: 18500231
Highly Cited. Review.
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Roy S Herbst, Jean-Charles Soria, +19 authors, F Stephen Hodi.
Nature, 2014 Nov 28; 515(7528). PMID: 25428504    Free PMC article.
Highly Cited.
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.
Jang-June Park, Ryusuke Omiya, +11 authors, Koji Tamada.
Blood, 2010 May 18; 116(8). PMID: 20472828    Free PMC article.
Highly Cited.
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, +25 authors, Julie R Brahmer.
N Engl J Med, 2015 Sep 29; 373(17). PMID: 26412456    Free PMC article.
Highly Cited.
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Manish J Butte, Mary E Keir, +2 authors, Gordon J Freeman.
Immunity, 2007 Jul 17; 27(1). PMID: 17629517    Free PMC article.
Highly Cited.
B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma.
Koichiro Matsumoto, Satoru Fukuyama, +13 authors, Hiromasa Inoue.
Biochem Biophys Res Commun, 2007 Nov 06; 365(1). PMID: 17981145
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Jedd D Wolchok, Axel Hoos, +9 authors, F Stephen Hodi.
Clin Cancer Res, 2009 Nov 26; 15(23). PMID: 19934295
Highly Cited.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Louis Fehrenbacher, Alexander Spira, +16 authors, POPLAR Study Group.
Lancet, 2016 Mar 14; 387(10030). PMID: 26970723
Highly Cited.
Oncology meets immunology: the cancer-immunity cycle.
Daniel S Chen, Ira Mellman.
Immunity, 2013 Jul 31; 39(1). PMID: 23890059
Highly Cited. Review.
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
Thomas Powles, Joseph Paul Eder, +12 authors, Nicholas J Vogelzang.
Nature, 2014 Nov 28; 515(7528). PMID: 25428503
Highly Cited.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, +22 authors, David R Spigel.
N Engl J Med, 2015 Jun 02; 373(2). PMID: 26028407    Free PMC article.
Highly Cited.
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
Alison M Paterson, Keturah E Brown, +7 authors, Arlene H Sharpe.
J Immunol, 2011 Jun 24; 187(3). PMID: 21697456    Free PMC article.
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
Daniel S Chen, Bryan A Irving, F Stephen Hodi.
Clin Cancer Res, 2012 Oct 23; 18(24). PMID: 23087408
Highly Cited.
Immunotherapy: Benefit with anti-PD-L1.
Diana Romero.
Nat Rev Clin Oncol, 2016 Dec 30; 14(2). PMID: 28031557
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
Takuro Noguchi, Jeffrey P Ward, +8 authors, Robert D Schreiber.
Cancer Immunol Res, 2017 Jan 12; 5(2). PMID: 28073774    Free PMC article.
Highly Cited.
[Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer].
Zhansheng Jiang, Zhanyu Pan, Xiubao Ren.
Zhongguo Fei Ai Za Zhi, 2017 Feb 24; 20(2). PMID: 28228226    Free PMC article.
Review.
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.
Vivek Kumar, Neha Chaudhary, +3 authors, Abhinav B Chandra.
Front Pharmacol, 2017 Feb 24; 8. PMID: 28228726    Free PMC article.
Highly Cited. Review.
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Hong Li, Weijie Ma, +7 authors, Tianhong Li.
J Hematol Oncol, 2017 Mar 02; 10(1). PMID: 28245875    Free PMC article.
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
Guillermo De Velasco, Youjin Je, +8 authors, Toni K Choueiri.
Cancer Immunol Res, 2017 Mar 02; 5(4). PMID: 28246107    Free PMC article.
Highly Cited.
Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.
Motonobu Saito, Hiroyuki Suzuki, +2 authors, Takashi Kohno.
Surg Today, 2017 Mar 11; 48(1). PMID: 28280984
Review.
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Jordi Remon, Benjamin Besse, Jean-Charles Soria.
BMC Med, 2017 Mar 14; 15(1). PMID: 28285592    Free PMC article.
Review.
Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.
S Lheureux, C Denoyelle, +2 authors, F M Mottaghy.
Eur J Nucl Med Mol Imaging, 2017 Apr 12; 44(Suppl 1). PMID: 28396911    Free PMC article.
Review.
Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.
Stefan Langhammer, Joachim Scheerer.
Oncotarget, 2017 Apr 14; 8(26). PMID: 28402937    Free PMC article.
Review.
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.
Marco A J Iafolla, Rosalyn A Juergens.
Front Oncol, 2017 Apr 22; 7. PMID: 28428947    Free PMC article.
Review.
The next generation of immunotherapy: keeping lung cancer in check.
Ashwin Somasundaram, Timothy F Burns.
J Hematol Oncol, 2017 Apr 25; 10(1). PMID: 28434399    Free PMC article.
Review.
Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures.
Akito Hata, Nobuyuki Katakami, +3 authors, Yukihiro Imai.
In Vivo, 2017 Apr 26; 31(3). PMID: 28438882    Free PMC article.
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.
Lars M Wagner, Val R Adams.
Onco Targets Ther, 2017 Apr 27; 10. PMID: 28442918    Free PMC article.
Review.
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.
Daniel J Boffa, Ryon P Graf, +14 authors, Jorge Nieva.
Cancer Epidemiol Biomarkers Prev, 2017 Apr 28; 26(7). PMID: 28446544    Free PMC article.
A mighty oak in the rapidly expanding field of checkpoint inhibition for NSCLC.
Petros Christopoulos, Michael Thomas.
J Thorac Dis, 2017 Apr 30; 9(3). PMID: 28449524    Free PMC article.
AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.
Anil Vachani, Lecia V Sequist, Avrum Spira.
Am J Respir Crit Care Med, 2017 May 02; 195(9). PMID: 28459327    Free PMC article.
Review.
The KEY to the end of chemotherapy in non-small cell lung cancer?
Yiqing Huang, Ross A Soo.
Ann Transl Med, 2017 May 10; 5(7). PMID: 28480202    Free PMC article.
Clinical applications of PD-L1 bioassays for cancer immunotherapy.
Delong Liu, Shuhang Wang, Wendy Bindeman.
J Hematol Oncol, 2017 May 19; 10(1). PMID: 28514966    Free PMC article.
Review.
PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients.
Arik Bernard Schulze, Lars Henning Schmidt.
J Thorac Dis, 2017 May 20; 9(4). PMID: 28523184    Free PMC article.
Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim.
Oncotarget, 2017 May 20; 8(29). PMID: 28525386    Free PMC article.
Review.
Immunogenomics: using genomics to personalize cancer immunotherapy.
Rance C Siniard, Shuko Harada.
Virchows Arch, 2017 May 22; 471(2). PMID: 28528510
Review.
Correlation of immune phenotype with IDH mutation in diffuse glioma.
Anna Sophie Berghoff, Barbara Kiesel, +8 authors, Matthias Preusser.
Neuro Oncol, 2017 May 23; 19(11). PMID: 28531337    Free PMC article.
Highly Cited.
Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.
Shirish M Gadgeel.
Curr Treat Options Oncol, 2017 May 24; 18(6). PMID: 28534251
Review.
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management.
Caroline Prieux-Klotz, Marie Dior, +6 authors, Romain Coriat.
Target Oncol, 2017 May 26; 12(3). PMID: 28540478
Combining radiotherapy with immunotherapy: the past, the present and the future.
Evert J Van Limbergen, Dirk K De Ruysscher, +8 authors, Philippe Lambin.
Br J Radiol, 2017 May 26; 90(1076). PMID: 28541096    Free PMC article.
Review.
High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes.
Rieneke van de Ven, Anna-Larissa N Niemeijer, +7 authors, Adrianus J de Langen.
ERJ Open Res, 2017 Jun 01; 3(2). PMID: 28560238    Free PMC article.
Immunological effect of local ablation combined with immunotherapy on solid malignancies.
Yusuke Takahashi, Noriyuki Matsutani, +3 authors, Masafumi Kawamura.
Chin J Cancer, 2017 Jun 09; 36(1). PMID: 28592286    Free PMC article.
Review.
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Solange Peters, Scott Gettinger, +25 authors, Enriqueta Felip.
J Clin Oncol, 2017 Jun 14; 35(24). PMID: 28609226    Free PMC article.
Highly Cited.
PD-L1 protein expression in non-small cell lung cancer based on different immunohistochemical antibodies.
Minghui Zhang, Di Feng, +3 authors, Qingyuan Zhang.
J Thorac Dis, 2017 Jun 16; 9(5). PMID: 28616312    Free PMC article.
Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
Gideon M Blumenthal, Lijun Zhang, +7 authors, Richard Pazdur.
JAMA Oncol, 2017 Jun 16; 3(8). PMID: 28617920    Free PMC article.
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.
Olivier Bylicki, Nicolas Paleiron, +6 authors, Christos Chouaid.
Target Oncol, 2017 Jun 19; 12(5). PMID: 28624922
Review.
The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.
Roberta Visconti, Francesco Morra, Gianluca Guggino, Angela Celetti.
Int J Mol Sci, 2017 Jun 28; 18(7). PMID: 28653990    Free PMC article.
Review.
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.
Si-Yang Liu, Yi-Long Wu.
J Hematol Oncol, 2017 Jul 07; 10(1). PMID: 28679395    Free PMC article.
Review.
Novel immune checkpoint blocker to treat Merkel cell carcinoma.
Lorenzo Galluzzi, Guido Kroemer.
Oncoimmunology, 2017 Jul 07; 6(6). PMID: 28680746    Free PMC article.
Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
Clizia Zichi, Marcello Tucci, +5 authors, Massimo Di Maio.
Biomed Res Int, 2017 Jul 07; 2017. PMID: 28680882    Free PMC article.
Review.
PD1 functions by inhibiting CD28-mediated co-stimulation.
Jake S O'Donnell, Mark J Smyth, Michele W L Teng.
Clin Transl Immunology, 2017 Jul 12; 6(5). PMID: 28690844    Free PMC article.
Atezolizumab in non-small cell lung cancer: the era of precision immuno-oncology.
James Chung Hang Chow, Ka Man Cheung, William Chi Shing Cho.
Ann Transl Med, 2017 Jul 15; 5(12). PMID: 28706933    Free PMC article.
Cancer Immunotherapies: Are They as Effective in the Elderly?
Kate Poropatich, Joel Fontanarosa, +2 authors, Bin Zhang.
Drugs Aging, 2017 Jul 15; 34(8). PMID: 28707274
Review.
Atezolizumab for the treatment of non-small cell lung cancer.
Fernando C Santini, Charles M Rudin.
Expert Rev Clin Pharmacol, 2017 Jul 18; 10(9). PMID: 28714780    Free PMC article.
Review.
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
Hyun Tae Lee, Ju Yeon Lee, +6 authors, Yong-Seok Heo.
Sci Rep, 2017 Jul 19; 7(1). PMID: 28717238    Free PMC article.
Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression.
Kazuki Takada, Tatsuro Okamoto, +10 authors, Yoshihiko Maehara.
PLoS One, 2017 Jul 21; 12(7). PMID: 28727766    Free PMC article.
Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults.
Rawad Elias, Joshua Morales, Carolyn Presley.
Curr Oncol Rep, 2017 Jul 30; 19(9). PMID: 28755314
Review.
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Nagashree Seetharamu, Isabel R Preeshagul, Kevin M Sullivan.
Lung Cancer (Auckl), 2017 Aug 02; 8. PMID: 28761384    Free PMC article.
Review.
Checkpoint inhibitors in the treatment of urological malignancies.
Lazar S Popovic, Gorana Matovina-Brko, Maja Popovic.
ESMO Open, 2017 Aug 02; 2(2). PMID: 28761743    Free PMC article.
Review.
ESMO Copenhagen 2016: a lung cancer 'grand cru'.
Jean-Yves Douillard.
ESMO Open, 2017 Aug 02; 2(2). PMID: 28761753    Free PMC article.
Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review.
Da-Ping Yu, Xu Cheng, Zhi-Dong Liu, Shao-Fa Xu.
Oncol Lett, 2017 Aug 10; 14(2). PMID: 28789381    Free PMC article.
Lung cancer as a cardiotoxic state: a review.
David Pérez-Callejo, María Torrente, +2 authors, Mariano Provencio.
Med Oncol, 2017 Aug 11; 34(9). PMID: 28795306
Review.
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.
Lihu Gu, Manman Chen, +7 authors, Xianfa Wang.
PLoS One, 2017 Aug 11; 12(8). PMID: 28796808    Free PMC article.
Highly Cited. Systematic Review.
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.
Dylan J Martini, Aly-Khan A Lalani, +5 authors, Toni K Choueiri.
J Immunother Cancer, 2017 Aug 16; 5(1). PMID: 28807048    Free PMC article.
Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.
Sabrina Rossi, Luca Toschi, +3 authors, Egesta Lopci.
Eur J Nucl Med Mol Imaging, 2017 Aug 18; 44(13). PMID: 28815334
Review.
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.
Karim Rihawi, Francesco Gelsomino, +4 authors, Andrea Ardizzoni.
Ther Adv Respir Dis, 2017 Aug 19; 11(9). PMID: 28818019    Free PMC article.
Review.
Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.
Roberto Chalela, Víctor Curull, +3 authors, Joaquim Gea.
J Thorac Dis, 2017 Aug 26; 9(7). PMID: 28840016    Free PMC article.
Review.
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
Rachel M Gibbons Johnson, Haidong Dong.
Front Immunol, 2017 Aug 30; 8. PMID: 28848559    Free PMC article.
Review.
Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Carmelo Tibaldi, Alice Lunghi, Editta Baldini.
World J Clin Oncol, 2017 Aug 30; 8(4). PMID: 28848698    Free PMC article.
Review.
The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions.
Angel Qin, Shirish Gadgeel.
Target Oncol, 2017 Sep 01; 12(6). PMID: 28856564    Free PMC article.
Review.
Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
Hamzeh Albaba, Charles Lim, Natasha B Leighl.
Pharmacoeconomics, 2017 Sep 02; 35(12). PMID: 28861770
Review.
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
Valsamo Anagnostou, Mark Yarchoan, +6 authors, Patrick M Forde.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864724    Free PMC article.
Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.
Christina S Baik, Eric H Rubin, +5 authors, Laura Q M Chow.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864727    Free PMC article.
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
Xiao-Ming Jiang, Yu-Lian Xu, +4 authors, Jin-Jian Lu.
Acta Pharmacol Sin, 2017 Sep 08; 38(11). PMID: 28880013    Free PMC article.
Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.
Marianne Davies, Emily A Duffield.
Immunotargets Ther, 2017 Sep 13; 6. PMID: 28894725    Free PMC article.
Review.
Current chemotherapeutic regimens for brain metastases treatment.
Joo Yeon Nam, Barbara J O'Brien.
Clin Exp Metastasis, 2017 Sep 18; 34(6-7). PMID: 28918542
Review.
Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy.
Sameera S Kumar, Kristin A Higgins, Ronald C McGarry.
Front Oncol, 2017 Sep 21; 7. PMID: 28929083    Free PMC article.
Review.
A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.
Jin Li, Yaoqi Chen, +9 authors, Yu Zhang.
J Thorac Dis, 2017 Sep 22; 9(8). PMID: 28932563    Free PMC article.
PD-1/PD-L1 antibodies efficacy and safety versus docetaxel monotherapy in advanced NSCLC patients after first-line treatment option: systems assessment.
Qiang Su, Zhigang Sun, +2 authors, Bangwei Cao.
Oncotarget, 2017 Sep 25; 8(35). PMID: 28938671    Free PMC article.
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.
Ashley M Hopkins, Andrew Rowland, +5 authors, Michael J Sorich.
Br J Cancer, 2017 Sep 28; 117(7). PMID: 28950287    Free PMC article.
Highly Cited. Review.
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study.
A Necchi, R W Joseph, +9 authors, J E Rosenberg.
Ann Oncol, 2017 Sep 28; 28(12). PMID: 28950298    Free PMC article.
PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung.
Urska Janzic, Izidor Kern, +2 authors, Tanja Cufer.
Radiol Oncol, 2017 Sep 30; 51(3). PMID: 28959173    Free PMC article.
Secreted protein acidic and rich in cysteine (SPARC) induces cell migration and epithelial mesenchymal transition through WNK1/snail in non-small cell lung cancer.
Jen-Yu Hung, Meng-Chi Yen, +6 authors, Po-Lin Kuo.
Oncotarget, 2017 Oct 04; 8(38). PMID: 28969021    Free PMC article.
Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes.
Paweł Krawczyk, Bożena Jarosz, +8 authors, Janusz Milanowski.
Oncotarget, 2017 Oct 04; 8(38). PMID: 28969070    Free PMC article.
Immune checkpoint blockade in infectious diseases.
Michelle N Wykes, Sharon R Lewin.
Nat Rev Immunol, 2017 Oct 11; 18(2). PMID: 28990586    Free PMC article.
Highly Cited. Review.
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).
Leora Horn, David R Spigel, +26 authors, Wilfried E E Eberhardt.
J Clin Oncol, 2017 Oct 13; 35(35). PMID: 29023213    Free PMC article.
Highly Cited.
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Scott Gettinger, Jungmin Choi, +23 authors, Katerina Politi.
Cancer Discov, 2017 Oct 14; 7(12). PMID: 29025772    Free PMC article.
Highly Cited.
PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.
Pei Zhang, Zhang Bao, +7 authors, Jianying Zhou.
Oncotarget, 2017 Oct 17; 8(39). PMID: 29029512    Free PMC article.
Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy.
Di Wu, Chongyang Duan, +2 authors, Size Chen.
Oncotarget, 2017 Oct 17; 8(39). PMID: 29029530    Free PMC article.
[Lung cancer : What has been confirmed in therapy?]
D F Heigener, M Reck.
Internist (Berl), 2017 Oct 19; 58(12). PMID: 29043377
Review.
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
H Nokihara, S Lu, +17 authors, T Tamura.
Ann Oncol, 2017 Oct 19; 28(11). PMID: 29045553    Free PMC article.
PD-L1 as a biomarker in NSCLC: challenges and future directions.
Matthen Mathew, Rachael A Safyan, Catherine A Shu.
Ann Transl Med, 2017 Oct 24; 5(18). PMID: 29057235    Free PMC article.
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.
Khinh Ranh Voong, Josephine Feliciano, Daniel Becker, Benjamin Levy.
Ann Transl Med, 2017 Oct 24; 5(18). PMID: 29057236    Free PMC article.
Review.
[A Reflection of the New Wave of Immunotherapy on the Clinical Study of 
Chinese Lung Cancer Immunotherapy].
Jingjing Liu, Shuang Zhang, Shuang Li, Ying Cheng.
Zhongguo Fei Ai Za Zhi, 2017 Oct 25; 20(10). PMID: 29061217    Free PMC article.
Review.
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.
Peng-Fei Wang, Yang Chen, +5 authors, Chang-Xiang Yan.
Front Pharmacol, 2017 Nov 03; 8. PMID: 29093678    Free PMC article.
Highly Cited.
Cardiotoxicity of immune checkpoint inhibitors.
Gilda Varricchi, Maria Rosaria Galdiero, +5 authors, Carlo Gabriele Tocchetti.
ESMO Open, 2017 Nov 07; 2(4). PMID: 29104763    Free PMC article.
Highly Cited. Review.
Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.
Mari Mino-Kenudson.
Transl Lung Cancer Res, 2017 Nov 09; 6(5). PMID: 29114473    Free PMC article.
Review.
The combination of checkpoint immunotherapy and targeted therapy in cancer.
Niki Karachaliou, Maria Gonzalez-Cao, +4 authors, Rafael Rosell.
Ann Transl Med, 2017 Nov 09; 5(19). PMID: 29114546    Free PMC article.
Review.
Saudi lung cancer management guidelines 2017: Improving lung cancer care in Saudi region.
Christian Rolfo, Christoph C Zielinski.
Ann Thorac Med, 2017 Nov 10; 12(4). PMID: 29118854    Free PMC article.
Saudi lung cancer management guidelines 2017.
AR Jazieh on Behalf of Saudi Lung Cancer Guidelines Association, Saudi Lung Cancer Guidelines Members, Abdul Rahman Jazieh, +26 authors, Marie Datario.
Ann Thorac Med, 2017 Nov 10; 12(4). PMID: 29118855    Free PMC article.
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.
Katerina Ancevski Hunter, Mark A Socinski, Liza C Villaruz.
Mol Diagn Ther, 2017 Nov 10; 22(1). PMID: 29119407    Free PMC article.
Review.
Immune checkpoint inhibitors: new strategies to checkmate cancer.
R A M Wilson, T R J Evans, A R Fraser, R J B Nibbs.
Clin Exp Immunol, 2017 Nov 16; 191(2). PMID: 29139554    Free PMC article.
Review.
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.
Zhong-Yi Dong, Jia-Tao Zhang, +10 authors, Yi-Long Wu.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147605    Free PMC article.
Highly Cited.
Trial watch: Immune checkpoint blockers for cancer therapy.
Claire Vanpouille-Box, Claire Lhuillier, +10 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147629    Free PMC article.
Highly Cited. Review.
Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization.
Hye Ryun Kim, Yoon Jin Cha, +8 authors, Hyo Sup Shim.
Oncotarget, 2017 Nov 21; 8(50). PMID: 29152077    Free PMC article.
Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.
Misako Nagasaka, Shirish M Gadgeel.
Expert Rev Anticancer Ther, 2017 Nov 24; 18(1). PMID: 29168933    Free PMC article.
Review.
Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200.
Reginald M Gorczynski, Fang Zhu.
Cancer Manag Res, 2017 Nov 29; 9. PMID: 29180896    Free PMC article.
Review.
Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials.
Allan Ramos-Esquivel, Alicia van der Laat, +2 authors, Luis Corrales-Rodríguez.
ESMO Open, 2017 Nov 29; 2(3). PMID: 29181191    Free PMC article.
CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells.
Meagan R Rollins, Rachel M Gibbons Johnson.
J Immunol Res, 2017 Nov 29; 2017. PMID: 29181416    Free PMC article.
Programmed cell death ligand 1 protein levels predicted survival of non-small cell lung cancer.
Shaohua Cui, Xinying Su, +9 authors, Liyan Jiang.
J Cancer, 2017 Dec 01; 8(19). PMID: 29187883    Free PMC article.
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.
Claudia Fumarola, Daniele Cretella, +14 authors, Andrea Ardizzoni.
Oncotarget, 2017 Dec 02; 8(54). PMID: 29190880    Free PMC article.
Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim.
Oncotarget, 2017 Dec 02; 8(54). PMID: 29190984    Free PMC article.
Product review on the Anti-PD-L1 antibody atezolizumab.
Neil J Shah, William J Kelly, +2 authors, Alexander Spira.
Hum Vaccin Immunother, 2017 Dec 02; 14(2). PMID: 29194007    Free PMC article.
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.
Bingshan Liu, Yongping Song, Delong Liu.
J Hematol Oncol, 2017 Dec 03; 10(1). PMID: 29195503    Free PMC article.
Highly Cited. Review.
EGFR mutation positive non-small cell lung cancer: can we identify predictors of benefit from immune checkpoint inhibitors.
Ying Wang, Peter Ellis.
Ann Transl Med, 2017 Dec 05; 5(21). PMID: 29201876    Free PMC article.
Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets.
Pedro Nazareth Aguiar, Ramon Andrade De Mello, +4 authors, Gilberto de Lima Lopes.
ESMO Open, 2017 Dec 07; 2(3). PMID: 29209522    Free PMC article.
Review.
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.
Robert J Torphy, Richard D Schulick, Yuwen Zhu.
Int J Mol Sci, 2017 Dec 07; 18(12). PMID: 29211042    Free PMC article.
Review.
Role of afatinib in the treatment of advanced lung squamous cell carcinoma.
Tiziana Vavalà.
Clin Pharmacol, 2017 Dec 12; 9. PMID: 29225480    Free PMC article.
Review.
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.
Luca Toschi, Sabrina Rossi, Giovanna Finocchiaro, Armando Santoro.
Ecancermedicalscience, 2017 Dec 12; 11. PMID: 29225694    Free PMC article.
Review.
The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer.
Jonathan Lu, Robert A Ramirez.
Ochsner J, 2017 Dec 13; 17(4). PMID: 29230122    Free PMC article.
Review.
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Michael Dougan.
Front Immunol, 2017 Dec 13; 8. PMID: 29230210    Free PMC article.
Highly Cited. Review.
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Andrea Botticelli, Concetta Elisa Onesti, +15 authors, Paolo Marchetti.
Oncotarget, 2017 Dec 17; 8(59). PMID: 29245905    Free PMC article.
ASCO update: lung cancer.
Gudrun Absenger, Jasmin Terzic, Angelika Bezan.
Memo, 2017 Dec 19; 10(4). PMID: 29250201    Free PMC article.
Review.
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H Young.
Front Immunol, 2017 Dec 20; 8. PMID: 29255458    Free PMC article.
Highly Cited. Review.
Atezolizumab in advanced non-small cell lung cancer.
Marius Ilie, Paul Hofman.
J Thorac Dis, 2017 Dec 23; 9(10). PMID: 29268352    Free PMC article.
KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer.
Hidehito Horinouchi.
J Thorac Dis, 2017 Dec 23; 9(11). PMID: 29268467    Free PMC article.
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Chee Khoon Lee, Johnathan Man, +7 authors, James Chih-Hsin Yang.
JAMA Oncol, 2017 Dec 23; 4(2). PMID: 29270615    Free PMC article.
Highly Cited. Systematic Review.
Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells.
Shaohua Cui, Lili Dong, +2 authors, Liyan Jiang.
J Cancer, 2018 Jan 02; 9(1). PMID: 29290777    Free PMC article.
Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy.
Xiang Yan, Li Wang, +11 authors, Bingliang Fang.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296537    Free PMC article.
Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer.
Ignacio Gil-Bazo.
Transl Lung Cancer Res, 2018 Jan 05; 6(Suppl 1). PMID: 29299406    Free PMC article.
Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.
Hao Xie, Alex A Adjei.
Transl Lung Cancer Res, 2018 Jan 05; 6(Suppl 1). PMID: 29299408    Free PMC article.
Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them.
Marius Ilie, Paul Hofman.
Transl Lung Cancer Res, 2018 Jan 05; 6(Suppl 1). PMID: 29299411    Free PMC article.
Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles.
Ju Hwan Cho.
Immune Netw, 2018 Jan 06; 17(6). PMID: 29302251    Free PMC article.
Review.
Inhibitors of the PD-1 Pathway in Tumor Therapy.
Martin W LaFleur, Yuki Muroyama, Charles G Drake, Arlene H Sharpe.
J Immunol, 2018 Jan 10; 200(2). PMID: 29311378    Free PMC article.
Review.
High response rate to PD-1 blockade in desmoplastic melanomas.
Zeynep Eroglu, Jesse M Zaretsky, +22 authors, Antoni Ribas.
Nature, 2018 Jan 11; 553(7688). PMID: 29320474    Free PMC article.
Highly Cited.
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Laura Mezquita, Edouard Auclin, +19 authors, Benjamin Besse.
JAMA Oncol, 2018 Jan 13; 4(3). PMID: 29327044    Free PMC article.
Highly Cited.
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Chi Young Jung, Scott J Antonia.
Tuberc Respir Dis (Seoul), 2018 Jan 15; 81(1). PMID: 29332322    Free PMC article.
Review.
Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
Hua Zheng, Masha Zeltsman, +3 authors, Prasad S Adusumilli.
Immunotherapy, 2018 Jan 18; 9(11). PMID: 29338609    Free PMC article.
Review.
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia.
J Immunother Cancer, 2018 Jan 24; 6(1). PMID: 29357948    Free PMC article.
Highly Cited. Review.
PD-1/PD-L1 Axis in Lung Cancer.
Fernando C Santini, Matthew D Hellmann.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360723    Free PMC article.
Review.
The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff.
Nature, 2018 Jan 25; 553(7689). PMID: 29364287
Highly Cited. Review.
Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.
Shifaa M Abdin, Dana M Zaher, El-Shaimaa A Arafa, Hany A Omar.
Cancers (Basel), 2018 Jan 26; 10(2). PMID: 29370105    Free PMC article.
Review.
Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.
Akito Hata, Nobuyuki Katakami, +8 authors, Yukio Hirata.
Oncotarget, 2018 Jan 27; 8(69). PMID: 29371947    Free PMC article.
Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
Haiying Cheng, Alain Borczuk, +6 authors, Xingxing Zang.
Clin Cancer Res, 2018 Jan 28; 24(8). PMID: 29374053    Free PMC article.
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).
Irene Moya-Horno, Santiago Viteri, Niki Karachaliou, Rafael Rosell.
Ther Adv Med Oncol, 2018 Feb 01; 10. PMID: 29383034    Free PMC article.
Highly Cited. Review.
Role of immune-checkpoint inhibitors in lung cancer.
Prantesh Jain, Chhavi Jain, Vamsidhar Velcheti.
Ther Adv Respir Dis, 2018 Feb 02; 12. PMID: 29385894    Free PMC article.
Review.
PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
Bruna Cerbelli, Angelina Pernazza, +10 authors, Leopoldo Costarelli.
Biomed Res Int, 2018 Feb 02; 2017. PMID: 29387716    Free PMC article.
Immune Checkpoint Inhibitors in Advanced-Stage Non-small Cell Lung Cancer.
Seher Nazlı Kazaz, İlhan Öztop.
Turk Thorac J, 2018 Feb 07; 18(4). PMID: 29404172    Free PMC article.
Review.
The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis.
Guanghong Huang, Xin Sun, +9 authors, Sida Qin.
Oncotarget, 2018 Feb 10; 9(3). PMID: 29423118    Free PMC article.
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
Daniel P Petrylak, Thomas Powles, +10 authors, Nicholas J Vogelzang.
JAMA Oncol, 2018 Feb 10; 4(4). PMID: 29423515    Free PMC article.
Highly Cited.
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.
Jeffrey M Clarke, Daniel J George, Stacey Lisi, April K S Salama.
Target Oncol, 2018 Feb 15; 13(1). PMID: 29441437
Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?
Alessandro Morabito.
BMC Med, 2018 Feb 17; 16(1). PMID: 29448944    Free PMC article.
Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy.
Fanny Jean, Pascale Tomasini, Fabrice Barlesi.
Ther Adv Med Oncol, 2018 Feb 17; 9(12). PMID: 29449897    Free PMC article.
Review.
The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.
Helmy M Guirgis.
J Immunother Cancer, 2018 Feb 22; 6(1). PMID: 29463302    Free PMC article.
Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
Marzia Del Re, Eleonora Rofi, +6 authors, Romano Danesi.
Oncotarget, 2018 Feb 22; 9(5). PMID: 29464099    Free PMC article.
Review.
Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples.
Ross A Soo, Joey Sze Yun Lim, +11 authors, Richie Soong.
Oncotarget, 2018 Feb 23; 9(6). PMID: 29467933    Free PMC article.
A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma.
Tadashi Sakane, Takayuki Murase, +11 authors, Hiroshi Inagaki.
Oncotarget, 2018 Feb 23; 9(6). PMID: 29467945    Free PMC article.
Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
Georgia Ritchie, Harry Gasper, +4 authors, Chee Khoon Lee.
JAMA Oncol, 2018 Feb 23; 4(4). PMID: 29470579    Free PMC article.
Systematic Review.
Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer.
Qi Jiang, Mixue Xie, +3 authors, Sufen Yu.
Oncotarget, 2018 Feb 28; 9(7). PMID: 29484143    Free PMC article.
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.
Alberto Carretero-González, David Lora, +6 authors, Guillermo de Velasco.
Oncotarget, 2018 Mar 02; 9(9). PMID: 29492229    Free PMC article.
Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer.
Ju Hwan Cho, Filiz Oezkan, +3 authors, Kai He.
Curr Pharmacol Rep, 2018 Mar 06; 3(6). PMID: 29503796    Free PMC article.
Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.
Wei Wei, Bin Xu, +3 authors, Changping Wu.
Medicine (Baltimore), 2018 Mar 06; 97(3). PMID: 29504990    Free PMC article.
Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.
Niamh Coleman, Malaka Ameratunga, Juanita Lopez.
Clin Med Insights Oncol, 2018 Mar 08; 12. PMID: 29511362    Free PMC article.
Review.
Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
Hiroki Nagai, Manabu Muto.
Int J Clin Oncol, 2018 Mar 09; 23(3). PMID: 29516216
Review.
[Research Advances of Pan-negative Type of Non-small Cell Lung Cancer].
Li Sun, Zhicheng Xiong, Chengbo Han.
Zhongguo Fei Ai Za Zhi, 2018 Mar 13; 21(2). PMID: 29526181    Free PMC article.
Review.
Do EGFR tyrosine kinase inhibitors (TKIs) still have a role in EGFR wild-type pre-treated advanced non-small cell lung cancer (NSCLC)?-the shifting paradigm of therapeutics.
Malinda Itchins, Stephen Clarke, Nick Pavlakis.
Transl Lung Cancer Res, 2018 Mar 14; 7(Suppl 1). PMID: 29531903    Free PMC article.
Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments.
Alessia Pellerino, Luca Bertero, Roberta Rudà, Riccardo Soffietti.
Ther Adv Neurol Disord, 2018 Mar 15; 11. PMID: 29535794    Free PMC article.
Review.
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.
Shrujal Baxi, Annie Yang, +4 authors, Deborah Korenstein.
BMJ, 2018 Mar 16; 360. PMID: 29540345    Free PMC article.
Highly Cited. Systematic Review.
Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis.
Hao Hu, Qian Zhu, +3 authors, Chang Ying Guo.
Oncotarget, 2018 Mar 17; 9(14). PMID: 29545941    Free PMC article.
Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis.
Junqi Liu, Chuanfeng Zhang, +6 authors, Ruitai Fan.
Oncotarget, 2018 Mar 20; 9(15). PMID: 29552320    Free PMC article.
Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report.
Taiki Hakozaki, Yusuke Okuma, Jumpei Kashima.
BMC Cancer, 2018 Mar 21; 18(1). PMID: 29554874    Free PMC article.
Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer.
Maher Albitar, Sucha Sudarsanam, +5 authors, Sally Agersborg.
Oncotarget, 2018 Mar 24; 9(17). PMID: 29568386    Free PMC article.
Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
Wolfgang M Brueckl, H Jost Achenbach, Joachim H Ficker, Wolfgang Schuette.
BMC Cancer, 2018 Mar 29; 18(1). PMID: 29587656    Free PMC article.
Immunotherapy in surgically resectable non-small cell lung cancer.
Dwight Owen, Jamie E Chaft.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593886    Free PMC article.
Review.
Immunotherapy in treatment naïve advanced non-small cell lung cancer.
Vinicius Ernani, Apar Kishor Ganti.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593887    Free PMC article.
Review.
Immunotherapy in previously treated non-small cell lung cancer (NSCLC).
Ticiana A Leal, Suresh S Ramalingam.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593888    Free PMC article.
Review.
Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer.
Justin Yeh, Kristen A Marrone, Patrick M Forde.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593890    Free PMC article.
Review.
Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer.
Justin F Gainor.
J Thorac Dis, 2018 Mar 31; 10(1). PMID: 29600014    Free PMC article.
A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.
Matthew A Gubens, Jody C Chuang, +7 authors, Heather A Wakelee.
J Thorac Dis, 2018 Mar 31; 10(1). PMID: 29600052    Free PMC article.
Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma.
Jorien Minnema-Luiting, Heleen Vroman, Joachim Aerts, Robin Cornelissen.
Int J Mol Sci, 2018 Mar 31; 19(4). PMID: 29601534    Free PMC article.
Review.
Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer.
Chen Pang, Limei Yin, +14 authors, You Lu.
J Thorac Dis, 2018 Apr 03; 10(2). PMID: 29607153    Free PMC article.
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.
Rawad Elias, Anita Giobbie-Hurder, +3 authors, Osama Rahma.
J Immunother Cancer, 2018 Apr 06; 6(1). PMID: 29618381    Free PMC article.
Systematic Review.
Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges.
Niki Karachaliou, Rafael Rosell.
Ther Adv Med Oncol, 2018 Apr 06; 10. PMID: 29619092    Free PMC article.
STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.
Ilaria Attili, Niki Karachaliou, +6 authors, Rafael Rosell.
Ther Adv Med Oncol, 2018 Apr 11; 10. PMID: 29636826    Free PMC article.
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima.
Front Oncol, 2018 Apr 13; 8. PMID: 29644214    Free PMC article.
Highly Cited. Review.
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
Patrick M Forde, Jamie E Chaft, +32 authors, Drew M Pardoll.
N Engl J Med, 2018 Apr 17; 378(21). PMID: 29658848    Free PMC article.
Highly Cited.
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Chiara Lazzari, Niki Karachaliou, +7 authors, Vanesa Gregorc.
Ther Adv Med Oncol, 2018 Apr 18; 10. PMID: 29662546    Free PMC article.
Highly Cited. Review.
PD-L1 expression testing in non-small cell lung cancer.
Cristina Teixidó, Noelia Vilariño, Roxana Reyes, Noemí Reguart.
Ther Adv Med Oncol, 2018 Apr 18; 10. PMID: 29662547    Free PMC article.
Highly Cited. Review.
Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer: a pragmatic approach in clinical practice.
Efimia Boutsikou, Kalliopi Domvri, +3 authors, Theodoros Kontakiotis.
Ther Adv Med Oncol, 2018 Apr 18; 10. PMID: 29662549    Free PMC article.
Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer.
Florian Huemer, Gabriel Rinnerthaler, +5 authors, Richard Greil.
Oncotarget, 2018 Apr 18; 9(23). PMID: 29662663    Free PMC article.
Immune checkpoint pathways in non-small cell lung cancer.
Young Kwang Chae, Ayush Arya, +4 authors, Francis J Giles.
Ann Transl Med, 2018 Apr 19; 6(5). PMID: 29666811    Free PMC article.
Review.
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel.
Alessandro Russo, Tindara Franchina, +5 authors, Vincenzo Adamo.
J Cell Physiol, 2018 Apr 20; 233(10). PMID: 29672849    Free PMC article.
A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer.
Wei You, Mei Liu, +5 authors, Hao Peng.
J Cancer, 2018 Apr 21; 9(7). PMID: 29675101    Free PMC article.
Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
Joseph A Pinto, Carlos S Vallejos, +10 authors, Christian Rolfo.
ESMO Open, 2018 Apr 24; 3(3). PMID: 29682332    Free PMC article.
Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer.
Adrien Costantini, Jennifer Corny, +12 authors, Jacques Cadranel.
ERJ Open Res, 2018 Apr 26; 4(2). PMID: 29692997    Free PMC article.
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Benjamin A Weinberg, Joanne Xiu, +3 authors, John L Marshall.
Oncologist, 2018 Apr 29; 23(10). PMID: 29703766    Free PMC article.
Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC).
Silvia Vecchiarelli, Francesco Passiglia, +12 authors, Federico Cappuzzo.
Oncotarget, 2018 May 01; 9(25). PMID: 29707129    Free PMC article.
The evolving understanding of immunoediting and the clinical impact of immune escape.
Caroline E McCoach, Trever G Bivona.
J Thorac Dis, 2018 May 01; 10(3). PMID: 29708132    Free PMC article.
Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine.
Masaru Katoh.
J Thorac Dis, 2018 May 01; 10(3). PMID: 29708143    Free PMC article.
Current PD-L1 immunohistochemistry for non-small cell lung cancer.
Andreas H Scheel, Stephan C Schäfer.
J Thorac Dis, 2018 May 01; 10(3). PMID: 29708172    Free PMC article.
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.
Yayi He, Sangtian Liu, +3 authors, Daniel Chan.
Drug Des Devel Ther, 2018 May 08; 12. PMID: 29731605    Free PMC article.
PD-L1 receptor expression in vulvar carcinomas is HPV-independent.
M Choschzick, A Gut, D Fink.
Virchows Arch, 2018 May 08; 473(4). PMID: 29736798
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.
Jaafar Jaafar, Eugenio Fernandez, Heba Alwan, Jacques Philippe.
Endocr Connect, 2018 May 10; 7(5). PMID: 29739808    Free PMC article.
Review.
Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
Hossein Maymani, Kenneth Hess, +14 authors, Vivek Subbiah.
Lung Cancer, 2018 May 12; 120. PMID: 29748008    Free PMC article.
Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.
Takuya Watanabe, Katsuhiro Okuda, +8 authors, Ryoichi Nakanishi.
Oncotarget, 2018 May 15; 9(29). PMID: 29755688    Free PMC article.
Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.
Michael R Shafique, Lary A Robinson, Scott Antonia.
Cancer Manag Res, 2018 May 16; 10. PMID: 29760563    Free PMC article.
Review.
Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment.
Qiang Su, Xiaochen Zhang, +3 authors, Zu Hua Gao.
J Cancer, 2018 May 16; 9(9). PMID: 29760800    Free PMC article.
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
Ioannis Zerdes, Alexios Matikas, +2 authors, Theodoros Foukakis.
Oncogene, 2018 May 17; 37(34). PMID: 29765155    Free PMC article.
Highly Cited. Review.
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
Young Kwang Chae, Ayush Arya, +4 authors, Francis Giles.
J Immunother Cancer, 2018 May 18; 6(1). PMID: 29769148    Free PMC article.
Highly Cited. Review.
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, +66 authors, John V Heymach.
Cancer Discov, 2018 May 19; 8(7). PMID: 29773717    Free PMC article.
Highly Cited.
Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?
Griet Deslypere, Dorothée Gullentops, Els Wauters, Johan Vansteenkiste.
Ther Adv Med Oncol, 2018 May 19; 10. PMID: 29774061    Free PMC article.
Review.
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).
Shirish M Gadgeel, Nathan A Pennell, +11 authors, Gregory P Kalemkerian.
J Thorac Oncol, 2018 May 19; 13(9). PMID: 29775808    Free PMC article.
Highly Cited.
Durvalumab for non-resectable stage IIIB non-small cell lung cancer-a small step or a big leap?
Wolfram C M Dempke, Klaus Fenchel.
Transl Lung Cancer Res, 2018 May 22; 7(Suppl 2). PMID: 29780708    Free PMC article.
Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease.
Osamu Kanai, Young Hak Kim, +7 authors, Toyohiro Hirai.
Thorac Cancer, 2018 May 22; 9(7). PMID: 29782069    Free PMC article.
Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution.
Massimiliano Salati, Cinzia Baldessari, Bruna Cerbelli, Andrea Botticelli.
Transl Lung Cancer Res, 2018 May 22; 7(Suppl 2). PMID: 29782565    Free PMC article.
Quality of life for non-small cell lung cancer patients in the age of immunotherapy.
Robert A Ramirez, Jonathan Lu, Katharine E H Thomas.
Transl Lung Cancer Res, 2018 May 22; 7(Suppl 2). PMID: 29782567    Free PMC article.
Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer.
Hannah A Blair.
Target Oncol, 2018 May 23; 13(3). PMID: 29785577
Review.
Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.
Grainne M O'Kane, Natasha B Leighl.
CNS Drugs, 2018 May 26; 32(6). PMID: 29799091
Review.
Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
Nicholas Borcherding, Ryan Kolb, +3 authors, Weizhou Zhang.
J Mol Biol, 2018 May 26; 430(14). PMID: 29800567    Free PMC article.
Review.
Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience.
Mohammed Salhab, Yazan Migdady, +5 authors, James Liebmann.
J Immunother Cancer, 2018 May 31; 6(1). PMID: 29843803    Free PMC article.
Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer.
Habeeb Majeed, Eitan Amir.
J Thorac Dis, 2018 Jun 01; 10(Suppl 9). PMID: 29849197    Free PMC article.
Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study.
Takehiro Uemura, Toyoaki Hida.
J Thorac Dis, 2018 Jun 01; 10(Suppl 9). PMID: 29850190    Free PMC article.
Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
Hyojin Kim, Hyun Jung Kwon, +3 authors, Jin-Haeng Chung.
PLoS One, 2018 Jun 02; 13(6). PMID: 29856861    Free PMC article.
Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations.
Yusuke Okuma, Jumpei Kashima, Kageaki Watanabe, Sadamu Homma.
J Cancer Res Clin Oncol, 2018 Jun 03; 144(8). PMID: 29858682
The emerging treatment landscape of advanced non-small cell lung cancer.
Panagiota Economopoulou, Giannis Mountzios.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862227    Free PMC article.
Review.
Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
Anna Tsiara, Michalis Liontos, +3 authors, Meletios-Athanasios Dimopoulos.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862233    Free PMC article.
Review.
Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Georgios Tsironis, Dimitrios C Ziogas, +4 authors, Meletios-Athanasios Dimopoulos.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862232    Free PMC article.
Review.
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.
Jun Gong, Thang Q Le, +2 authors, Richard Tuli.
J Immunother Cancer, 2018 Jun 06; 6(1). PMID: 29866197    Free PMC article.
Review.
Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.
Guoying Zhou, Lisanne Noordam, +14 authors, Marco J Bruno.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900067    Free PMC article.
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.
Glenwood D Goss, Enriqueta Felip, +20 authors, Jean-Charles Soria.
JAMA Oncol, 2018 Jun 15; 4(9). PMID: 29902295    Free PMC article.
Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms.
Megan B Barnet, Wendy A Cooper, Michael J Boyer, Steven Kao.
J Clin Med, 2018 Jun 16; 7(6). PMID: 29904031    Free PMC article.
Review.
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
P D Bonomi, D Gandara, +22 authors, N Thatcher.
Ann Oncol, 2018 Jun 16; 29(8). PMID: 29905778    Free PMC article.
Review.
Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer.
B Melosky.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910649    Free PMC article.
Review.
Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview.
N Daaboul, G Nicholas, S A Laurie.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910650    Free PMC article.
Review.
Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
A Pabani, C A Butts.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910652    Free PMC article.
Review.
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
Patrick Danaher, Sarah Warren, +6 authors, Alessandra Cesano.
J Immunother Cancer, 2018 Jun 23; 6(1). PMID: 29929551    Free PMC article.
Highly Cited.
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Yukihiro Toi, Shunichi Sugawara, +14 authors, Yoshihiro Honda.
Oncologist, 2018 Jun 24; 23(11). PMID: 29934411    Free PMC article.
Highly Cited.
Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies.
Peng-Peng Xu, Chun Sun, +15 authors, Wei-Li Zhao.
EBioMedicine, 2018 Jun 25; 33. PMID: 29936139    Free PMC article.
Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab.
Kenji Nakahama, Akihiro Tamiya, +8 authors, Shinji Atagi.
In Vivo, 2018 Jun 25; 32(4). PMID: 29936475    Free PMC article.
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).
Filippo de Marinis, Fortunato Ciardiello, +10 authors, Cesare Gridelli.
ESMO Open, 2018 Jun 27; 3(4). PMID: 29942662    Free PMC article.
Review.
Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer.
Jin-Hua Chen, Jia-Lian Yang, +2 authors, Chin-Chuan Hung.
Sci Rep, 2018 Jun 28; 8(1). PMID: 29946182    Free PMC article.
Review.
Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Shota Omori, Hirotsugu Kenmotsu, +14 authors, Toshiaki Takahashi.
Int J Clin Oncol, 2018 Jun 28; 23(6). PMID: 29948239
Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.
David F Heigener, Martin Reck.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951298    Free PMC article.
Review.
Lung cancer, elderly and immune checkpoint inhibitors.
Francesca Casaluce, Assunta Sgambato, +2 authors, Cesare Gridelli.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951299    Free PMC article.
Review.
Immunotherapy in the Asiatic population: any differences from Caucasian population?
Lunxi Peng, Yi-Long Wu.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951300    Free PMC article.
Review.
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.
Jordi Remon, Laura Mezquita, +2 authors, Noemi Reguart.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951303    Free PMC article.
Review.
A review of guidelines for lung cancer.
Paolo Bironzo, Massimo Di Maio.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951306    Free PMC article.
Review.
Oncogene-addicted non-small cell lung cancer and immunotherapy.
Georgios Tsakonas, Simon Ekman.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951305    Free PMC article.
Review.
Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.
Meng Qiao, Tao Jiang, Caicun Zhou.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951304    Free PMC article.
Review.
Do immune checkpoint inhibitors need new studies methodology?
Roberto Ferrara, Sara Pilotto, +7 authors, Emilio Bria.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951307    Free PMC article.
Review.
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy.
Long Jia, Qi Zhang, Rongxin Zhang.
Cancer Biol Med, 2018 Jun 29; 15(2). PMID: 29951336    Free PMC article.
Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.
Jacqueline V Aredo, Sukhmani K Padda.
Curr Treat Options Oncol, 2018 Jun 29; 19(8). PMID: 29951788
Review.
Immune checkpoint inhibitors and small cell lung cancer: what's new?
Sabine Schmid, Martin Früh.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29953115    Free PMC article.
Review.
Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.
Akito Hata, Daijiro Harada, +6 authors, Nobuyuki Katakami.
Oncotarget, 2018 Jul 03; 9(45). PMID: 29963237    Free PMC article.
Editorial: Controversies in the Local Management of Lung Cancer.
John M Varlotto, Giulia Veronesi.
Front Oncol, 2018 Jul 04; 8. PMID: 29967762    Free PMC article.
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Muhammad Umair Mushtaq, Athanasios Papadas, +4 authors, Fotis Asimakopoulos.
J Immunother Cancer, 2018 Jul 05; 6(1). PMID: 29970158    Free PMC article.
Review.
Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis.
Qiang Su, Xiao-Chen Zhang, +3 authors, Bang-Wei Cao.
J Immunol Res, 2018 Jul 05; 2018. PMID: 29971244    Free PMC article.
Systematic Review.
Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis.
Bingjia Li, Xiaoyu Huang, Linlin Fu.
Onco Targets Ther, 2018 Jul 10; 11. PMID: 29983577    Free PMC article.
Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives.
Andreas Tiefenbacher, Robert Pirker.
Memo, 2018 Jul 10; 11(2). PMID: 29983826    Free PMC article.
Review.
Management of adverse events related to checkpoint inhibition therapy.
Jakob Daniel Rudzki.
Memo, 2018 Jul 10; 11(2). PMID: 29983828    Free PMC article.
Review.
Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries.
Marion Ferreira, Eric Pichon, +6 authors, Sylvain Marchand-Adam.
Target Oncol, 2018 Jul 15; 13(4). PMID: 30006825
Review.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Julie R Brahmer, Ramaswamy Govindan, +18 authors, Roy S Herbst.
J Immunother Cancer, 2018 Jul 18; 6(1). PMID: 30012210    Free PMC article.
Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Wenxin Luo, Zhoufeng Wang, Panwen Tian, Weimin Li.
J Cancer Res Clin Oncol, 2018 Jul 19; 144(10). PMID: 30019319
Review.
Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.
Wolfgang Willenbacher, Andreas Seeber, +5 authors, Semir Vranic.
Int J Mol Sci, 2018 Jul 20; 19(7). PMID: 30021955    Free PMC article.
Review.
A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC.
Juliet A Carmichael, Daisy Wing-San Mak, Mary O'Brien.
Cancers (Basel), 2018 Jul 20; 10(7). PMID: 30021993    Free PMC article.
Review.
The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel.
Wu Zhuang, Junxun Ma, +14 authors, Zhijie Wang.
J Cancer, 2018 Jul 22; 9(13). PMID: 30026825    Free PMC article.
The evolving immunotherapeutic landscape in advanced oesophagogastric cancer.
Michael Flynn, Kate Young, David Cunningham, Naureen Starling.
Ther Adv Med Oncol, 2018 Jul 24; 10. PMID: 30034550    Free PMC article.
Review.
New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab.
Olivier Bylicki, Nicolas Paleiron, Gaëlle Rousseau-Bussac, Christos Chouaïd.
Onco Targets Ther, 2018 Jul 25; 11. PMID: 30038505    Free PMC article.
Review.
Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Paul Scorer, Marietta Scott, +4 authors, Jill Walker.
Diagn Pathol, 2018 Jul 26; 13(1). PMID: 30041679    Free PMC article.
Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis.
Xavier Armoiry, Alexander Tsertsvadze, +4 authors, Aileen Clarke.
PLoS One, 2018 Jul 26; 13(7). PMID: 30044785    Free PMC article.
Systematic Review.
Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma.
Xiao-Yu Chen, Jing Zhang, +6 authors, Jin-Shui Zhu.
Int J Immunopathol Pharmacol, 2018 Jul 27; 32. PMID: 30045644    Free PMC article.
Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience.
Mª Carmen Areses Manrique, Joaquín Mosquera Martínez, +17 authors, José Luis Fírvida Pérez.
Transl Lung Cancer Res, 2018 Jul 28; 7(3). PMID: 30050778    Free PMC article.
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel.
Yi-Long Wu, Chang-Li Wang, +53 authors, Wen-Zhao Zhong.
Transl Lung Cancer Res, 2018 Jul 28; 7(3). PMID: 30050780    Free PMC article.
Review.
Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer.
Yosuke Miura, Noriaki Sunaga.
Cancers (Basel), 2018 Aug 01; 10(8). PMID: 30060457    Free PMC article.
Review.
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Cancers (Basel), 2018 Aug 01; 10(8). PMID: 30060526    Free PMC article.
Highly Cited. Review.
Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years.
Agnieszka Rybarczyk-Kasiuchnicz, Rodryg Ramlau.
Kardiochir Torakochirurgia Pol, 2018 Aug 03; 15(2). PMID: 30069193    Free PMC article.
Review.
Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.
Rimas V Lukas, Jordi Rodon, +9 authors, Joachim Baehring.
J Neurooncol, 2018 Aug 04; 140(2). PMID: 30073642
Use of Atezolizumab for Bladder and Non-Small Cell Lung Cancers.
Kayla Faith Moore.
J Adv Pract Oncol, 2018 Aug 07; 8(5). PMID: 30079270    Free PMC article.
Review.
Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis.
Jinchul Kim, Jinhyun Cho, Moon Hee Lee, Joo Han Lim.
Sci Rep, 2018 Aug 08; 8(1). PMID: 30082893    Free PMC article.
Review.
Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects.
Rachel Ryu, Kristina E Ward.
Front Oncol, 2018 Aug 09; 8. PMID: 30087855    Free PMC article.
Review.
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer.
Beatriz Wills, Julie R Brahmer, Jarushka Naidoo.
Curr Treat Options Oncol, 2018 Aug 14; 19(9). PMID: 30101402    Free PMC article.
Review.
Review of checkpoint immunotherapy for the management of non-small cell lung cancer.
Shine Raju, Ranjit Joseph, Sameep Sehgal.
Immunotargets Ther, 2018 Aug 15; 7. PMID: 30105218    Free PMC article.
Review.
The Role of Targeted Agents and Immunotherapy in Older Patients with Non-small Cell Lung Cancer.
Fabio Gomes, Rebecca Tay, Jaseela Chiramel, Raffaele Califano.
Drugs Aging, 2018 Aug 15; 35(9). PMID: 30105645
Review.
Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective.
Wenxiao Jiang, Guiqing Cai, Peter C Hu, Yue Wang.
Acta Pharm Sin B, 2018 Aug 16; 8(4). PMID: 30109178    Free PMC article.
Review.
Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer.
D E Meyers, P M Bryan, S Banerji, D G Morris.
Curr Oncol, 2018 Aug 17; 25(4). PMID: 30111979    Free PMC article.
Review.
Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Muhammad Khan, Jie Lin, +5 authors, Yawei Yuan.
Medicine (Baltimore), 2018 Aug 17; 97(33). PMID: 30113497    Free PMC article.
Review.
Atezolizumab for non-small cell lung cancer.
Aust Prescr, 2018 Aug 18; 41(4). PMID: 30116082    Free PMC article.
Review.
Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
Robert Pirker.
ESMO Open, 2018 Aug 18; 3(5). PMID: 30116594    Free PMC article.
Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors.
Yingming Zhu, Fen Zhao, Zhenxiang Li, Jinming Yu.
Cancer Manag Res, 2018 Aug 21; 10. PMID: 30122997    Free PMC article.
Review.
PD-L1 immunohistochemistry in patients with non-small cell lung cancer.
Takanobu Jotatsu, Keishi Oda, Kazuhiro Yatera.
J Thorac Dis, 2018 Aug 21; 10(Suppl 18). PMID: 30123540    Free PMC article.
Patient performance status and cancer immunotherapy efficacy: a meta-analysis.
Melissa Bersanelli, Matteo Brighenti, +2 authors, Fausto Petrelli.
Med Oncol, 2018 Aug 22; 35(10). PMID: 30128793
Review.
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
Ming Yi, Dechao Jiao, +4 authors, Kongming Wu.
Mol Cancer, 2018 Aug 25; 17(1). PMID: 30139382    Free PMC article.
Highly Cited. Review.
Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies.
Toshiki Iwai, Masamichi Sugimoto, +3 authors, Kaname Yamamoto.
Oncotarget, 2018 Aug 25; 9(59). PMID: 30140379    Free PMC article.
Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer.
Ana Turkaj, Anna M Morelli, Tiziana Vavalà, Silvia Novello.
Front Oncol, 2018 Aug 25; 8. PMID: 30140655    Free PMC article.
Review.
sLAG-3 in non-small-cell lung cancer patients' serum.
Yayi He, Yan Wang, +3 authors, Fred R Hirsch.
Onco Targets Ther, 2018 Aug 28; 11. PMID: 30147330    Free PMC article.
Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.
Maako Ide, Kentaro Tanaka, +5 authors, Isamu Okamoto.
Thorac Cancer, 2018 Aug 29; 9(11). PMID: 30152594    Free PMC article.
Strategies for Predicting Response to Checkpoint Inhibitors.
Roberta Zappasodi, Jedd D Wolchok, Taha Merghoub.
Curr Hematol Malig Rep, 2018 Aug 31; 13(5). PMID: 30159703    Free PMC article.
Review.
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
J K Sabari, G C Leonardi, +23 authors, A Drilon.
Ann Oncol, 2018 Aug 31; 29(10). PMID: 30165371    Free PMC article.
Highly Cited.
[Research Progress of Immunotherapy for Brain Metastases in Patients 
with Drive Gene Negative NSCLC].
Shuang Zhang, Jingjing Liu, +2 authors, Ying Cheng.
Zhongguo Fei Ai Za Zhi, 2018 Sep 03; 21(8). PMID: 30172268    Free PMC article.
Review.
[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation 
Treated by Immune Checkpoint Inhibitors].
Rilan Bai, Naifei Chen, Jiuwei Cui.
Zhongguo Fei Ai Za Zhi, 2018 Sep 03; 21(8). PMID: 30172273    Free PMC article.
Review.
New drugs in thoracic oncology: needs and knowledge - an online ERS Lung Cancer Assembly survey.
Thierry Berghmans, Matthew Evison, +2 authors, Jacques Cadranel.
ERJ Open Res, 2018 Sep 07; 4(3). PMID: 30186846    Free PMC article.
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Roberto Ferrara, Laura Mezquita, +25 authors, Caroline Caramella.
JAMA Oncol, 2018 Sep 08; 4(11). PMID: 30193240    Free PMC article.
Highly Cited.
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.
Xian Shen, Bin Zhao.
BMJ, 2018 Sep 12; 362. PMID: 30201790    Free PMC article.
Highly Cited.
Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients.
Noman Paracha, Ahmed Abdulla, Katherine S MacGilchrist.
Health Qual Life Outcomes, 2018 Sep 14; 16(1). PMID: 30208899    Free PMC article.
Systematic Review.
A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.
Jhanelle E Gray, Alberto Chiappori, +15 authors, Scott J Antonia.
Cancer Immunol Immunother, 2018 Sep 14; 67(12). PMID: 30209589    Free PMC article.
New advances in immunotherapy for non-small cell lung cancer.
Haifeng Qin, Fang Wang, +4 authors, Hongjun Gao.
Am J Transl Res, 2018 Sep 14; 10(8). PMID: 30210667    Free PMC article.
Review.
Efficacy and safety of Nivolumab in non-small cell lung cancer patients in Tel-Aviv tertiary medical center: Facing the reality.
Sivan Shamai, Ofer Merimsky.
Mol Clin Oncol, 2018 Sep 15; 9(4). PMID: 30214730    Free PMC article.
[Molecular predictors in immune oncology].
W Weichert.
Pathologe, 2018 Sep 15; 39(6). PMID: 30215118
Review.
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.
Nicolas Villanueva, Lyudmila Bazhenova.
Ther Adv Respir Dis, 2018 Sep 15; 12. PMID: 30215300    Free PMC article.
Review.
Cure in metastatic breast cancer.
Theresa Westphal, Simon Peter Gampenrieder, Gabriel Rinnerthaler, Richard Greil.
Memo, 2018 Sep 18; 11(3). PMID: 30220923    Free PMC article.
Review.
Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer.
Shuai Wang, Jiatao Hao, +2 authors, Lijie Tan.
Oncoimmunology, 2018 Sep 18; 7(8). PMID: 30221052    Free PMC article.
Lung cancer in never smokers-the East Asian experience.
Fei Zhou, Caicun Zhou.
Transl Lung Cancer Res, 2018 Sep 19; 7(4). PMID: 30225210    Free PMC article.
Review.
Autochthonous murine models for the study of smoker and never-smoker associated lung cancers.
Esra A Akbay, James Kim.
Transl Lung Cancer Res, 2018 Sep 19; 7(4). PMID: 30225211    Free PMC article.
Review.
Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis.
Qingcheng Du, Guanming Jiang, +2 authors, Zunnan Huang.
Oncoscience, 2018 Sep 21; 5(7-8). PMID: 30234144    Free PMC article.
Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
Francesco Facchinetti, Paola Bordi, +2 authors, Marcello Tiseo.
Drug Des Devel Ther, 2018 Sep 22; 12. PMID: 30237696    Free PMC article.
Review.
Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors.
Da Hyun Kang, Chaeuk Chung, +6 authors, Jeong Eun Lee.
Thorac Cancer, 2018 Sep 27; 9(11). PMID: 30253080    Free PMC article.
The intracellular signalosome of PD-L1 in cancer cells.
David Escors, María Gato-Cañas, +4 authors, Grazyna Kochan.
Signal Transduct Target Ther, 2018 Oct 03; 3. PMID: 30275987    Free PMC article.
Highly Cited. Review.
Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment.
Hongge Liang, Xiaoyan Liu, Mengzhao Wang.
Onco Targets Ther, 2018 Oct 06; 11. PMID: 30288054    Free PMC article.
Review.
Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy.
Jianjun Jin, Jiming Si, +3 authors, Jing Wang.
Respir Res, 2018 Oct 07; 19(1). PMID: 30290817    Free PMC article.
Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences.
Xinyu Yan, Shouyue Zhang, +3 authors, Heng Xu.
Front Pharmacol, 2018 Oct 09; 9. PMID: 30294272    Free PMC article.
Review.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Marcin Kowanetz, Wei Zou, +27 authors, Priti S Hegde.
Proc Natl Acad Sci U S A, 2018 Oct 10; 115(43). PMID: 30297397    Free PMC article.
Highly Cited.
Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms.
Jianli Ma, Decai Chi, +6 authors, Minghui Zhang.
J Cancer, 2018 Oct 13; 9(19). PMID: 30310505    Free PMC article.
Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint inhibitor.
Qiao Yang, Zihan Xu, +3 authors, Jianguo Sun.
Am J Cancer Res, 2018 Oct 17; 8(9). PMID: 30323963    Free PMC article.
Review.
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time.
Wouter W van Willigen, Martine Bloemendal, +3 authors, Kalijn F Bol.
Front Immunol, 2018 Oct 18; 9. PMID: 30327656    Free PMC article.
Highly Cited. Review.
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers.
Takefumi Komiya, Chao H Huang.
Front Oncol, 2018 Oct 20; 8. PMID: 30338242    Free PMC article.
Highly Cited. Review.
Durvalumab in NSCLC: latest evidence and clinical potential.
Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis Paz-Ares.
Ther Adv Med Oncol, 2018 Oct 23; 10. PMID: 30344651    Free PMC article.
Review.
Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials.
Qiuling Zhao, Ruixiang Xie, +2 authors, Xiuhua Weng.
Biomed Res Int, 2018 Oct 23; 2018. PMID: 30345301    Free PMC article.
Systematic Review.
Predictive biomarkers for tumor immune checkpoint blockade.
Mengting Tong, Jing Wang, +4 authors, Hongliang Zhang.
Cancer Manag Res, 2018 Oct 24; 10. PMID: 30349382    Free PMC article.
Review.
Atezolizumab in non-squamous non-small cell lung cancer.
Takaki Akamine, Gouji Toyokawa, Tetsuzo Tagawa, Takashi Seto.
J Thorac Dis, 2018 Oct 30; 10(Suppl 26). PMID: 30370103    Free PMC article.
Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit?
Mohammed Amine Achhal El Kadmiri, Arun Rajan.
J Thorac Dis, 2018 Oct 30; 10(Suppl 26). PMID: 30370113    Free PMC article.
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.
Samantha L Bucktrout, Jeffrey A Bluestone, Fred Ramsdell.
Genome Med, 2018 Nov 01; 10(1). PMID: 30376867    Free PMC article.
Review.
TIM-3 expression in breast cancer.
Samantha Burugu, Dongxia Gao, +2 authors, Torsten O Nielsen.
Oncoimmunology, 2018 Nov 01; 7(11). PMID: 30377566    Free PMC article.
A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer.
Jie Yin, Jingyin Dong, Wei Gao, Yina Wang.
Medicine (Baltimore), 2018 Nov 02; 97(44). PMID: 30383701    Free PMC article.
Histology versus cytology: PD-L1 testing in non-small cell lung cancer.
Nagio Takigawa, Nobuaki Ochi, Hiromichi Yamane.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393608    Free PMC article.
Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?
Wolfram C M Dempke, Klaus Fenchel, Stephen P Dale.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393621    Free PMC article.
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Alfredo Addeo, Giuseppe Luigi Banna.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393623    Free PMC article.
Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Giulio Metro, Massimo Di Maio.
Transl Lung Cancer Res, 2018 Nov 06; 7(Suppl 3). PMID: 30393625    Free PMC article.
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
A N Niemeijer, D Leung, +20 authors, A J de Langen.
Nat Commun, 2018 Nov 09; 9(1). PMID: 30405135    Free PMC article.
Highly Cited.
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.
Vamsidhar Velcheti, Pallavi D Patwardhan, +3 authors, Thomas Burke.
PLoS One, 2018 Nov 09; 13(11). PMID: 30408065    Free PMC article.
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance.
Xingxiang Pu, Lin Wu, +2 authors, Bingliang Fang.
BMC Cancer, 2018 Nov 10; 18(1). PMID: 30409126    Free PMC article.
Review.
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.
Cheng Xu, Yu-Pei Chen, +12 authors, Jun Ma.
BMJ, 2018 Nov 10; 363. PMID: 30409774    Free PMC article.
Highly Cited. Systematic Review.
TIM-3, a promising target for cancer immunotherapy.
Yayi He, Jie Cao, +3 authors, Fred R Hirsch.
Onco Targets Ther, 2018 Nov 10; 11. PMID: 30410357    Free PMC article.
Highly Cited. Review.
Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer.
Masaru Katoh.
J Thorac Dis, 2018 Nov 13; 10(9). PMID: 30416762    Free PMC article.
A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer.
Konstantin H Dragnev, Jeremy D Whyman, +4 authors, James R Rigas.
J Thorac Dis, 2018 Nov 13; 10(9). PMID: 30416803    Free PMC article.
Immunotherapy strategy of EGFR mutant lung cancer.
Shaorong Yu, Delin Liu, +2 authors, Jifeng Feng.
Am J Cancer Res, 2018 Nov 13; 8(10). PMID: 30416860    Free PMC article.
Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?
Wei Guo, Su Yang, +2 authors, Bo Lu.
J Thorac Dis, 2018 Nov 16; 10(Suppl 26). PMID: 30430027    Free PMC article.
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Francesco Sabbatino, Antonio Marra, +5 authors, Stefano Pepe.
J Immunother Cancer, 2018 Nov 22; 6(1). PMID: 30458852    Free PMC article.
Review.
Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials.
Nan Zhang, Nan Guo, Liang Tian, Zhigang Miao.
Oncotarget, 2018 Nov 22; 9(83). PMID: 30459935    Free PMC article.
Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis.
Yi Ming Weng, Min Peng, +2 authors, Qi Bin Song.
Onco Targets Ther, 2018 Nov 23; 11. PMID: 30464501    Free PMC article.
Review.
Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges.
N A Nixon, N Blais, +5 authors, S Verma.
Curr Oncol, 2018 Nov 23; 25(5). PMID: 30464687    Free PMC article.
Review.
Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer.
Xingxiang Pu, Ran Zhang, +13 authors, Bingliang Fang.
J Transl Med, 2018 Nov 28; 16(1). PMID: 30477533    Free PMC article.
B2M, JAK2 and MET in the genetic landscape of immunotolerance in lung cancer.
Montse Sanchez-Cespedes.
Oncotarget, 2018 Nov 28; 9(86). PMID: 30479688    Free PMC article.
The clinical utility of tumor mutational burden in non-small cell lung cancer.
Laurent Greillier, Pascale Tomasini, Fabrice Barlesi.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505708    Free PMC article.
Review.
Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.
Lizza E Hendriks, Etienne Rouleau, Benjamin Besse.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505709    Free PMC article.
Review.
Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?
Matthew Evans, Brendan O'Sullivan, Matthew Smith, Philippe Taniere.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505713    Free PMC article.
Review.
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC.
Niki Karachaliou, Manuel Fernandez-Bruno, Jillian Wilhelmina Paulina Bracht, Rafael Rosell.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505714    Free PMC article.
Review.
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment.
Stefan Diem, Mirjam Fässler, +9 authors, Lukas Flatz.
Cancer Manag Res, 2018 Dec 07; 10. PMID: 30519101    Free PMC article.
Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials.
Qingyuan Huang, Hua Zhang, +4 authors, Justin Stebbing.
Oncoimmunology, 2018 Dec 14; 7(12). PMID: 30524878    Free PMC article.
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.
Ammar Sukari, Misako Nagasaka, +9 authors, Shirish Gadgeel.
Anticancer Res, 2019 Feb 04; 39(2). PMID: 30711957    Free PMC article.
Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer.
M Provencio, E Carcereny, Á Artal.
Clin Transl Oncol, 2019 Mar 25; 21(11). PMID: 30903517
Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab.
Hayato Kawachi, Daichi Fujimoto, +7 authors, Keisuke Tomii.
Invest New Drugs, 2019 Apr 03; 37(6). PMID: 30937690
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.
Lucio Crinò, Paolo Bidoli, +17 authors, Domenico Galetta.
Oncologist, 2019 Apr 19; 24(11). PMID: 30996007    Free PMC article.
The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma.
Liang Peng, Jin-Qi Liu, Yu-Pei Chen, Jun Ma.
Br J Radiol, 2019 May 22; 92(1102). PMID: 31112398    Free PMC article.
Review.
The miRNA hsa-miR-6515-3p potentially contributes to lncRNA H19-mediated-lung cancer metastasis.
YouZu Xu, Jian Lin, +3 authors, JiaXi Feng.
J Cell Biochem, 2019 May 28; 120(10). PMID: 31131469    Free PMC article.
From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.
Deepa Rangachari, Daniel B Costa.
J Clin Oncol, 2019 Jun 04; 37(28). PMID: 31154918    Free PMC article.
Application of PD-1 Blockade in Cancer Immunotherapy.
Xiaomo Wu, Zhongkai Gu, +4 authors, Xiaolong Liu.
Comput Struct Biotechnol J, 2019 Jun 18; 17. PMID: 31205619    Free PMC article.
Highly Cited. Review.
Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Jingjing Liu, Shuang Li, +7 authors, Ying Cheng.
J Clin Lab Anal, 2019 Jul 10; 33(8). PMID: 31282096    Free PMC article.
Highly Cited.
Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma.
Hong Jian, Yuchen Han, Yongfeng Yu, Shun Lu.
Anticancer Drugs, 2019 Jul 10; 30(8). PMID: 31283542    Free PMC article.
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy.
Heng-Huan Lee, Ying-Nai Wang, +15 authors, Mien-Chie Hung.
Cancer Cell, 2019 Jul 23; 36(2). PMID: 31327656    Free PMC article.
Highly Cited.
Practical Application of Real-World Evidence in Developing Cancer Therapies.
Marjorie G Zauderer.
JCO Clin Cancer Inform, 2019 Jul 25; 3. PMID: 31335165    Free PMC article.
The biological functions and clinical applications of exosomes in lung cancer.
Rui Chen, Xin Xu, +6 authors, Yongchun Yu.
Cell Mol Life Sci, 2019 Jul 29; 76(23). PMID: 31352532
Review.
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Yoshiya Matsumoto, Kenji Sawa, +12 authors, Tomoya Kawaguchi.
Cancer Sci, 2019 Aug 02; 110(10). PMID: 31368625    Free PMC article.
Novel Delivery Systems for Checkpoint Inhibitors.
Purushottam Lamichhane, Rahul Deshmukh, +8 authors, Narottam Lamichhane.
Medicines (Basel), 2019 Aug 03; 6(3). PMID: 31373327    Free PMC article.
Review.
Imaging of Precision Therapy for Lung Cancer: Current State of the Art.
Hyesun Park, Lynette M Sholl, +2 authors, Mizuki Nishino.
Radiology, 2019 Aug 07; 293(1). PMID: 31385753    Free PMC article.
Review.
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Motohiro Tamiya, Akihiro Tamiya, +16 authors, Daichi Fujimoto.
Invest New Drugs, 2019 Aug 09; 37(6). PMID: 31392549
Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan.
Kosuke Sakai, Joji Kuramoto, +12 authors, Kazutsugu Uematsu.
Int J Clin Oncol, 2019 Aug 28; 24(12). PMID: 31452019
Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?
Adrien Costantini, Paul Takam Kamga, +3 authors, Etienne Giroux Leprieur.
Cancers (Basel), 2019 Sep 01; 11(9). PMID: 31470546    Free PMC article.
Review.
High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
Mari Tone, Takehiro Izumo, +8 authors, Hideo Kunitoh.
Thorac Cancer, 2019 Sep 05; 10(10). PMID: 31482678    Free PMC article.
Quantifying treatment effects using the personalized chance of longer survival.
Ying-Qi Zhao, Mary W Redman, Michael L LeBlanc.
Stat Med, 2019 Sep 11; 38(28). PMID: 31502297    Free PMC article.
Pembrolizumab-induced interstitial lung disease following thoracic surgery in a patient with non-small cell lung cancer.
Tetsuo Fujita, Nami Hayama, +9 authors, Sukeyuki Nakamura.
Thorac Cancer, 2019 Sep 13; 10(11). PMID: 31512401    Free PMC article.
[Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation 
in Non-small Cell Lung Cancer].
Xia Liu, Diansheng Zhong.
Zhongguo Fei Ai Za Zhi, 2019 Sep 19; 22(9). PMID: 31526463    Free PMC article.
Review.
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
Amber J Giles, Shuyu Hao, +18 authors, Deric M Park.
JCI Insight, 2019 Sep 20; 4(20). PMID: 31536478    Free PMC article.
Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Yu Chen, Gang Chen, +14 authors, Jian-Ji Pan.
JAMA Netw Open, 2019 Sep 21; 2(9). PMID: 31539077    Free PMC article.
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Kari M Morrissey, Mathilde Marchand, +8 authors, René Bruno.
Cancer Chemother Pharmacol, 2019 Sep 23; 84(6). PMID: 31542806    Free PMC article.
Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors.
Ewelina Grywalska, Małgorzata Sobstyl, Lechosław Putowski, Jacek Roliński.
Int J Mol Sci, 2019 Sep 25; 20(19). PMID: 31547532    Free PMC article.
Review.
Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Steven D Criss, Meghan J Mooradian, +3 authors, Chung Yin Kong.
JAMA Netw Open, 2019 Sep 26; 2(9). PMID: 31553470    Free PMC article.
Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities.
Antonio Santaniello, Fabiana Napolitano, +5 authors, Roberto Bianco.
Cancers (Basel), 2019 Sep 27; 11(10). PMID: 31554160    Free PMC article.
Review.
Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients.
Valentina Magri, Teodor Gottfried, +6 authors, Amir Onn.
Cancer Manag Res, 2019 Oct 01; 11. PMID: 31564979    Free PMC article.
Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?
Hira Latif, Stephen V Liu.
Ann Transl Med, 2019 Oct 03; 7(Suppl 3). PMID: 31576285    Free PMC article.
Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain.
Jose M Pacheco, Dexiang Gao, D Ross Camidge.
Ann Transl Med, 2019 Oct 03; 7(Suppl 3). PMID: 31576334    Free PMC article.
Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
Willemijn S M E Theelen, Paul Baas.
Ann Transl Med, 2019 Oct 03; 7(Suppl 3). PMID: 31576347    Free PMC article.
Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.
Valli De Re, Laura Caggiari, +2 authors, Maurizio Mascarin.
J Clin Med, 2019 Oct 05; 8(10). PMID: 31581738    Free PMC article.
Review.
Local ablative radiotherapy for oligometastatic non-small cell lung cancer.
Yang-Gun Suh, Jaeho Cho.
Radiat Oncol J, 2019 Oct 09; 37(3). PMID: 31591862    Free PMC article.
Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: A single-center experience.
Aneet Kaur, Taylor Doberstein, +3 authors, Namrata Singh.
Medicine (Baltimore), 2019 Oct 09; 98(41). PMID: 31593084    Free PMC article.
Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.
Aung Myint Tun, Kyaw Zin Thein, Wai Lin Thein, Elizabeth Guevara.
Future Sci OA, 2019 Oct 15; 5(9). PMID: 31608159    Free PMC article.
Review.
Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis.
Mike Nguyen, Md Rafiqul Islam, +2 authors, Babak Tamjid.
Front Oncol, 2019 Oct 15; 9. PMID: 31608234    Free PMC article.
Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer.
Hongge Liang, Mengzhao Wang.
Cancer Manag Res, 2019 Oct 17; 11. PMID: 31616186    Free PMC article.
Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature.
Hiroki Izumi, Masahiro Kodani, +13 authors, Akira Yamasaki.
Mol Clin Oncol, 2019 Oct 17; 11(5). PMID: 31616560    Free PMC article.
Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood.
Mariana Aris, Alicia Inés Bravo, +8 authors, José Mordoh.
Front Immunol, 2019 Oct 18; 10. PMID: 31620131    Free PMC article.
Immunotherapy of brain metastases: breaking a "dogma".
Anna Maria Di Giacomo, Monica Valente, +6 authors, Michele Maio.
J Exp Clin Cancer Res, 2019 Oct 19; 38(1). PMID: 31623643    Free PMC article.
Review.
Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer.
Yi-Ming Li, Jing-Min Yu, +3 authors, Zhi-Nan Chen.
Int J Mol Sci, 2019 Oct 20; 20(20). PMID: 31627272    Free PMC article.
KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49.
Daniel Morgensztern.
J Thorac Dis, 2019 Oct 22; 11(Suppl 15). PMID: 31632798    Free PMC article.
Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis.
Ya-Fang Huang, Wen-Jie Xie, Hai-Yu Fan, Juan Du.
Front Oncol, 2019 Oct 22; 9. PMID: 31632907    Free PMC article.
Systematic Review.
Structural and In Vitro Functional Analyses of Novel Plant-Produced Anti-Human PD1 Antibody.
Kaewta Rattanapisit, Tanapati Phakham, +7 authors, Waranyoo Phoolcharoen.
Sci Rep, 2019 Oct 28; 9(1). PMID: 31645587    Free PMC article.
Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
Takeo Hasegawa, Yuki Ozaki, +8 authors, Hiroyuki Suzuki.
J Med Case Rep, 2019 Oct 28; 13(1). PMID: 31647029    Free PMC article.
Review.
Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
David Lang, Florian Huemer, +9 authors, Bernd Lamprecht.
Target Oncol, 2019 Oct 28; 14(6). PMID: 31654203    Free PMC article.
Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab.
Taro Ohba, Shinkichi Takamori, +9 authors, Mitsuhiro Takenoyama.
J Thorac Dis, 2019 Oct 28; 11(9). PMID: 31656648    Free PMC article.
Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer.
Guanghui Gao, Meng Qiao, +8 authors, Caicun Zhou.
J Thorac Dis, 2019 Oct 28; 11(9). PMID: 31656652    Free PMC article.
A modified recursive partitioning analysis for predicting overall survival in patients with non-small cell lung cancer and central nervous system metastases.
Thiago Pimentel Muniz, Victor Hugo Fonseca de Jesus, +2 authors, Vladmir Cláudio Cordeiro de Lima.
J Thorac Dis, 2019 Oct 28; 11(9). PMID: 31656665    Free PMC article.
Are we facing a cure in lung cancer?-KEYNOTE-001 insights.
Aharon Y Cohen, Waleed Kian, +3 authors, Yulia Dudnik.
Ann Transl Med, 2019 Oct 28; 7(Suppl 6). PMID: 31656794    Free PMC article.
PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer.
Andrew Bang, Jonathan D Schoenfeld, Alexander Y Sun.
Transl Lung Cancer Res, 2019 Nov 02; 8(Suppl 2). PMID: 31673518    Free PMC article.
Review.
Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.
Yuzo Suzuki, Naoki Inui, +17 authors, Takafumi Suda.
Int J Chron Obstruct Pulmon Dis, 2019 Nov 07; 14. PMID: 31686799    Free PMC article.
The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
Qing-Qing Chai, Jiang-Yang Du, Jun Zhu, Bin Wu.
Front Pharmacol, 2019 Nov 12; 10. PMID: 31708783    Free PMC article.
Systematic Review.
Neoadjuvant treatment with tyrosine kinase inhibitors in patients with resectable non-small cell lung cancer.
Fernando Franco, Mariano Provencio.
J Thorac Dis, 2019 Nov 19; 11(10). PMID: 31737290    Free PMC article.
Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?
Debora Bruno, Afshin Dowlati.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737508    Free PMC article.
Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?
Andrew J Piper, Kartik Sehgal, Daniel B Costa, Deepa Rangachari.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737509    Free PMC article.
KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?
Jose M Pacheco.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737510    Free PMC article.
Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis.
Hazem E El-Osta, Frank E Mott, +2 authors, Anita L Sabichi.
Oncoimmunology, 2019 Nov 20; 8(12). PMID: 31741764    Free PMC article.
Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients.
Takuya Aoki, Takeshi Akiba, +21 authors, Koichiro Asano.
Respir Res, 2019 Nov 23; 20(1). PMID: 31752884    Free PMC article.
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Marika Cinausero, Noemi Laprovitera, +13 authors, Andrea Ardizzoni.
Ther Adv Med Oncol, 2019 Dec 05; 11. PMID: 31798692    Free PMC article.
Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
Kana Kurokawa, Munechika Hara, +6 authors, Kazuhisa Takahashi.
Intern Med, 2019 Nov 19; 58(22). PMID: 31735738    Free PMC article.
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer.
Lorenza Landi, Federica D'Incà, +18 authors, Federico Cappuzzo.
J Immunother Cancer, 2019 Nov 23; 7(1). PMID: 31752994    Free PMC article.
[A Single Center Analysis of Advanced Non-small Cell Lung Cancer Patients Treated with Immunotherapy in Real-world Practice].
Yanxia Liu, Tongmei Zhang, +7 authors, Baolan Li.
Zhongguo Fei Ai Za Zhi, 2019 Nov 28; 22(11). PMID: 31771737    Free PMC article.
Immune checkpoint inhibitors win the 2018 Nobel Prize.
Pei-Wei Huang, John Wen-Cheng Chang.
Biomed J, 2019 Dec 01; 42(5). PMID: 31783990    Free PMC article.
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway.
Grace Wakabayashi, Yu-Ching Lee, +3 authors, Yun Yen.
J Biomed Sci, 2019 Dec 06; 26(1). PMID: 31801525    Free PMC article.
Review.
Setting the scene - a future 'epidemic' of immune-related adverse events in association with checkpoint inhibitor therapy.
Maria V Bermudez, Sophie Papa.
Rheumatology (Oxford), 2019 Dec 10; 58(Suppl 7). PMID: 31816083    Free PMC article.
Review.
Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma.
Aruna Nambirajan, Nuzhat Husain, +2 authors, Deepali Jain.
Indian J Med Res, 2019 Dec 12; 150(4). PMID: 31823919    Free PMC article.
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer.
Carmine Carbone, Geny Piro, +9 authors, Emilio Bria.
Mediators Inflamm, 2019 Dec 13; 2019. PMID: 31827379    Free PMC article.
Review.
Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.
Sean Khozin, Rebecca A Miksad, +10 authors, Amy P Abernethy.
Cancer, 2019 Aug 06; 125(22). PMID: 31381142    Free PMC article.
Biomarker for personalized immunotherapy.
Si-Yang Liu, Yi-Long Wu.
Transl Lung Cancer Res, 2019 Dec 21; 8(Suppl 3). PMID: 31857954    Free PMC article.
Review.
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.
Jong Yeob Kim, Keum Hwa Lee, +12 authors, Gabriele Gamerith.
Cancers (Basel), 2019 Nov 07; 11(11). PMID: 31683809    Free PMC article.
Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target.
Frank Aboubakar Nana, Marie Vanderputten, Sebahat Ocak.
Cancers (Basel), 2019 Nov 02; 11(11). PMID: 31671774    Free PMC article.
Review.
Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Jong Yeob Kim, Andreas Kronbichler, +5 authors, Gabriele Gamerith.
Cancers (Basel), 2019 Nov 17; 11(11). PMID: 31731749    Free PMC article.
Retrospective Evaluation of Lung Adenocarcinoma Patients Progressing on 1st Line Chemotherapy.
Heikki Vilhonen, Samu Kurki, Tarja Laitinen, Samuli Hirsjärvi.
Medicina (Kaunas), 2019 Nov 21; 55(11). PMID: 31744064    Free PMC article.
The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases.
Fabio Cofano, Matteo Monticelli, +10 authors, Diego Garbossa.
Cancer Control, 2019 Dec 24; 26(1). PMID: 31865766    Free PMC article.
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.
Min Yuan, Li-Li Huang, +2 authors, Qing Xu.
Signal Transduct Target Ther, 2019 Dec 25; 4. PMID: 31871778    Free PMC article.
Highly Cited. Review.
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
M D Hellmann, T-W Kim, +18 authors, J Bendell.
Ann Oncol, 2019 Mar 29; 30(7). PMID: 30918950    Free PMC article.
Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Elizabeth Ahern, Annette Cubitt, +7 authors, Brett G M Hughes.
Trials, 2019 Dec 21; 20(1). PMID: 31856909    Free PMC article.
Bone Metastasis: Current State of Play.
Anthony Turpin, Martine Duterque-Coquillaud, Marie-Hélène Vieillard.
Transl Oncol, 2019 Dec 27; 13(2). PMID: 31877463    Free PMC article.
Review.
The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies.
Kroopa Joshi, Benjamin M Chain, Karl S Peggs, Sergio A Quezada.
Cold Spring Harb Perspect Med, 2017 Jun 21; 8(1). PMID: 28630228    Free PMC article.
Review.
Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report.
Hirokazu Tokuyasu, Mika Horie, +3 authors, Akira Yamasaki.
Respir Med Case Rep, 2019 Dec 31; 29. PMID: 31886125    Free PMC article.
Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens.
Lei Zhao, Jing Yu, +3 authors, Bangwei Cao.
J Cancer, 2020 Jan 02; 11(1). PMID: 31892971    Free PMC article.
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Jacqulyne P Robichaux, Yasir Y Elamin, +28 authors, John V Heymach.
Cancer Cell, 2019 Oct 08; 36(4). PMID: 31588020    Free PMC article.
Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.
Kohei Fujita, Yuki Yamamoto, +5 authors, Tadashi Mio.
Thorac Cancer, 2019 Nov 09; 11(1). PMID: 31701630    Free PMC article.
Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC.
Arik Bernard Schulze, Lars Henning Schmidt, +8 authors, Georg Evers.
Thorac Cancer, 2019 Nov 25; 11(1). PMID: 31760702    Free PMC article.
The effect of PD-L1/PD-1 immunotherapy in the treatment of squamous non-small-cell lung cancer: a meta-analysis of randomized controlled clinical trials.
Shuang Li, Shuang Zhang, +3 authors, Ying Cheng.
J Thorac Dis, 2020 Jan 07; 11(11). PMID: 31903233    Free PMC article.
Osteoclast-like Giant Cell-type Pancreatic Anaplastic Carcinoma Presenting with a Duodenal Polypoid Lesion.
Hiroyuki Matsubayashi, Junichi Kaneko, +7 authors, Hiroyuki Ono.
Intern Med, 2019 Aug 30; 58(24). PMID: 31462592    Free PMC article.
Efficacy of anti-PD-1 therapy for recurrence after chemoradiotherapy in locally advanced NSC LC.
Yoshiaki Amino, Satoru Kitazono, +8 authors, Makoto Nishio.
Int J Clin Oncol, 2019 Sep 12; 25(1). PMID: 31506751
Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Jon Zugazagoitia, Yuting Liu, +8 authors, David L Rimm.
J Thorac Oncol, 2019 Oct 13; 14(12). PMID: 31605795    Free PMC article.
[Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors].
Guoqiang Pan, Yun Fan.
Zhongguo Fei Ai Za Zhi, 2019 Dec 26; 22(12). PMID: 31874675    Free PMC article.
Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer.
Haipeng Xu, Xueyan Chen, +4 authors, Xianfen Zhang.
Onco Targets Ther, 2020 Jan 11; 12. PMID: 31920342    Free PMC article.
Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis.
Jing Qi, Liming Xu, +2 authors, Lujun Zhao.
Cancer Manag Res, 2020 Jan 11; 11. PMID: 31920386    Free PMC article.
Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies.
Jingli Lu, Jing Yang, +3 authors, Xiaojian Zhang.
Front Pharmacol, 2020 Jan 11; 10. PMID: 31920646    Free PMC article.
Systematic Review.
Isolation and Identification of Cancer Stem-Like Cells in Adenocarcinoma and Squamous Cell Carcinoma of the Lung: A Pilot Study.
Valentina Masciale, Giulia Grisendi, +7 authors, Beatrice Aramini.
Front Oncol, 2020 Jan 11; 9. PMID: 31921651    Free PMC article.
Maximum Somatic Allele Frequency in Combination With Blood-Based Tumor Mutational Burden to Predict the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer: A Pooled Analysis of the Randomized POPLAR and OAK Studies.
Yu-Tong Chen, Sharvesh Raj Seeruttun, Xiang-Yuan Wu, Zi-Xian Wang.
Front Oncol, 2020 Jan 11; 9. PMID: 31921683    Free PMC article.
Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer.
Qian Chen, Yi-Yun Fu, +5 authors, Li-Li Jiang.
Int J Clin Exp Pathol, 2020 Jan 15; 12(3). PMID: 31933885    Free PMC article.
Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer.
Zhengwei Dong, Yiwei Liu, +16 authors, Fred R Hirsch.
J Cancer, 2020 Jan 17; 11(3). PMID: 31942178    Free PMC article.
Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer.
Fan Zhang, Di Huang, +13 authors, Yi Hu.
J Cancer, 2020 Jan 17; 11(3). PMID: 31942197    Free PMC article.
Challenges of evaluating immunotherapy efficacy in solid tumors.
Rilan Bai, Wenqian Li, Nawen Du, Jiuwei Cui.
Chin J Cancer Res, 2020 Jan 18; 31(6). PMID: 31949388    Free PMC article.
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Barbara Melosky, Rosalyn Juergens, +5 authors, Quincy Chu.
Oncologist, 2019 May 30; 25(1). PMID: 31138727    Free PMC article.
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Hiroyuki Nishiyama, Yoshiaki Yamamoto, +13 authors, Joaquim Bellmunt.
Int J Clin Oncol, 2019 Nov 16; 25(1). PMID: 31729625    Free PMC article.
Current Status of Immunotherapy for Lung Cancer and Future Perspectives.
Ho Cheol Kim, Chang Min Choi.
Tuberc Respir Dis (Seoul), 2020 Jan 07; 83(1). PMID: 31905428    Free PMC article.
Review.
Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP).
Carol C Cheung, Penny Barnes, +27 authors, Canadian Association of Pathologists-Association Canadienne Des Pathologistes’ National Standards Committee for High Complexity Testing (CAP-ACP NSCHCT).
Appl Immunohistochem Mol Morphol, 2019 Oct 05; 27(10). PMID: 31584451    Free PMC article.
Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer: A systematic review and meta-analysis.
Jian Xie, Zewen Zhang, +4 authors, Yuan Tian.
Medicine (Baltimore), 2019 Dec 20; 98(50). PMID: 31852114    Free PMC article.
Systematic Review.
Preliminary data on circulating tumor cells in metastatic NSCLC patients candidate to immunotherapy.
Simona Monterisi, Angelo Castello, +4 authors, Egesta Lopci.
Am J Nucl Med Mol Imaging, 2020 Jan 25; 9(6). PMID: 31976158    Free PMC article.
Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries.
Biancamaria Cembrola, Valentino Ruzza, +13 authors, Alfredo Nicosia.
Biomed Res Int, 2020 Jan 25; 2019. PMID: 31976323    Free PMC article.
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors.
Nicholas Gravbrot, Kacy Gilbert-Gard, +4 authors, Srinath Sundararajan.
Antibodies (Basel), 2019 Oct 24; 8(4). PMID: 31640266    Free PMC article.
Review.
Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis.
Jiahang Mo, Xiao Hu, +7 authors, Jiequan Liu.
World J Surg Oncol, 2020 Jan 22; 18(1). PMID: 31959178    Free PMC article.
Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer.
Sohyun Hwang, Ah-Young Kwon, +7 authors, Hee Jung An.
Sci Rep, 2020 Jan 22; 10(1). PMID: 31959763    Free PMC article.
First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.
Thierry Landre, Gaetan Des Guetz, +3 authors, Christos Chouaïd.
J Cancer Res Clin Oncol, 2019 Nov 07; 146(2). PMID: 31686247
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Hayato Kawachi, Motohiro Tamiya, +17 authors, Toru Kumagai.
Invest New Drugs, 2019 Dec 01; 38(1). PMID: 31784866
Cancer immunotherapy experience in the Integral Oncology Centre "Diana Laura Riojas de Colosio", Médica Sur Hospital.
Ricardo Fernández-Ferreira, Daniel Motola-Kuba, +2 authors, María Eugenia Torres-Pérez.
Contemp Oncol (Pozn), 2020 Jan 30; 23(4). PMID: 31992957    Free PMC article.
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Tina Krieger, Isobel Pearson, +2 authors, Paul Robbins.
Diagn Pathol, 2020 Feb 01; 15(1). PMID: 32000815    Free PMC article.
Review.
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort.
Arsela Prelaj, Roberto Ferrara, +19 authors, Giuseppe Lo Russo.
Cancers (Basel), 2019 Dec 11; 11(12). PMID: 31817541    Free PMC article.
Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials.
Stéphane Faury, Jérôme Foucaud.
PLoS One, 2020 Jan 25; 15(1). PMID: 31978145    Free PMC article.
Systematic Review.
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
Wungki Park, Laura Mezquita, +14 authors, Gilberto Lopes.
Br J Cancer, 2019 Nov 26; 122(3). PMID: 31761899    Free PMC article.
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Alejandro Ruiz-Patiño, Oscar Arrieta, +28 authors, CLICaP.
Thorac Cancer, 2019 Dec 13; 11(2). PMID: 31828967    Free PMC article.
Combined Atezolizumab and Chemotherapy for a Patient With Double Primary Cancers.
Shinichiro Okauchi, Yuika Sasatani, +2 authors, Hiroaki Satoh.
In Vivo, 2019 Dec 29; 34(1). PMID: 31882503    Free PMC article.
Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer.
Yajun Sun, Changyun Zhai, +4 authors, Tao Jiang.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010554    Free PMC article.
The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer.
Yuki Katayama, Tadaaki Yamada, +4 authors, Koichi Takayama.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010563    Free PMC article.
Analysis of the association between prior chemotherapy regimens and outcomes of subsequent anti-PD-(L)1 monotherapy in advanced non-small cell lung cancer.
Guanghui Gao, Keyi Jia, +7 authors, Caicun Zhou.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010570    Free PMC article.
Presence of allele frequency heterogeneity defined by ctDNA profiling predicts unfavorable overall survival of NSCLC.
Zhichao Liu, Zhanhong Xie, +12 authors, Wenhua Liang.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010581    Free PMC article.
Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy.
Juan Ruiz-Bañobre, María C Areses-Manrique, +12 authors, Sergio Vázquez.
Transl Lung Cancer Res, 2020 Feb 06; 8(6). PMID: 32010585    Free PMC article.
Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?
Cesare Gridelli, Assunta Sgambato.
Ann Transl Med, 2020 Feb 06; 7(Suppl 8). PMID: 32016001    Free PMC article.
The role of immune checkpoint inhibitors (ICI) in the treatment of metastatic non-small cell lung carcinoma in the elderly.
Johan Chan, Ravindran Kanesvaran.
Ann Transl Med, 2020 Feb 06; 7(Suppl 8). PMID: 32016101    Free PMC article.
Beyond PD-L1 Markers for Lung Cancer Immunotherapy.
Kamila Wojas-Krawczyk, Ewa Kalinka, +2 authors, Janusz Milanowski.
Int J Mol Sci, 2019 Apr 21; 20(8). PMID: 31003463    Free PMC article.
Review.
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort.
Giulio Metro, Alfredo Addeo, +19 authors, Giannis Mountzios.
J Thorac Dis, 2020 Feb 08; 11(12). PMID: 32030213    Free PMC article.
Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.
Yuichi Saito, Sho Horiuchi, +5 authors, Eishin Hoshi.
J Thorac Dis, 2020 Feb 08; 11(12). PMID: 32030214    Free PMC article.
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Jianchun Duan, Longgang Cui, +17 authors, Jie Wang.
JAMA Oncol, 2019 Dec 27; 6(3). PMID: 31876895    Free PMC article.
Systematic Review.
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Ganessan Kichenadasse, John O Miners, +3 authors, Michael J Sorich.
JAMA Oncol, 2019 Dec 27; 6(4). PMID: 31876896    Free PMC article.
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
Corey J Langer, Mary W Redman, +11 authors, Vassiliki A Papadimitrakopoulou.
J Thorac Oncol, 2019 Jun 04; 14(10). PMID: 31158500    Free PMC article.
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
E M Presotto, G Rastrelli, +10 authors, A Peri.
J Endocrinol Invest, 2019 Sep 23; 43(3). PMID: 31542865
Targeted next-generation sequencing to assess tumor mutation burden: ready for prime-time in non-small cell lung cancer?
Pascale Tomasini, Laurent Greillier.
Transl Lung Cancer Res, 2020 Feb 11; 8(Suppl 4). PMID: 32038906    Free PMC article.
Broad-based genomic sequencing in advanced non-small cell lung cancer in the dock.
Caterina Fumagalli, Elena Guerini-Rocco, Massimo Barberis.
Transl Lung Cancer Res, 2020 Feb 11; 8(Suppl 4). PMID: 32038915    Free PMC article.
Inhibition Mechanism of Indoleamine 2, 3-Dioxygenase 1 (IDO1) by Amidoxime Derivatives and Its Revelation in Drug Design: Comparative Molecular Dynamics Simulations.
Xinyu Liu, Yiwen Zhang, +7 authors, Hubing Shi.
Front Mol Biosci, 2020 Feb 13; 6. PMID: 32047753    Free PMC article.
Sequential MR Image-Guided Local Immune Checkpoint Blockade Cancer Immunotherapy Using Ferumoxytol Capped Ultralarge Pore Mesoporous Silica Carriers after Standard Chemotherapy.
Bongseo Choi, Huijin Jung, +3 authors, Dong-Hyun Kim.
Small, 2019 Nov 08; 15(52). PMID: 31697036    Free PMC article.
Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.
Dan Pu, Liyuan Yin, +4 authors, Qinghua Zhou.
Medicine (Baltimore), 2020 Feb 01; 99(5). PMID: 32000444    Free PMC article.
Systematic Review.
In Search of the Long-Desired 'Copernican Therapeutic Revolution' in Small-Cell Lung Cancer.
Noemí Reguart, Elba Marin, +2 authors, Cristina Teixido.
Drugs, 2020 Jan 09; 80(3). PMID: 31912414
Review.
Tumor Time-Course Predicts Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow-Up Time.
Ida Netterberg, René Bruno, +4 authors, Lena E Friberg.
CPT Pharmacometrics Syst Pharmacol, 2020 Jan 29; 9(2). PMID: 31991070    Free PMC article.
Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment.
Christine Hsu, John L Marshall, Aiwu Ruth He.
Oncologist, 2020 Feb 12; 25(2). PMID: 32043797    Free PMC article.
[Expert Consensus on the Diagnosis and Treatment of Bone Metastasis in Lung Cancer (2019 Version)].
Youth Specialists Committee of Lung Cancer, Beijing Medical Award Foundaton, Chinese Lung Cancer Union.
Zhongguo Fei Ai Za Zhi, 2019 Apr 25; 22(4). PMID: 31014437    Free PMC article.
Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis.
Xuewen Wang, Shijie Wu, +4 authors, Xiong Chen.
Front Pharmacol, 2020 Feb 23; 11. PMID: 32076409    Free PMC article.
Systematic Review.
Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer.
Bin Zhao, Hong Zhao, Jiaxin Zhao.
Ther Adv Med Oncol, 2020 Feb 23; 12. PMID: 32082425    Free PMC article.
[Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer].
Shuyang Yao, Yi Zhang.
Zhongguo Fei Ai Za Zhi, 2020 Jan 18; 23(1). PMID: 31948539    Free PMC article.
The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Chengdi Wang, Wenliang Qiao, +5 authors, Weimin Li.
J Cell Physiol, 2019 Nov 07; 235(5). PMID: 31693178    Free PMC article.
Systematic Review.
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.
Ferdinandos Skoulidis, John V Heymach.
Nat Rev Cancer, 2019 Aug 14; 19(9). PMID: 31406302    Free PMC article.
Highly Cited. Review.
The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
Rui Kitadai, Yusuke Okuma, Taiki Hakozaki, Yukio Hosomi.
J Cancer Res Clin Oncol, 2019 Dec 13; 146(3). PMID: 31828427
Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.
Hiroyuki Inoue, Isamu Okamoto.
Lung Cancer (Auckl), 2020 Feb 27; 10. PMID: 32099495    Free PMC article.
Review.
Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.
Federico Nichetti, Francesca Ligorio, +11 authors, Marina Chiara Garassino.
Cancers (Basel), 2019 Dec 29; 12(1). PMID: 31881699    Free PMC article.
Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy.
Julijan Kabiljo, Felix Harpain, Sebastian Carotta, Michael Bergmann.
Cancers (Basel), 2020 Jan 08; 12(1). PMID: 31905723    Free PMC article.
Review.
Behavioral, psychological, and supportive care interventions in geriatric oncology: The Cancer and Aging Research Group infrastructure core.
Rawad Elias, Kah Poh Loh, +5 authors, Supriya Mohile.
J Geriatr Oncol, 2019 Aug 07; 11(2). PMID: 31383630    Free PMC article.
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.
Selene Ottonello, Carlo Genova, +16 authors, Gabriella Pietra.
Front Immunol, 2020 Mar 03; 11. PMID: 32117275    Free PMC article.
Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
Peng Song, Jingcheng Zhang, Congcong Shang, Li Zhang.
Sci Rep, 2019 Mar 14; 9(1). PMID: 30862891    Free PMC article.
Neuropsychiatric Immune-related Adverse Events Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma and Systemic Lupus Erythematosus.
Misato Jono, Yuhei Kinehara, +10 authors, Isao Tachibana.
Intern Med, 2019 Nov 02; 59(4). PMID: 31666468    Free PMC article.
Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Ning Wan, Tian-Tian Zhang, +7 authors, Jian Li.
Cancer Med, 2020 Jan 17; 9(5). PMID: 31945265    Free PMC article.
Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR / ALK wild-type advanced non-small cell lung cancer.
Xiao-Xiao Peng, Ruoying Yu, +9 authors, Qing Zhou.
J Immunother Cancer, 2020 Jan 22; 8(1). PMID: 31959728    Free PMC article.
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
Ryoji Kato, Hidetoshi Hayashi, +19 authors, Kazuhiko Nakagawa.
J Immunother Cancer, 2020 Feb 19; 8(1). PMID: 32066647    Free PMC article.
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
Flora Mulkey, Marc R Theoret, +2 authors, Rajeshwari Sridhara.
J Immunother Cancer, 2020 Feb 29; 8(1). PMID: 32107275    Free PMC article.
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders.
Giulia C Leonardi, Justin F Gainor, +8 authors, Mark M Awad.
J Clin Oncol, 2018 May 11; 36(19). PMID: 29746230    Free PMC article.
Highly Cited.
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients.
Ida Netterberg, Chi-Chung Li, +5 authors, Lena E Friberg.
Clin Pharmacol Ther, 2018 Jul 31; 105(2). PMID: 30058723    Free PMC article.
Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
Howard L Kaufman, Lawrence H Schwartz, +5 authors, Andrea Vergara-Silva.
J Cancer Res Clin Oncol, 2018 Aug 23; 144(11). PMID: 30132118
Systematic Review.
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
Karthik Suresh, Jarushka Naidoo, Cheng Ting Lin, Sonye Danoff.
Chest, 2018 Sep 07; 154(6). PMID: 30189190    Free PMC article.
Highly Cited. Review.
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Leisha A Emens, Cristina Cruz, +16 authors, Peter Schmid.
JAMA Oncol, 2018 Sep 23; 5(1). PMID: 30242306    Free PMC article.
Highly Cited.
Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma.
Hui Yu, Zhengming Chen, +21 authors, Fred R Hirsch.
J Thorac Oncol, 2018 Sep 27; 14(1). PMID: 30253973    Free PMC article.
Critical Appraisal of Programmed Death Ligand 1 Reflex Diagnostic Testing: Current Standards and Future Opportunities.
Matthew P Humphries, Stephen McQuaid, +9 authors, Manuel Salto-Tellez.
J Thorac Oncol, 2018 Oct 09; 14(1). PMID: 30296485    Free PMC article.
Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy.
Martina Vrankar, Mojca Unk.
Radiol Oncol, 2018 Oct 28; 52(4). PMID: 30367809    Free PMC article.
Systematic Review.
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.
Francesco Passiglia, Federico Cappuzzo, +19 authors, Domenico Galetta.
Br J Cancer, 2018 Nov 01; 120(1). PMID: 30377342    Free PMC article.
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
Harriet M Kluger, Veronica Chiang, +14 authors, Lucia B Jilaveanu.
J Clin Oncol, 2018 Nov 09; 37(1). PMID: 30407895    Free PMC article.
Highly Cited.
PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.
Laure Hirsch, Laurence Zitvogel, Alexander Eggermont, Aurelien Marabelle.
Br J Cancer, 2018 Nov 11; 120(1). PMID: 30413824    Free PMC article.
Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Eri Ishikawa, Seiichi Kato, +11 authors, Yoshiki Hirooka.
Cancer Med, 2018 Nov 19; 7(12). PMID: 30449068    Free PMC article.
Product review: avelumab, an anti-PD-L1 antibody.
Julie M Collins, James L Gulley.
Hum Vaccin Immunother, 2018 Nov 28; 15(4). PMID: 30481100    Free PMC article.
Review.
Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Steven D Criss, Meghan J Mooradian, +5 authors, Chung Yin Kong.
JAMA Oncol, 2018 Dec 14; 5(3). PMID: 30543349    Free PMC article.
Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment.
A Pawłowska, D Suszczyk, +3 authors, I Wertel.
Clin Exp Immunol, 2018 Dec 26; 195(3). PMID: 30582756    Free PMC article.
Review.
Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.
Keisuke Baba, Hisashi Tanaka, +6 authors, Sadatomo Tasaka.
Thorac Cancer, 2019 Jan 03; 10(2). PMID: 30600919    Free PMC article.
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis.
Christopher J D Wallis, Mohit Butaney, +5 authors, Zachary Klaassen.
JAMA Oncol, 2019 Jan 04; 5(4). PMID: 30605213    Free PMC article.
Highly Cited. Systematic Review.
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, +14 authors, James L Gulley.
JAMA Oncol, 2019 Jan 25; 5(3). PMID: 30676622    Free PMC article.
Highly Cited.
GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
Adriaan A van Beek, Guoying Zhou, +14 authors, Jaap Kwekkeboom.
Int J Cancer, 2019 Feb 06; 145(4). PMID: 30719701    Free PMC article.
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Rui Chen, Xiaoming Hou, Liping Yang, Da Zhao.
Thorac Cancer, 2019 Feb 09; 10(4). PMID: 30734504    Free PMC article.
Systematic Review.
Base excision repair regulates PD-L1 expression in cancer cells.
Tiara Bunga Mayang Permata, Yoshihiko Hagiwara, +6 authors, Atsushi Shibata.
Oncogene, 2019 Feb 14; 38(23). PMID: 30755733
PD-L1 and tumor-associated macrophages in de novo DLBCL.
Ronald McCord, Christopher R Bolen, +5 authors, Jeffrey M Venstrom.
Blood Adv, 2019 Feb 17; 3(4). PMID: 30770362    Free PMC article.
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Jong Woo Lee, Yu Zhang, +11 authors, Ja Seok Koo.
J Thorac Oncol, 2019 Feb 17; 14(6). PMID: 30771521    Free PMC article.
Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Qiang Su, Emily C Zhu, +4 authors, Zu-Hua Gao.
Front Immunol, 2019 Feb 20; 10. PMID: 30778352    Free PMC article.
Systematic Review.
Curative effect assessment of immunotherapy for non-small cell lung cancer: The "blind area" of Immune Response Evaluation Criteria in Solid Tumors (iRECIST).
Peng Song, Jingcheng Zhang, Congcong Shang, Li Zhang.
Thorac Cancer, 2019 Feb 20; 10(4). PMID: 30779329    Free PMC article.
Review.
Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Norimichi Akiyama, Masato Karayama, +17 authors, Takafumi Suda.
Invest New Drugs, 2019 Feb 23; 37(3). PMID: 30790149
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer.
Tadaaki Yamada, Soichi Hirai, +14 authors, Koichi Takayama.
Cancer Med, 2019 Feb 23; 8(4). PMID: 30790471    Free PMC article.
Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
Ilke Tunali, Jhanelle E Gray, +5 authors, Matthew B Schabath.
Lung Cancer, 2019 Feb 25; 129. PMID: 30797495    Free PMC article.
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Liliang Xia, Yuanyong Liu, Ying Wang.
Oncologist, 2019 Mar 02; 24(Suppl 1). PMID: 30819829    Free PMC article.
Review.
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Deborah B Doroshow, Miguel F Sanmamed, +6 authors, Roy S Herbst.
Clin Cancer Res, 2019 Mar 03; 25(15). PMID: 30824587    Free PMC article.
Highly Cited. Review.
The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy.
Gui-Zhen Wang, Li Zhang, +11 authors, Guang-Biao Zhou.
Nat Commun, 2019 Mar 10; 10(1). PMID: 30850589    Free PMC article.
Highly Cited.
Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer.
P K Cheema, J Rothenstein, +2 authors, V Hirsh.
Curr Oncol, 2019 Mar 12; 26(1). PMID: 30853796    Free PMC article.
Review.
Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.
S A Laurie, S Banerji, +15 authors, M S Tsao.
Curr Oncol, 2019 Mar 12; 26(1). PMID: 30853813    Free PMC article.
Efficacy and safety of immune checkpoint blockade for brain metastases.
Maya Harary, David A Reardon, J Bryan Iorgulescu.
CNS Oncol, 2019 Mar 12; 8(2). PMID: 30854898    Free PMC article.
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
Re-I Chin, Kevin Chen, +6 authors, Aadel A Chaudhuri.
Mol Diagn Ther, 2019 Apr 04; 23(3). PMID: 30941670    Free PMC article.
Review.
Risk of immune-related pneumonitis for PD1/PD-L1 inhibitors: Systematic review and network meta-analysis.
Yafang Huang, Haiyu Fan, Ning Li, Juan Du.
Cancer Med, 2019 Apr 06; 8(5). PMID: 30950194    Free PMC article.
Systematic Review.
Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Heng Sheng Sow, Jiang Ren, +2 authors, Peter Ten Dijke.
Cells, 2019 Apr 10; 8(4). PMID: 30959852    Free PMC article.
Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability.
Paul Germonpré, Tim Van den Wyngaert.
PLoS One, 2019 Apr 12; 14(4). PMID: 30973926    Free PMC article.
Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
Miyuki Sato, Satoshi Watanabe, +13 authors, Toshiaki Kikuchi.
PLoS One, 2019 Apr 13; 14(4). PMID: 30978241    Free PMC article.
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Yucai Wang, Shouhao Zhou, +16 authors, Michael L Wang.
JAMA Oncol, 2019 Apr 26; 5(7). PMID: 31021376    Free PMC article.
Highly Cited. Systematic Review.
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
Fiamma Berner, David Bomze, +27 authors, Lukas Flatz.
JAMA Oncol, 2019 Apr 26; 5(7). PMID: 31021392    Free PMC article.
Highly Cited.
Emerging therapies for non-small cell lung cancer.
Chao Zhang, Natasha B Leighl, Yi-Long Wu, Wen-Zhao Zhong.
J Hematol Oncol, 2019 Apr 27; 12(1). PMID: 31023335    Free PMC article.
Highly Cited. Review.
Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice.
Wenwen Yue, Liang Chen, +10 authors, Yu Chen.
Nat Commun, 2019 May 03; 10(1). PMID: 31048681    Free PMC article.
Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Zi-Xian Wang, Hao-Xiang Wu, +10 authors, Rui-Hua Xu.
JAMA Netw Open, 2019 May 06; 2(5). PMID: 31050784    Free PMC article.
Systematic Review.
Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice.
Timothy Affolter, Heather P Llewellyn, +4 authors, Changhua Ji.
PLoS One, 2019 May 22; 14(5). PMID: 31112568    Free PMC article.
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.
Siwen Hu-Lieskovan, Aaron Lisberg, +16 authors, Edward B Garon.
Clin Cancer Res, 2019 May 23; 25(16). PMID: 31113840    Free PMC article.
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
Willemijn S M E Theelen, Thomas Kuilman, +14 authors, Marcin Kowanetz.
PLoS One, 2019 May 28; 14(5). PMID: 31125352    Free PMC article.
Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma.
Kazuki Takada, Mototsugu Shimokawa, +8 authors, Masaki Mori.
PLoS One, 2019 Jun 05; 14(6). PMID: 31163080    Free PMC article.
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Diego Signorelli, Patrizia Giannatempo, +11 authors, Immune-Oncology YOUNG Group.
Biomed Res Int, 2019 Jun 11; 2019. PMID: 31179334    Free PMC article.
Review.
China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Ming Zhou, Xiaoyuan Chen, +14 authors, Zhimin Yang.
Cancer Commun (Lond), 2019 Jun 22; 39(1). PMID: 31221221    Free PMC article.
Review.
Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.
Yaru Tian, Xiaoyang Zhai, +2 authors, Jinming Yu.
J Hematol Oncol, 2019 Jun 30; 12(1). PMID: 31253167    Free PMC article.
Review.
Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.
Maria Saigi, Juan J Alburquerque-Bejar, Montse Sanchez-Cespedes.
Oncogene, 2019 Jun 30; 38(31). PMID: 31253869
Review.
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.
Miren Zuazo, Hugo Arasanz, +12 authors, David Escors.
EMBO Mol Med, 2019 Jul 06; 11(7). PMID: 31273938    Free PMC article.
Highly Cited.
Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.
B P Levy, J E Signorovitch, +3 authors, M Parisi.
Curr Oncol, 2019 Jul 10; 26(3). PMID: 31285672    Free PMC article.
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
Tao Jiang, Jinpeng Shi, +13 authors, Caicun Zhou.
J Hematol Oncol, 2019 Jul 14; 12(1). PMID: 31299995    Free PMC article.
Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
Vera Kloten, Rita Lampignano, Thomas Krahn, Thomas Schlange.
Cells, 2019 Aug 04; 8(8). PMID: 31374957    Free PMC article.
Review.
An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.
Hiroki Tsukamoto, Kanae Kubota, +5 authors, Yoshihisa Tomioka.
Immunology, 2019 Sep 14; 158(2). PMID: 31515801    Free PMC article.
Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
Anqi Lin, Ting Wei, +2 authors, Jian Zhang.
Mol Cancer, 2019 Sep 19; 18(1). PMID: 31526368    Free PMC article.
Review.
Advances in Engineering Cells for Cancer Immunotherapy.
Xiao Xu, Teng Li, +4 authors, Ran Mo.
Theranostics, 2019 Nov 07; 9(25). PMID: 31695806    Free PMC article.
Review.
Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer.
Yuki Katayama, Takayuki Shimamoto, +9 authors, Koichi Takayama.
J Clin Med, 2020 Jan 08; 9(1). PMID: 31906082    Free PMC article.
Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection.
Sanna Iivanainen, Jussi P Koivunen.
Int J Mol Sci, 2020 Jan 19; 21(2). PMID: 31952311    Free PMC article.
Review.
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.
Kei Kunimasa, Taichiro Goto.
Int J Mol Sci, 2020 Jan 23; 21(2). PMID: 31963413    Free PMC article.
Review.
Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review.
Nagla Abdel Karim, Karen Kelly.
Oncologist, 2019 Mar 28; 24(9). PMID: 30914465    Free PMC article.
Review.
A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials.
Saba S Shaikh, Priya U Kumthekar, Nisha A Mohindra.
J Neurooncol, 2019 Jun 27; 144(1). PMID: 31240523
Review.
Romo1 is involved in the immune response of glioblastoma by regulating the function of macrophages.
Guan Sun, Ying Cao, +4 authors, Lei Shi.
Aging (Albany NY), 2020 Jan 17; 12(2). PMID: 31945745    Free PMC article.
Mass Spectrometry-Based Multivariate Proteomic Tests for Prediction of Outcomes on Immune Checkpoint Blockade Therapy: The Modern Analytical Approach.
Julia Grigorieva, Senait Asmellash, +3 authors, Joanna Roder.
Int J Mol Sci, 2020 Feb 06; 21(3). PMID: 32012941    Free PMC article.
Review.
Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study.
Ilya Tsimafeyeu, Evgeny Imyanitov, +10 authors, Sergei Tjulandin.
Sci Rep, 2020 Mar 05; 10(1). PMID: 32127616    Free PMC article.
Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer.
Shiqiang Wang, Chongling Hu, Fei Xie, Yanhui Liu.
Onco Targets Ther, 2020 Mar 12; 13. PMID: 32158220    Free PMC article.
Review.
Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies.
Sonam Puri, Michael Shafique.
Drugs Context, 2020 Mar 12; 9. PMID: 32158484    Free PMC article.
Review.
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives.
Sun Min Lim, Min Hee Hong, Hye Ryun Kim.
Immune Netw, 2020 Mar 12; 20(1). PMID: 32158598    Free PMC article.
Review.
A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab.
Wei Nie, Jie Qian, +15 authors, Bao-Hui Han.
Oncoimmunology, 2020 Mar 12; 9(1). PMID: 32158623    Free PMC article.
Early Phase I Study of a 99mTc-Labeled Anti-Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non-Small Cell Lung Cancer.
Yan Xing, Gitasha Chand, +7 authors, Jinhua Zhao.
J Nucl Med, 2019 Feb 24; 60(9). PMID: 30796165    Free PMC article.
High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.
Maria I Toki, Christopher R Merritt, +7 authors, David L Rimm.
Clin Cancer Res, 2019 Jun 14; 25(18). PMID: 31189645    Free PMC article.
Patterns of care for older patients with stage IV non-small cell lung cancer in the immunotherapy era.
Kenneth L Kehl, Michael J Hassett, Deborah Schrag.
Cancer Med, 2020 Jan 29; 9(6). PMID: 31989786    Free PMC article.
[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)].
Caicun Zhou, Jie Wang, +13 authors, Shukui Qin.
Zhongguo Fei Ai Za Zhi, 2020 Feb 26; 23(2). PMID: 32093450    Free PMC article.
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors.
Takehiro Tozuka, Satoru Kitazono, +12 authors, Makoto Nishio.
BMC Cancer, 2020 Mar 14; 20(1). PMID: 32164651    Free PMC article.
Checkpoint Inhibitors.
Lucie Heinzerling, Enrico N de Toni, +2 authors, Lisa Zimmer.
Dtsch Arztebl Int, 2019 Apr 04; 116(8). PMID: 30940340    Free PMC article.
Review.
Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics.
Hugo Arasanz, Miren Zuazo, +13 authors, David Escors.
Cancers (Basel), 2020 Feb 09; 12(2). PMID: 32033028    Free PMC article.
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
Mari Aso, Yukihiro Toi, +15 authors, Shunichi Sugawara.
Oncologist, 2020 Mar 13; 25(3). PMID: 32162801    Free PMC article.
Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy.
Leyre Zubiri, Ian M Allen, +16 authors, Kerry L Reynolds.
Oncologist, 2020 Mar 13; 25(3). PMID: 32162817    Free PMC article.
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future.
Hyojin Kim, Jin-Haeng Chung.
J Pathol Transl Med, 2019 May 03; 53(4). PMID: 31042863    Free PMC article.
Review.
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.
Akintunde Akinleye, Zoaib Rasool.
J Hematol Oncol, 2019 Sep 07; 12(1). PMID: 31488176    Free PMC article.
Highly Cited. Review.
Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment.
Stefano Frega, Alessandra Ferro, +3 authors, Giulia Pasello.
Int J Mol Sci, 2020 Mar 01; 21(5). PMID: 32111093    Free PMC article.
Review.
Integrative Analysis of Siglec-15 mRNA in Human Cancers Based on Data Mining.
Qiu-Ting Li, Zao-Zao Huang, +7 authors, Sheng-Li Yang.
J Cancer, 2020 Mar 24; 11(9). PMID: 32201516    Free PMC article.
A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer.
Michelle Chiu, Mary Beth Lipka, +2 authors, Afshin Dowlati.
Transl Lung Cancer Res, 2020 Mar 25; 9(1). PMID: 32206553    Free PMC article.
KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer.
Jose M Pacheco.
Transl Lung Cancer Res, 2020 Mar 25; 9(1). PMID: 32206562    Free PMC article.
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.
Chennianci Zhu, Weihao Zhuang, +2 authors, Wen-Bin Ou.
Transl Lung Cancer Res, 2020 Mar 25; 9(1). PMID: 32206559    Free PMC article.
Review.
Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma.
Jiangdian Song, Jie Tian, +10 authors, Mingfang Zhao.
Eur Radiol, 2019 Jan 16; 29(5). PMID: 30643941    Free PMC article.
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Neal Ready, Matthew D Hellmann, +25 authors, Suresh S Ramalingam.
J Clin Oncol, 2019 Feb 21; 37(12). PMID: 30785829    Free PMC article.
Highly Cited.
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.
Steve Lu, Julie E Stein, +11 authors, Janis M Taube.
JAMA Oncol, 2019 Jul 19; 5(8). PMID: 31318407    Free PMC article.
Highly Cited.
EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells.
Shaorong Yu, Huanhuan Sha, +4 authors, Jifeng Feng.
Oncogene, 2020 Feb 01; 39(13). PMID: 32001818
Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy.
Wei Mu, Ilke Tunali, +3 authors, Robert J Gillies.
Eur J Nucl Med Mol Imaging, 2019 Dec 07; 47(5). PMID: 31807885    Free PMC article.
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.
Peter T Harrison, Simon Vyse, Paul H Huang.
Semin Cancer Biol, 2019 Sep 29; 61. PMID: 31562956    Free PMC article.
Review.
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Tomoya Fukui, Shinji Hosotani, +13 authors, Katsuhiko Naoki.
Thorac Cancer, 2020 Feb 15; 11(4). PMID: 32057187    Free PMC article.
Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Hidenobu Ishii, Koichi Azuma, +7 authors, Tomoaki Hoshino.
Thorac Cancer, 2020 Feb 16; 11(4). PMID: 32061060    Free PMC article.
Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
Teppei Sugano, Masahiro Seike, +12 authors, Akihiko Gemma.
Thorac Cancer, 2020 Feb 26; 11(4). PMID: 32096610    Free PMC article.
Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.
Hongge Liang, Yan Xu, +3 authors, Jing Zhao.
Thorac Cancer, 2020 Mar 05; 11(4). PMID: 32129934    Free PMC article.
Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.
Mototsugu Shimokawa, Kaname Nosaki, +10 authors, Kiyotaka Yoh.
Trials, 2020 Apr 02; 21(1). PMID: 32228679    Free PMC article.
Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer.
Chengdi Wang, Wenliang Qiao, +5 authors, Weimin Li.
Cancer Med, 2019 Jun 06; 8(8). PMID: 31165589    Free PMC article.
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Karim Amrane, Margaux Geier, +14 authors, Renaud Descourt.
Cancer Med, 2020 Feb 06; 9(7). PMID: 32022459    Free PMC article.
A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer.
Yasuhiro Kato, Yusuke Okuma, +4 authors, Tatsuru Okamura.
Cancer Chemother Pharmacol, 2019 Apr 18; 84(2). PMID: 30993397    Free PMC article.
Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer.
Yuxin Cheng, Ting Wang, +7 authors, Lifeng Wang.
Cancer Manag Res, 2020 Apr 08; 12. PMID: 32256114    Free PMC article.
Intratumor Heterogeneity in Early Lung Adenocarcinoma.
Maria-Fernanda Senosain, Pierre P Massion.
Front Oncol, 2020 Apr 08; 10. PMID: 32257951    Free PMC article.
Review.
Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy.
Rama Soundararajan, Jared J Fradette, +18 authors, Sendurai A Mani.
Cancers (Basel), 2019 May 30; 11(5). PMID: 31137625    Free PMC article.
Review.
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
D Isla, J de Castro, +5 authors, J M Trigo.
Clin Transl Oncol, 2019 Aug 02; 22(5). PMID: 31368078
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept.
Thierry Berghmans, Valérie Durieux, Lizza E L Hendriks, Anne-Marie Dingemans.
Front Med (Lausanne), 2020 Apr 09; 7. PMID: 32266275    Free PMC article.
Systematic Review.
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents.
Paola Ciciola, Priscilla Cascetta, +2 authors, Roberto Bianco.
J Clin Med, 2020 Mar 07; 9(3). PMID: 32138216    Free PMC article.
Review.
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer.
Kosuke Hashimoto, Kyoichi Kaira, +7 authors, Ichiei Kuji.
J Clin Med, 2020 Mar 12; 9(3). PMID: 32156047    Free PMC article.
Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.
Kazuki Takada, Yasuto Yoneshima, +11 authors, Masaki Mori.
J Cancer Res Clin Oncol, 2020 Feb 07; 146(5). PMID: 32025867
The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
Angelo Castello, Luca Toschi, +2 authors, Egesta Lopci.
J Cancer Res Clin Oncol, 2020 Feb 13; 146(5). PMID: 32048008
A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy.
Kripa Guram, Sangwoo S Kim, +6 authors, Andrew B Sharabi.
Front Immunol, 2019 Apr 03; 10. PMID: 30936880    Free PMC article.
Review.
Neoadjuvant therapy for locally advanced non-small cell lung cancer: TKIs or immunotherapy?
Zhenyang Zhang, Jiangbo Lin, Mingqiang Kang.
J Thorac Dis, 2020 Apr 11; 12(3). PMID: 32274192    Free PMC article.
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Yilun Wu, Weiyu Chen, Zhi Ping Xu, Wenyi Gu.
Front Immunol, 2019 Sep 12; 10. PMID: 31507611    Free PMC article.
Highly Cited. Review.
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Satomi Watanabe, Hidetoshi Hayashi, +10 authors, Kazuhiko Nakagawa.
Cancer Sci, 2018 Nov 06; 110(1). PMID: 30390416    Free PMC article.
Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Rong Guo, Yong Li, +5 authors, Jie Wang.
Cancer Sci, 2019 Mar 08; 110(5). PMID: 30844110    Free PMC article.
Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
Yusuke Shinchi, Yoshihiro Komohara, +8 authors, Makoto Suzuki.
Cancer Sci, 2019 Jul 12; 110(9). PMID: 31294893    Free PMC article.
Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
Yuan-Sheng Zang, Chun Dai, +7 authors, Qiang Xu.
Cancer Med, 2019 Jul 05; 8(10). PMID: 31270941    Free PMC article.
CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients.
Kayoko Waki, Kouichiro Kawano, +2 authors, Akira Yamada.
Cancer Sci, 2020 Feb 15; 111(4). PMID: 32058620    Free PMC article.
The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma.
Ping-Chih Hsu, Chih-Wei Wang, +5 authors, Cheng-Ta Yang.
Biomedicines, 2020 Feb 26; 8(2). PMID: 32092879    Free PMC article.
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Jeffrey C Thompson, Wei-Ting Hwang, +9 authors, Steven M Albelda.
Lung Cancer, 2019 Nov 05; 139. PMID: 31683225    Free PMC article.
Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
Jonas Kuon, Adriane Hommertgen, +8 authors, Michael Thomas.
Trials, 2020 Apr 24; 21(1). PMID: 32321565    Free PMC article.
Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment.
Liang Zhang, Lianwei Bai, +7 authors, Ying Cheng.
Thorac Cancer, 2020 Mar 07; 11(5). PMID: 32134200    Free PMC article.
Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer.
Alain Gelibter, Mario Occhipinti, +3 authors, Paolo Marchetti.
Lung Cancer Manag, 2020 Apr 30; 9(2). PMID: 32346402    Free PMC article.
Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens.
Huihong Xu, Laura Bratton, +2 authors, Zhongren Zhou.
Cytojournal, 2019 Jan 22; 15. PMID: 30662515    Free PMC article.
Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Tzu-Rong Peng, Ta-Wei Wu.
Thorac Cancer, 2019 Apr 11; 10(5). PMID: 30969033    Free PMC article.
Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.
Peng Song, Xiaoxia Cui, +14 authors, Li Zhang.
Thorac Cancer, 2019 Apr 25; 10(5). PMID: 31016875    Free PMC article.
Salvage treatment with anlotinib for advanced non-small cell lung cancer.
Di Wu, Jun Nie, +11 authors, Jian Fang.
Thorac Cancer, 2019 Jun 12; 10(7). PMID: 31183998    Free PMC article.
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Scott J Antonia, Hossein Borghaei, +17 authors, Julie Brahmer.
Lancet Oncol, 2019 Aug 20; 20(10). PMID: 31422028    Free PMC article.
Highly Cited.
Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy.
Satoshi Watanabe, Takeshi Ota, +17 authors, Toshiaki Kikuchi.
Cancer Med, 2020 Mar 10; 9(9). PMID: 32150668    Free PMC article.
Precision Medicine in Non Communicable Diseases.
Mandana Hasanzad, Negar Sarhangi, +3 authors, Bagher Larijani.
Int J Mol Cell Med, 2019 Jan 01; 8(Suppl1). PMID: 32351905    Free PMC article.
Review.
Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab.
Julia Ouaknine Krief, Pierre Helly de Tauriers, +9 authors, Etienne Giroux Leprieur.
J Immunother Cancer, 2019 Jul 12; 7(1). PMID: 31292005    Free PMC article.
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment.
Hiro Sato, Noriyuki Okonogi, Takashi Nakano.
Int J Clin Oncol, 2020 Apr 05; 25(5). PMID: 32246277    Free PMC article.
Review.
Clinical and immune profiling for cancer of unknown primary site.
Koji Haratani, Hidetoshi Hayashi, +13 authors, Kazuhiko Nakagawa.
J Immunother Cancer, 2019 Sep 15; 7(1). PMID: 31519206    Free PMC article.
Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review.
Xiangyu Su, Jing Zhang, +2 authors, Cailian Wang.
Onco Targets Ther, 2020 May 06; 13. PMID: 32368090    Free PMC article.
Immuno-oncology-the new paradigm of lung cancer treatment.
D E Dawe, C H Harlos, R A Juergens.
Curr Oncol, 2020 May 06; 27(Suppl 2). PMID: 32368177    Free PMC article.
Review.
Biomarkers of immune checkpoint inhibitor efficacy in cancer.
D E Meyers, S Banerji.
Curr Oncol, 2020 May 06; 27(Suppl 2). PMID: 32368180    Free PMC article.
Review.
p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
Jinghui Liu, Daheng He, +12 authors, Xiaoqi Liu.
Oncogene, 2020 Mar 24; 39(19). PMID: 32203167    Free PMC article.
Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma.
Max S Topp, Johannes Duell, +7 authors, Tomasz Wrobel.
Haematologica, 2020 Feb 08; 105(5). PMID: 32029506    Free PMC article.
The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab.
Taichi Matsubara, Shinkichi Takamori, +6 authors, Mitsuhiro Takenoyama.
J Thorac Dis, 2020 May 13; 12(4). PMID: 32395289    Free PMC article.
Predictive value of integrated 18F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer.
Yukihiro Umeda, Miwa Morikawa, +8 authors, Tamotsu Ishizuka.
J Immunother Cancer, 2020 Apr 30; 8(1). PMID: 32345624    Free PMC article.
Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer.
Yuxin Mu, Ke Yang, +6 authors, Puyuan Xing.
Front Oncol, 2020 May 16; 10. PMID: 32411601    Free PMC article.
Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition.
Madhawa de Silva, Malinda Itchins, Nick Pavlakis.
Ann Transl Med, 2020 May 16; 8(8). PMID: 32411778    Free PMC article.
Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia.
Ilaria Maggio, Lisa Manuzzi, +3 authors, Davide Campana.
Cancers (Basel), 2020 Apr 03; 12(4). PMID: 32235636    Free PMC article.
Review.
Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
Chethan Ramamurthy, James L Godwin, Hossein Borghaei.
Curr Treat Options Oncol, 2017 May 24; 18(6). PMID: 28534248
Review.
Reversal of EGFR inhibitors' resistance by co-delivering EGFR and integrin αvβ3 inhibitors with nanoparticles in non-small cell lung cancer.
Fei He, Yanzhong Wang, +2 authors, Lei Dong.
Biosci Rep, 2019 Jul 19; 39(8). PMID: 31316001    Free PMC article.
Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
Camille Travert, Pascale Tomasini, Fabrice Barlesi.
Transl Lung Cancer Res, 2020 May 19; 9(2). PMID: 32420082    Free PMC article.
Anti-PDL1 effect in squamous non-small cell lung cancer.
Mohamed Rahouma, Massimo Baudo, +2 authors, Nasser Altorki.
Transl Lung Cancer Res, 2020 May 19; 9(2). PMID: 32420083    Free PMC article.
The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Yi Lu, Yuxuan Song, +9 authors, Xiaoqiang Liu.
Transl Androl Urol, 2020 May 19; 9(2). PMID: 32420142    Free PMC article.
RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial.
Daniel Martin, Panagiotis Balermpas, +20 authors, Emmanouil Fokas.
Clin Transl Radiat Oncol, 2020 May 19; 23. PMID: 32420463    Free PMC article.
A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study.
Satoshi Ikeda, Terufumi Kato, +8 authors, Hiroaki Okamoto.
Ther Adv Med Oncol, 2020 May 20; 12. PMID: 32426051    Free PMC article.
Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
Robert D Carlson, John C Flickinger, Adam E Snook.
Toxins (Basel), 2020 Apr 15; 12(4). PMID: 32283684    Free PMC article.
Review.
A guide to cancer immunotherapy: from T cell basic science to clinical practice.
Alex D Waldman, Jill M Fritz, Michael J Lenardo.
Nat Rev Immunol, 2020 May 21; 20(11). PMID: 32433532    Free PMC article.
Review.
Immune checkpoint inhibitor-related myositis associated with atezolizumab therapy.
Anthony Khoo, YiZhong Zhuang, Karyn Boundy, Joseph Frasca.
Neurol Clin Pract, 2019 Jul 26; 9(3). PMID: 31341722    Free PMC article.
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yunfang Yu, Dongqiang Zeng, +8 authors, Herui Yao.
JAMA Netw Open, 2019 Jul 11; 2(7). PMID: 31290993    Free PMC article.
Highly Cited.
Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients.
Peng Song, Dongliang Yang, +4 authors, Li Zhang.
Thorac Cancer, 2020 Apr 29; 11(6). PMID: 32342665    Free PMC article.
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Jia-Xin Li, Ju-Min Huang, +4 authors, Pei-Yu Yan.
Integr Cancer Ther, 2019 Dec 17; 18. PMID: 31838881    Free PMC article.
Review.
Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
Peng Song, Dongliang Yang, +4 authors, Li Zhang.
Thorac Cancer, 2020 Apr 25; 11(6). PMID: 32329229    Free PMC article.
Current Molecular Targeted Agents for Advanced Gastric Cancer.
Shanshan Nie, Guoping Yang, Hongwei Lu.
Onco Targets Ther, 2020 Jun 05; 13. PMID: 32494161    Free PMC article.
Review.
The efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer patients of different age groups: a meta-analysis.
S-Y Zheng, H-J Cui, +8 authors, X Jiang.
Clin Transl Oncol, 2019 Nov 22; 22(7). PMID: 31748961    Free PMC article.
The top 100 cited articles in lung cancer - a bibliometric analysis.
Nilay Sengul Samanci, Emir Celik.
Contemp Oncol (Pozn), 2020 Jun 10; 24(1). PMID: 32514234    Free PMC article.
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.
Olivier Bylicki, Florian Guisier, +8 authors, Christos Chouaid.
Medicine (Baltimore), 2020 Feb 06; 99(3). PMID: 32011450    Free PMC article.
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Shintaro Kanda, Yuichiro Ohe, +6 authors, Tomohide Tamura.
Cancer Sci, 2020 Apr 12; 111(6). PMID: 32277531    Free PMC article.
CD20+ tumor-infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma.
Jun Sato, Shigehisa Kitano, +5 authors, Nobuyoshi Hiraoka.
Cancer Sci, 2020 Apr 12; 111(6). PMID: 32277550    Free PMC article.
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient.
Giovanni Rossi, Alessandro Russo, +13 authors, Carlo Genova.
Cancers (Basel), 2020 May 06; 12(5). PMID: 32365882    Free PMC article.
Review.
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab.
Ashley M Hopkins, Ganessan Kichenadasse, +2 authors, Michael J Sorich.
J Immunother Cancer, 2020 Jun 07; 8(1). PMID: 32503948    Free PMC article.
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Oscar Arrieta, Feliciano Barrón, +12 authors, Rafael Rosell.
JAMA Oncol, 2020 Apr 10; 6(6). PMID: 32271354    Free PMC article.
From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses.
Julijan Kabiljo, Johannes Laengle, Michael Bergmann.
Cell Death Discov, 2020 Jun 17; 6. PMID: 32542113    Free PMC article.
Review.
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review.
Keisuke Onoi, Yusuke Chihara, +6 authors, Koichi Takayama.
J Clin Med, 2020 May 10; 9(5). PMID: 32384677    Free PMC article.
Review.
Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Miriam Grazia Ferrara, Vincenzo Di Noia, +8 authors, Emilio Bria.
Cancers (Basel), 2020 May 14; 12(5). PMID: 32397295    Free PMC article.
Review.
Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice.
Yu Chen, Yanqing Pei, +3 authors, Xiangjiao Meng.
Front Immunol, 2020 Jun 18; 11. PMID: 32547566    Free PMC article.
Review.
Non-Small Cell Lung Cancer Patient Preferences for First-Line Treatment: A Discrete Choice Experiment.
Joanna P MacEwan, Komal Gupte-Singh, Lauren M Zhao, Karen L Reckamp.
MDM Policy Pract, 2020 Jun 18; 5(1). PMID: 32548305    Free PMC article.
Novel Nuclear Medicine Imaging Applications in Immuno-Oncology.
Stefano Frega, Alessandro Dal Maso, +4 authors, Laura Evangelista.
Cancers (Basel), 2020 May 28; 12(5). PMID: 32455666    Free PMC article.
Review.
Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer.
Tamjeed Ahmed, Thomas Lycan, +8 authors, W Jeffrey Petty.
Clin Lung Cancer, 2020 Feb 25; 21(4). PMID: 32089478    Free PMC article.
Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.
Sohita Dhillon, Yahiya Y Syed.
Target Oncol, 2019 Nov 16; 14(6). PMID: 31728860
Review.
Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench.
Rui Jin, Jing Zhao, +4 authors, Yang Xia.
Ther Adv Med Oncol, 2020 Jun 23; 12. PMID: 32565926    Free PMC article.
Review.
Effect of erlotinib combined with cisplatin on IL-6 and IL-12 in mice with Lewis lung cancer.
Xu Zhang, Jinliang Chen, +3 authors, Huijing Wu.
Oncol Lett, 2020 Jun 23; 20(1). PMID: 32566018    Free PMC article.
Proposals for managing patients with thoracic malignancies during COVID-19 pandemic.
N Girard, L Greillier, +14 authors, French-Language Society of Pulmonology SPLF French-language Oncology Group.
Respir Med Res, 2020 Jun 22; 78. PMID: 32563968    Free PMC article.
Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
Enrique Podaza, Ibel Carri, +9 authors, María Marcela Barrio.
Front Immunol, 2020 Jun 26; 11. PMID: 32582212    Free PMC article.
Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer.
Jian Chen, Yun Tan, +16 authors, Peng Zhang.
Genome Biol, 2020 Jun 26; 21(1). PMID: 32580738    Free PMC article.
Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhibo Zhang, Fang Yuan, +14 authors, Jinliang Wang.
Front Immunol, 2020 Jun 27; 11. PMID: 32587591    Free PMC article.
Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review.
Bregje M Koomen, Sushil K Badrising, Michel M van den Heuvel, Stefan M Willems.
Histopathology, 2019 Dec 04; 76(6). PMID: 31793055    Free PMC article.
Systematic Review.
Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer.
Seung Eun Lee, Ha Young Park, +3 authors, Wan Seop Kim.
J Breast Cancer, 2020 Jul 01; 23(3). PMID: 32595992    Free PMC article.
Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.
Etienne Giroux Leprieur, Zofia Hélias-Rodzewicz, +10 authors, Jean-François Emile.
J Immunother Cancer, 2020 Jun 26; 8(1). PMID: 32581058    Free PMC article.
Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non-small cell lung cancer.
Xiayao Diao.
Thorac Cancer, 2020 May 07; 11(7). PMID: 32374445    Free PMC article.
Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Shingo Kitagawa, Taiki Hakozaki, Rui Kitadai, Yukio Hosomi.
Thorac Cancer, 2020 May 19; 11(7). PMID: 32421224    Free PMC article.
The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Extrapulmonary Small Cell Carcinoma.
Ragia Aly, Sachin Gupta, Rashmika Potdar.
Cureus, 2020 Jul 04; 12(6). PMID: 32617246    Free PMC article.
Review.
The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.
Kirstin Perdrizet, Natasha B Leighl.
Curr Treat Options Oncol, 2019 Feb 20; 20(3). PMID: 30778772
Review.
Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers.
Antti Tikkanen, Sanna Iivanainen, Jussi P Koivunen.
J Cancer Res Clin Oncol, 2020 Apr 20; 146(8). PMID: 32306129    Free PMC article.
Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.
Yoshitaka Yamaguchi, Hikaru Nagasawa, Yuji Katagiri, Manabu Wada.
J Med Case Rep, 2020 Jul 06; 14(1). PMID: 32620173    Free PMC article.
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review).
Wenjie You, Bin Shang, +3 authors, Shujuan Jiang.
Oncol Rep, 2020 Jul 07; 44(2). PMID: 32627031    Free PMC article.
Review.
PD-L1 Expression Affects Neoantigen Presentation.
Masahiro Okada, Kanako Shimizu, +6 authors, Shin-Ichiro Fujii.
iScience, 2020 Jul 08; 23(6). PMID: 32629606    Free PMC article.
Evolving treatment strategies of brain metastases from breast cancer: current status and future direction.
Jae Sik Kim, In Ah Kim.
Ther Adv Med Oncol, 2020 Jul 09; 12. PMID: 32636942    Free PMC article.
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.
Josée Golay, Alain E Andrea.
Antibodies (Basel), 2020 May 24; 9(2). PMID: 32443877    Free PMC article.
Review.
Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer.
Ana I Velazquez, Caroline E McCoach.
J Thorac Dis, 2020 Jul 10; 12(5). PMID: 32642202    Free PMC article.
Review.
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
Willemijn S M E Theelen, Heike M U Peulen, +9 authors, Paul Baas.
JAMA Oncol, 2019 Jul 12; 5(9). PMID: 31294749    Free PMC article.
Highly Cited.
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors.
Da Hyun Kang, Cheol-Kyu Park, +9 authors, Jeong Eun Lee.
Immune Netw, 2020 Jul 14; 20(3). PMID: 32655975    Free PMC article.
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Florent Peyraud, Antoine Italiano.
Cancers (Basel), 2020 Jun 13; 12(6). PMID: 32526888    Free PMC article.
Review.
Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function.
Jin Wook Choi, Sita S Withers, +10 authors, Stephen J McSorley.
PLoS One, 2020 Jul 03; 15(7). PMID: 32614928    Free PMC article.
Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy.
Fan Zhang, Di Huang, +14 authors, Yi Hu.
Ther Adv Med Oncol, 2020 Jul 17; 12. PMID: 32670420    Free PMC article.
Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies.
Robert J Walsh, Ross A Soo.
Ther Adv Med Oncol, 2020 Jul 17; 12. PMID: 32670423    Free PMC article.
Review.
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system.
Arsela Prelaj, Claudia Proto, +14 authors, Mattia Boeri.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676324    Free PMC article.
A new chapter in immune checkpoint inhibitor therapy: starting with advanced lung squamous cell carcinoma.
Kailun Fei, Jiachen Xu, Zhijie Wang.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676348    Free PMC article.
Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies.
Sylvie Lantuejoul, Francesca Damiola, Julien Adam.
Transl Lung Cancer Res, 2020 Jul 18; 9(3). PMID: 32676356    Free PMC article.
Review.
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study.
Dominique Arpin, Marie-Christine Charpentier, +23 authors, Diane Damotte.
Ther Adv Med Oncol, 2020 Jul 21; 12. PMID: 32684990    Free PMC article.
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
J Nicholas Bodor, Yanis Boumber, Hossein Borghaei.
Cancer, 2019 Nov 07; 126(2). PMID: 31691957    Free PMC article.
Review.
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.
Iris Z Uras, Herwig P Moll, Emilio Casanova.
Int J Mol Sci, 2020 Jun 21; 21(12). PMID: 32560574    Free PMC article.
Review.
Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas ​.
Federica Riccardo, Giuseppina Barutello, +11 authors, Elena Quaglino.
Vaccines (Basel), 2020 Apr 10; 8(2). PMID: 32268572    Free PMC article.
Bibliometrics Analysis of Butyrophilins as Immune Regulators [1992-2019] and Implications for Cancer Prognosis.
Yixi Wang, Na Zhao, +13 authors, Jianlei Hao.
Front Immunol, 2020 Jul 23; 11. PMID: 32695099    Free PMC article.
Tumor Primary Location May Affect Metastasis Pattern for Patients with Stage IV NSCLC: A Population-Based Study.
Qinge Shan, Zhenxiang Li, +5 authors, Zhehai Wang.
J Oncol, 2020 Jul 23; 2020. PMID: 32695165    Free PMC article.
CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Jian Wang, Ruiguang Zhang, +14 authors, Gang Wu.
J Hematol Oncol, 2020 Jul 22; 13(1). PMID: 32690037    Free PMC article.
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Sarah B Goldberg, Kurt A Schalper, +21 authors, Harriet M Kluger.
Lancet Oncol, 2020 Apr 07; 21(5). PMID: 32251621    Free PMC article.
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials.
Bin Zhao, Hong Zhao, Jiaxin Zhao.
Ther Adv Med Oncol, 2020 Jul 31; 12. PMID: 32728392    Free PMC article.
Immunotherapy - new perspective in lung cancer.
Fillipe Dantas Pinheiro, Adriano Fernandes Teixeira, +3 authors, Fabrício Freire de Melo.
World J Clin Oncol, 2020 Jul 31; 11(5). PMID: 32728528    Free PMC article.
Review.
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer.
Martin Reck, Thomas Wehler, +16 authors, Mark A Socinski.
J Clin Oncol, 2020 May 28; 38(22). PMID: 32459597    Free PMC article.
Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies.
Swapnil Rajurkar, Isa Mambetsariev, +4 authors, Ravi Salgia.
J Clin Med, 2020 Jun 19; 9(6). PMID: 32549358    Free PMC article.
Review.
SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Yu Chen, Min Gao, +2 authors, Xiangjiao Meng.
J Hematol Oncol, 2020 Jul 30; 13(1). PMID: 32723363    Free PMC article.
Review.
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1.
Andrea Botticelli, Silvia Mezi, +11 authors, Paolo Marchetti.
Front Immunol, 2020 Aug 01; 11. PMID: 32733441    Free PMC article.
Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective.
Libin Guo, Ran Wei, Yao Lin, Hang Fai Kwok.
Front Immunol, 2020 Aug 01; 11. PMID: 32733486    Free PMC article.
Review.
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial).
Francesco Gelsomino, Giuseppe Lamberti, +15 authors, Andrea Ardizzoni.
Ther Adv Med Oncol, 2020 Aug 01; 12. PMID: 32733604    Free PMC article.
Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis.
Yan Chen, Junjie Hu, +3 authors, Peng Zhang.
BMC Cancer, 2020 Jul 31; 20(1). PMID: 32727409    Free PMC article.
Systematic Review.
Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma.
Bantita Phruttinarakorn, Thanyanan Reungwetwattana, Pimpin Incharoen.
Mol Clin Oncol, 2020 Aug 06; 13(3). PMID: 32754326    Free PMC article.
Association of CD8 T cell apoptosis and EGFR mutation in non-small lung cancer patients.
Chao Zhao, Chunxia Su, Xuefei Li, Caicun Zhou.
Thorac Cancer, 2020 Jun 06; 11(8). PMID: 32500560    Free PMC article.
Novel blood-based tumor mutation algorithm and nomogram predict survival of immune checkpoint inhibitor in non-small-cell lung cancer: Results from two multicenter, randomized clinical trials.
Yunfang Yu, Yongjian Chen, +10 authors, Herui Yao.
Clin Transl Med, 2020 Jun 09; 10(2). PMID: 32508050    Free PMC article.
Successful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions.
Satoshi Tobita, Yuhei Kinehara, +10 authors, Isao Tachibana.
Thorac Cancer, 2020 Jun 23; 11(8). PMID: 32567218    Free PMC article.
In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action.
Derek J Blevins, Ronan Hanley, +6 authors, Jeremy E Wulff.
ACS Med Chem Lett, 2019 Aug 16; 10(8). PMID: 31413804    Free PMC article.
Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance.
Anna Passarelli, Michele Aieta, Alessandro Sgambato, Cesare Gridelli.
Front Immunol, 2020 Aug 08; 11. PMID: 32760402    Free PMC article.
Review.
NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score.
Peng Song, Dongliang Yang, +4 authors, Li Zhang.
Cancer Manag Res, 2020 Aug 09; 12. PMID: 32765097    Free PMC article.
Relationship between SP142 PD-L1 Expression and 18F-FDG Uptake in Non-Small-Cell Lung Cancer.
Long Zhao, Jinjun Liu, Jingyun Shi, Huoqiang Wang.
Contrast Media Mol Imaging, 2020 Aug 09; 2020. PMID: 32765198    Free PMC article.
Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis.
Tingting Liu, Bo Jin, +4 authors, Guang Li.
Ther Adv Med Oncol, 2020 Aug 11; 12. PMID: 32774474    Free PMC article.
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China.
Yanhui Chen, Yating Wang, +5 authors, Henghui Zhang.
Exp Hematol Oncol, 2020 Aug 11; 9. PMID: 32775040    Free PMC article.
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm.
Giuseppe Luigi Banna, Ornella Cantale, +4 authors, Alfredo Addeo.
Oncol Rev, 2020 Aug 13; 14(2). PMID: 32782728    Free PMC article.
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes.
Marco Mazzotta, Marco Filetti, +25 authors, Marcello Maugeri-Saccà.
J Immunother Cancer, 2020 Aug 08; 8(2). PMID: 32759236    Free PMC article.
Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Fang Yang, Svetomir N Markovic, +10 authors, Yucai Wang.
JAMA Netw Open, 2020 Aug 09; 3(8). PMID: 32766800    Free PMC article.
Systematic Review.
Medical management of brain metastases.
Adam Lauko, Yasmeen Rauf, Manmeet S Ahluwalia.
Neurooncol Adv, 2020 Aug 15; 2(1). PMID: 32793881    Free PMC article.
Review.
Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons.
Elisa Aquilanti, Priscilla K Brastianos.
Neurosurgery, 2020 Apr 18; 87(3). PMID: 32302389    Free PMC article.
Review.
Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma.
Hong Kwan Kim, Je-Gun Joung, +18 authors, Jhingook Kim.
iScience, 2020 Aug 17; 23(8). PMID: 32795913    Free PMC article.
PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT.
Yan Cui, Xuena Li, +2 authors, Yaming Li.
Cancer Manag Res, 2020 Aug 18; 12. PMID: 32801879    Free PMC article.
Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
Jiyun Lee, Jong-Mu Sun, +3 authors, Myung-Ju Ahn.
J Thorac Dis, 2020 Aug 18; 12(7). PMID: 32802459    Free PMC article.
Review.
Identification of an Immune Gene Expression Signature for Predicting Lung Squamous Cell Carcinoma Prognosis.
Yubo Yan, Minghui Zhang, Shanqi Xu, Shidong Xu.
Biomed Res Int, 2020 Aug 18; 2020. PMID: 32802850    Free PMC article.
miR-502-5p affects gastric cancer progression by targeting PD-L1.
Wendao You, Xiaoyu Liu, +8 authors, Rui Li.
Cancer Cell Int, 2020 Aug 22; 20. PMID: 32821248    Free PMC article.
Plasma Level of Circular RNA hsa_circ_0000190 Correlates with Tumor Progression and Poor Treatment Response in Advanced Lung Cancers.
Yung-Hung Luo, Yi-Ping Yang, +14 authors, Mong-Lien Wang.
Cancers (Basel), 2020 Jul 08; 12(7). PMID: 32629833    Free PMC article.
Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?
Nagio Takigawa, Nobuaki Ochi, +7 authors, Hiromichi Yamane.
Cancers (Basel), 2020 Jul 28; 12(7). PMID: 32708291    Free PMC article.
Review.
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response.
Vishal Navani, Moira C Graves, Nikola A Bowden, Andre Van Der Westhuizen.
Br J Clin Pharmacol, 2020 May 10; 86(9). PMID: 32384184    Free PMC article.
Review.
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
David R Spigel, Jamie E Chaft, +11 authors, Naiyer A Rizvi.
J Thorac Oncol, 2018 May 19; 13(11). PMID: 29775807    Free PMC article.
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives.
Jin-Yu Sun, Dengke Zhang, +4 authors, Jiansong Ji.
Biomark Res, 2020 Aug 31; 8. PMID: 32864132    Free PMC article.
Review.
[Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
Di Zhang, Jiaqi Huang, +2 authors, Qisen Guo.
Zhongguo Fei Ai Za Zhi, 2019 Jun 15; 22(6). PMID: 31196371    Free PMC article.
Review.
[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
Sixuan Wu, Chunhong Hu, +2 authors, Ping Liu.
Zhongguo Fei Ai Za Zhi, 2019 Jul 19; 22(7). PMID: 31315783    Free PMC article.
Review.
[Basis of Tumor Microenvironment Relevant to Immunotherapies for Brain Metastases of NSCLC].
Qing Lan, Chunxia Ji, Yu Yao.
Zhongguo Fei Ai Za Zhi, 2019 Aug 28; 22(8). PMID: 31451142    Free PMC article.
Review.
[Immunotherapy in Epidermal Growth Factor Receptor-mutant 
Non-small Cell Lung Cancer].
Xin Wang, Diansheng Zhong.
Zhongguo Fei Ai Za Zhi, 2019 Aug 28; 22(8). PMID: 31451147    Free PMC article.
Review.
Immunoradiotherapy as An Effective Therapeutic Strategy in Lung Cancer: From Palliative Care to Curative Intent.
Rodolfo Chicas-Sett, Juan Zafra-Martin, +5 authors, Felipe Couñago.
Cancers (Basel), 2020 Aug 09; 12(8). PMID: 32764371    Free PMC article.
Review.
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
Ana Bocanegra, Ester Blanco, +7 authors, Grazyna Kochan.
Int J Mol Sci, 2020 Aug 23; 21(16). PMID: 32824655    Free PMC article.
Review.
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Jakob M Riedl, Dominik A Barth, +16 authors, Florian Posch.
Cancers (Basel), 2020 Aug 23; 12(8). PMID: 32824580    Free PMC article.
Patient-Centered Approach to Benefit-Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non-Small-Cell Lung Cancer.
Gokaraju K Raju, Sean Khozin, +2 authors, Janet Woodcock.
JCO Clin Cancer Inform, 2020 Aug 28; 4. PMID: 32853030    Free PMC article.
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
Wolfgang M Brueckl, Martin Reck, +10 authors, Eckart Laack.
Clin Med Insights Oncol, 2020 Sep 05; 14. PMID: 32884390    Free PMC article.
Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
Rudi Mao, Xiao Tan, +7 authors, Yongyu Shi.
Cancer Sci, 2020 Jun 17; 111(9). PMID: 32539182    Free PMC article.
Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report.
Yiruo Zhang, Mei Zhao, +2 authors, Yingying Du.
Thorac Cancer, 2020 Jul 14; 11(9). PMID: 32656988    Free PMC article.
Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases.
Takehiro Tozuka, Satoru Kitazono, +12 authors, Makoto Nishio.
Thorac Cancer, 2020 Jul 14; 11(9). PMID: 32657011    Free PMC article.
Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Peng Song, Dingding Zhang, Xiaoxia Cui, Li Zhang.
Thorac Cancer, 2020 Jul 10; 11(9). PMID: 32643323    Free PMC article.
A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer.
Elizabeth J Cathcart-Rake, Lindsey R Sangaralingham, +3 authors, Aaron S Mansfield.
Clin Lung Cancer, 2020 May 25; 21(5). PMID: 32446852    Free PMC article.
PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
S Klein, D Ghersi, +3 authors, A R M Kraft.
J Virol, 2020 Jul 10; 94(18). PMID: 32641478    Free PMC article.
Drug-Related Pneumonitis in the Era of Precision Cancer Therapy.
Mizuki Nishino, Hiroto Hatabu, F Stephen Hodi, Nikhil H Ramaiya.
JCO Precis Oncol, 2017 May 26; 1. PMID: 32913972    Free PMC article.
Review.
Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy.
Emily H Castellanos, Emily Feld, +5 authors, Leora Horn.
JCO Precis Oncol, 2017 Aug 15; 1. PMID: 32913978    Free PMC article.
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Gernot Wagner, Hannah Karolina Stollenwerk, +3 authors, Josef Singer.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923134    Free PMC article.
Systematic Review.
Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation.
Mei-Yin C Polley, Edward L Korn, Boris Freidlin.
JCO Precis Oncol, 2020 Sep 15; 3. PMID: 32923845    Free PMC article.
Review.
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
Changhee Park, Kwon Joong Na, +14 authors, Dae Seog Heo.
Theranostics, 2020 Sep 16; 10(23). PMID: 32929383    Free PMC article.
[Clinical Development of Immunotherapy for Small Cell Lung Cancer].
Tao Yu, Diansheng Zhong.
Zhongguo Fei Ai Za Zhi, 2018 Dec 29; 21(12). PMID: 30591100    Free PMC article.
Review.
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Samantha R Ellis, Aren T Vierra, +2 authors, Maija Kiuru.
J Am Acad Dermatol, 2020 May 04; 83(4). PMID: 32360716    Free PMC article.
Review.
Tracking the tail.
Alex Friedlaender, Stephen V Liu, Alfredo Addeo.
J Immunother Cancer, 2020 Sep 05; 8(2). PMID: 32883870    Free PMC article.
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Marta Soares, Luís Antunes, +12 authors, Francisco Rocha Gonçalves.
BMC Pulm Med, 2020 Sep 12; 20(1). PMID: 32912174    Free PMC article.
Biomarkers of immunotherapy in non-small cell lung cancer.
Lingling Wang, Yue Hu, +2 authors, Xiaochen Wang.
Oncol Lett, 2020 Sep 17; 20(5). PMID: 32934707    Free PMC article.
Review.
A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis.
Satoshi Ikeda, Terufumi Kato, +13 authors, Hiroaki Okamoto.
J Thorac Oncol, 2020 Aug 29; 15(12). PMID: 32858235    Free PMC article.
Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.
Benoit You, Pierre-Adrien Bolze, +16 authors, Francois Golfier.
J Clin Oncol, 2020 Jul 28; 38(27). PMID: 32716740    Free PMC article.
Lung cancer in women in 21th century.
Joanna Domagala-Kulawik, Anna Trojnar.
J Thorac Dis, 2020 Sep 19; 12(8). PMID: 32944353    Free PMC article.
Review.
Brain metastases: lessons and challenges in the targeted therapy and immunotherapy era.
Peter Kar Han Lau.
J Thorac Dis, 2020 Sep 19; 12(8). PMID: 32944368    Free PMC article.
Challenges of PD-L1 testing in non-small cell lung cancer and beyond.
Minyu Wang, Sen Wang, Joseph A Trapani, Paul J Neeson.
J Thorac Dis, 2020 Sep 19; 12(8). PMID: 32944371    Free PMC article.
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Runsen Jin, Chengming Liu, +5 authors, Jie He.
Cancer Biol Med, 2020 Sep 19; 17(3). PMID: 32944405    Free PMC article.
Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy.
Young Kwang Chae, Won Bin Kim, +11 authors, Pedro Viveiros.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953481    Free PMC article.
Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment.
Yumiko Samejima, Atsuhiko Iuchi, +11 authors, Tomonori Hirashima.
Intern Med, 2020 May 26; 59(16). PMID: 32448839    Free PMC article.
The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
Ping-Chih Hsu, Cheng-Ta Yang, David M Jablons, Liang You.
Biomedicines, 2018 Dec 14; 6(4). PMID: 30544524    Free PMC article.
Review.
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials.
Antonino Grassadonia, Isabella Sperduti, +11 authors, Nicola Tinari.
J Clin Med, 2018 Dec 14; 7(12). PMID: 30545122    Free PMC article.
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung.
Shun Lu, Wei Li, +10 authors, Li Zhang.
Onco Targets Ther, 2018 Dec 24; 11. PMID: 30573970    Free PMC article.
Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy.
Federico Pio Fabrizio, Domenico Trombetta, +3 authors, Lucia Anna Muscarella.
Ther Adv Med Oncol, 2018 Dec 24; 10. PMID: 30574211    Free PMC article.
Review.
Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.
Jixiang Liu, Yulan Zhong, +2 authors, Xin Gan.
Onco Targets Ther, 2018 Dec 26; 11. PMID: 30584321    Free PMC article.
Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease.
Deepa Rangachari, Daniel B Costa.
Transl Cancer Res, 2017 Feb 01; 6(Suppl 1). PMID: 30613479    Free PMC article.
Treatment of induction in resectable NSCLC with chemotherapy, followed by surgery and erlotinib.
Fernando Franco, Mariano Provencio.
Ann Transl Med, 2019 Jan 08; 6(Suppl 1). PMID: 30613606    Free PMC article.
The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis.
Ke Ma, Yali Lu, +3 authors, Yuyang Zhang.
Front Pharmacol, 2019 Jan 09; 9. PMID: 30618738    Free PMC article.
Review.
Atezolizumab-induced encephalitis in metastatic lung cancer: a case report and literature review.
Masafumi Arakawa, Mineo Yamazaki, +4 authors, Kazumi Kimura.
eNeurologicalSci, 2019 Jan 09; 14. PMID: 30619952    Free PMC article.
Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases.
Krupa Naran, Trishana Nundalall, Shivan Chetty, Stefan Barth.
Front Microbiol, 2019 Jan 10; 9. PMID: 30622524    Free PMC article.
Review.
PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer.
Bairavi Shankar, Jarushka Naidoo.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631548    Free PMC article.
Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?
Dwight H Owen, Gregory A Otterson.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631557    Free PMC article.
Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer.
Minoru Fukuda, Hiroyuki Yamaguchi, Hiroshi Mukae, Kazuto Ashizawa.
J Thorac Dis, 2019 Jan 12; 10(Suppl 33). PMID: 30631561    Free PMC article.
Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey.
Valentina Bertaglia, Stefania Vallone, Maria Vittoria Pacchiana, Silvia Novello.
Lung Cancer Manag, 2019 Jan 16; 6(3). PMID: 30643575    Free PMC article.
Review.
Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients.
Xiaobin Wang, Huihan Wang, Yongsheng Song.
Oncol Lett, 2019 Jan 19; 17(1). PMID: 30655756    Free PMC article.
Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia.
Kamil Wdowiak, Enrique Gallego-Colon, +7 authors, Jerzy Wojnar.
Oncol Lett, 2019 Jan 19; 17(1). PMID: 30655861    Free PMC article.
Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis.
Marcelo Bonomi, Tamjeed Ahmed, +7 authors, Pierre L Triozzi.
Oncol Lett, 2019 Jan 19; 17(1). PMID: 30655905    Free PMC article.
Statins improve survival in patients previously treated with nivolumab for advanced non-small cell lung cancer: An observational study.
Miwako Omori, Yusuke Okuma, Taiki Hakozaki, Yukio Hosomi.
Mol Clin Oncol, 2019 Jan 19; 10(1). PMID: 30655989    Free PMC article.
Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression.
Ziying Lin, Jincui Gu, +5 authors, Yanbin Zhou.
J Cancer, 2019 Jan 22; 10(1). PMID: 30662542    Free PMC article.
Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer-driving down a precarious road in driver-mutated lung cancer.
Rebecca Yin Tay, Christoph Jakob Ackermann, Raffaele Califano.
Transl Lung Cancer Res, 2019 Feb 02; 7(Suppl 4). PMID: 30705861    Free PMC article.
Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies.
Hugo Arasanz, Miren Zuazo, +2 authors, David Escors.
Lung Cancer Manag, 2019 Feb 05; 7(3). PMID: 30713587    Free PMC article.
Immunotherapy in extensive small cell lung cancer.
Vaibhav Verma, Geeti Sharma, Abhijai Singh.
Exp Hematol Oncol, 2019 Feb 12; 8. PMID: 30740266    Free PMC article.
Review.
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer.
Courèche Kaderbhaï, Zoé Tharin, François Ghiringhelli.
Cancers (Basel), 2019 Feb 13; 11(2). PMID: 30744168    Free PMC article.
Review.
Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
Kaikai Shen, Jinggang Cui, +8 authors, Dang Lin.
J Thorac Dis, 2019 Feb 13; 10(12). PMID: 30746209    Free PMC article.
PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs.
Yuchen Bai, Xiaoxia Chen, +4 authors, Maciej Ciebiada.
Cancer Biol Med, 2019 Feb 16; 15(4). PMID: 30766753    Free PMC article.
Treatment of advanced nonsmall cell lung cancer: First line, maintenance and second line - Indian consensus statement update.
Kumar Prabhash.
South Asian J Cancer, 2019 Feb 16; 8(1). PMID: 30766843    Free PMC article.
Review.
Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update.
Hélène Blons, Simon Garinet, Pierre Laurent-Puig, Jean-Baptiste Oudart.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775025    Free PMC article.
Review.
Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.
Sylvie Lantuejoul, Diane Damotte, Véronique Hofman, Julien Adam.
J Thorac Dis, 2019 Feb 19; 11(Suppl 1). PMID: 30775032    Free PMC article.
Review.
Combining stereotactic body radiation therapy with immunotherapy: current data and future directions.
Alexander J Lin, Michael Roach, Jeffrey Bradley, Clifford Robinson.
Transl Lung Cancer Res, 2019 Feb 23; 8(1). PMID: 30788240    Free PMC article.
Review.
From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC.
Maria Protopapa, Vassilis Kouloulias, +3 authors, Anna Zygogianni.
J Oncol, 2019 Mar 12; 2019. PMID: 30853981    Free PMC article.
Review.
Impact of prior antibiotic use on the efficacy of nivolumab for non-small cell lung cancer.
Taiki Hakozaki, Yusuke Okuma, Miwako Omori, Yukio Hosomi.
Oncol Lett, 2019 Mar 12; 17(3). PMID: 30854072    Free PMC article.
Highly Cited.
Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib.
Shun Lu.
Onco Targets Ther, 2019 Mar 14; 12. PMID: 30863118    Free PMC article.
Review.
Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials.
Jie Li, Qi He, +3 authors, Minjie Guan.
Cancer Manag Res, 2019 Mar 14; 11. PMID: 30863172    Free PMC article.
The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses.
Rémi Rosière, Thierry Berghmans, +2 authors, Nathalie Wauthoz.
Cancers (Basel), 2019 Mar 15; 11(3). PMID: 30866545    Free PMC article.
Review.
Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis.
Huayu Yang, Xiaoxiang Zhou, Lejia Sun, Yilei Mao.
Front Oncol, 2019 Mar 21; 9. PMID: 30891423    Free PMC article.
Making cold malignant pleural effusions hot: driving novel immunotherapies.
Pranav Murthy, Chigozirim N Ekeke, +6 authors, Michael T Lotze.
Oncoimmunology, 2019 Mar 25; 8(4). PMID: 30906651    Free PMC article.
Review.
Correlation between patients' age and cancer immunotherapy efficacy.
Qiong Wu, Qiuhong Wang, +10 authors, You Lang Zhou.
Oncoimmunology, 2019 Mar 25; 8(4). PMID: 30906662    Free PMC article.
Immunological Agents Used in Cancer Treatment.
Melih Simsek, Salim Basol Tekin, Mehmet Bilici.
Eurasian J Med, 2019 Mar 27; 51(1). PMID: 30911265    Free PMC article.
Review.
Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy.
Maxim Shevtsov, Hiro Sato, Gabriele Multhoff, Atsushi Shibata.
Front Oncol, 2019 Apr 04; 9. PMID: 30941308    Free PMC article.
Review.
Pneumonitis as a complication of immune system targeting drugs?-a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials.
Mohamed Rahouma, Massimo Baudo, +11 authors, Mario Gaudino.
J Thorac Dis, 2019 Apr 10; 11(2). PMID: 30962996    Free PMC article.
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.
Claudia Fumarola, Nicole Bozza, +13 authors, Pier Giorgio Petronini.
Front Oncol, 2019 Apr 12; 9. PMID: 30972293    Free PMC article.
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.
Chongkai Wang, Prakash Kulkarni, Ravi Salgia.
Mol Ther Oncolytics, 2019 Apr 13; 13. PMID: 30976658    Free PMC article.
Review.
The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination.
Kenichi Suda.
J Thorac Dis, 2019 Apr 19; 11(Suppl 3). PMID: 30997217    Free PMC article.
KEYNOTE-024: goodbye to chemotherapy?
Rossana Berardi.
J Thorac Dis, 2019 Apr 19; 11(Suppl 3). PMID: 30997239    Free PMC article.
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients.
Francesco Passiglia, Antonio Galvano, +10 authors, Antonio Russo.
Ther Adv Med Oncol, 2019 Apr 26; 11. PMID: 31019571    Free PMC article.
The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations.
Hiroaki Sakamoto, Hisashi Tanaka, +7 authors, Sadatomo Tasaka.
Mol Clin Oncol, 2019 Apr 30; 10(6). PMID: 31031976    Free PMC article.
Is an immune checkpoint inhibitor really a hopeless therapeutic choice for EGFR-mutant non-small cell lung cancer (NSCLC) patients?
Kei Kunimasa, Kazumi Nishino, Toru Kumagai.
Ann Transl Med, 2019 Apr 30; 7(Suppl 1). PMID: 31032311    Free PMC article.
Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer.
Marcos Magalhães Filho, Pedro N Aguiar, Ramon Andrade de Mello.
Ann Transl Med, 2019 Apr 30; 7(Suppl 1). PMID: 31032321    Free PMC article.
Systemic therapy of elderly patients with advanced non-small cell lung cancer-individualized treatment is key.
Robert Pirker.
Ann Transl Med, 2019 Apr 30; 7(Suppl 1). PMID: 31032327    Free PMC article.
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.
Alfredo Addeo, Giuseppe Luigi Banna, Giulio Metro, Massimo Di Maio.
Front Oncol, 2019 May 07; 9. PMID: 31058078    Free PMC article.
Highly Cited. Systematic Review.
Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer.
Arik Bernard Schulze, Georg Evers, +4 authors, Lars Henning Schmidt.
Cancers (Basel), 2019 May 22; 11(5). PMID: 31108964    Free PMC article.
Review.
Incidence risk of PD-1/PD-L1 related diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis.
Caiqing Zhang, Shuisheng Zhang, +5 authors, Yuan Tian.
Cancer Manag Res, 2019 May 24; 11. PMID: 31118808    Free PMC article.
Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies.
Ryo Sato, Kosuke Imamura, +13 authors, Takuro Sakagami.
J Clin Med, 2019 May 31; 8(6). PMID: 31146442    Free PMC article.
MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer.
Anna Grenda, Marcin Nicoś, +8 authors, Janusz Milanowski.
Oncol Lett, 2019 Jun 13; 17(6). PMID: 31186735    Free PMC article.
Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma.
Hyung-Wook Chun, Ran Hong.
Oncol Lett, 2019 Jun 13; 17(6). PMID: 31186768    Free PMC article.
TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas.
Shu Zhao, Mengqi Sun, +7 authors, Qingyuan Zhang.
Cancer Manag Res, 2019 Jun 14; 11. PMID: 31191027    Free PMC article.
Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB).
Fangping Ren, Tian Zhao, Bing Liu, Lei Pan.
Onco Targets Ther, 2019 Jun 27; 12. PMID: 31239702    Free PMC article.
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer.
Frank Weinberg, Shirish Gadgeel.
Lung Cancer (Auckl), 2019 Jun 27; 10. PMID: 31239797    Free PMC article.
Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer.
Anne Sibille, Romain Alfieri, +4 authors, Bernard Duysinx.
Front Oncol, 2019 Jun 28; 9. PMID: 31245290    Free PMC article.
Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis.
Jiaxin Zhu, Tiantian Zhang, +5 authors, Jie Jiang.
Front Pharmacol, 2019 Jul 02; 10. PMID: 31258479    Free PMC article.
Systematic Review.
Immunotherapy in inoperable stage III non-small cell lung cancer: a review.
Natasha A Jain, Gregory A Otterson.
Drugs Context, 2019 Jul 02; 8. PMID: 31258616    Free PMC article.
Review.
Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
Emmanuel Acheampong, Isaac Spencer, +3 authors, Elin Gray.
Cancers (Basel), 2019 Jul 03; 11(7). PMID: 31262041    Free PMC article.
Review.
Possible Biomarkers for Cancer Immunotherapy.
Takehiro Otoshi, Tatsuya Nagano, Motoko Tachihara, Yoshihiro Nishimura.
Cancers (Basel), 2019 Jul 07; 11(7). PMID: 31277279    Free PMC article.
Review.
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.
Florian Huemer, David Lang, +7 authors, Richard Greil.
J Clin Med, 2019 Jul 13; 8(7). PMID: 31295966    Free PMC article.
A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer.
Ning Wan, Bo Ji, +4 authors, Wenjie Huang.
Onco Targets Ther, 2019 Jul 16; 12. PMID: 31303759    Free PMC article.
Review.
Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers.
Luigi Pasini, Paola Ulivi.
J Clin Med, 2019 Jul 22; 8(7). PMID: 31323990    Free PMC article.
Review.
BH3 mimetic ABT-263 enhances the anticancer effects of apigenin in tumor cells with activating EGFR mutation.
Yihong Zhan, Yue Wang, +9 authors, Huanjie Shao.
Cell Biosci, 2019 Aug 02; 9. PMID: 31367332    Free PMC article.
Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.
Sawsan Rashdan, David E Gerber.
Transl Lung Cancer Res, 2019 Aug 02; 8(3). PMID: 31367533    Free PMC article.
Therapeutic outcomes in non-small cell lung cancer with BRAF mutations: a single institution, retrospective cohort study.
Irena Tan, Thomas E Stinchcombe, +6 authors, Jeffrey M Clarke.
Transl Lung Cancer Res, 2019 Aug 02; 8(3). PMID: 31367539    Free PMC article.
Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment.
Tianli Zhang, Bing Wan, +5 authors, Yong Song.
Transl Lung Cancer Res, 2019 Aug 02; 8(3). PMID: 31367543    Free PMC article.
Review.
Clinical utility of ramucirumab in non-small-cell lung cancer.
Dipesh Uprety.
Biologics, 2019 Aug 16; 13. PMID: 31413541    Free PMC article.
Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report.
Yuri Taniguchi, Momoko Yamamoto, +4 authors, Kazuhiro Usui.
Case Rep Oncol, 2019 Aug 21; 12(2). PMID: 31427953    Free PMC article.
Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells.
Nishant Mohan, Salman Hosain, +5 authors, Wen Jin Wu.
Oncoimmunology, 2019 Aug 21; 8(9). PMID: 31428520    Free PMC article.
Management of non-small cell lung cancer harboring epidermal growth factor receptor mutations in the era of first-line osimertinib.
Taiki Hakozaki, Yusuke Okuma.
J Thorac Dis, 2019 Aug 30; 11(7). PMID: 31463088    Free PMC article.
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer.
Zhenbin Qiu, Zihao Chen, Chao Zhang, Wenzhao Zhong.
Exp Hematol Oncol, 2019 Aug 30; 8. PMID: 31463163    Free PMC article.
Review.
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
Jia Li Low, Robert J Walsh, +2 authors, Ross A Soo.
Ther Adv Med Oncol, 2019 Sep 10; 11. PMID: 31497071    Free PMC article.
Review.
Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report.
David Arias Ron, Carmen M Labandeira, +6 authors, Jose Luis Fírvida.
Front Oncol, 2019 Sep 26; 9. PMID: 31552167    Free PMC article.
The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis.
Zhihua Si, Shuisheng Zhang, +9 authors, Yuan Tian.
Front Oncol, 2019 Sep 26; 9. PMID: 31552184    Free PMC article.
Systematic Review.
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients.
Akihiro Yoshimura, Tadaaki Yamada, +16 authors, Koichi Takayama.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555518    Free PMC article.
Measuring tumor mutation burden in cell-free DNA: advantages and limits.
Alfredo Addeo, Glen J Weiss.
Transl Lung Cancer Res, 2019 Sep 27; 8(4). PMID: 31555531    Free PMC article.
TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Longbin Guo, Xuanzi Li, +3 authors, Shasha Du.
Cancer Med, 2020 Jul 24; 9(18). PMID: 32700817    Free PMC article.
Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data.
Gang Chen, Yan Qin, +3 authors, Xue-Mei Li.
Cancer Med, 2020 Jul 29; 9(18). PMID: 32720449    Free PMC article.
The association between monocytic myeloid-derived suppressor cells levels and the anti-tumor efficacy of anti-PD-1 therapy in NSCLC patients.
Jiuxing Feng, Shujing Chen, +8 authors, Jinjun Jiang.
Transl Oncol, 2020 Sep 14; 13(12). PMID: 32920330    Free PMC article.
Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50.
Ou Yamaguchi, Kyoichi Kaira, +7 authors, Ichiei Kuji.
Sci Rep, 2020 Sep 16; 10(1). PMID: 32929123    Free PMC article.
Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications.
Feifei Teng, Min Li, Jinming Yu.
BMC Med, 2020 Sep 19; 18(1). PMID: 32943072    Free PMC article.
Review.
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Yusuke Inoue, Katsuhiro Yoshimura, +24 authors, Takafumi Suda.
JAMA Netw Open, 2020 Sep 22; 3(9). PMID: 32955570    Free PMC article.
Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer.
Marco Maria Aiello, Cinzia Solinas, +8 authors, Hector Josè Soto Parra.
Front Oncol, 2020 Sep 29; 10. PMID: 32983959    Free PMC article.
Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
Fabio Gomes, Melisa Wong, +4 authors, Andrea Luciani.
Br J Cancer, 2020 Jul 23; 123(6). PMID: 32694695    Free PMC article.
Review.
Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy.
Xianghua Zeng, Shicong Zhu, +5 authors, Bo Zhu.
Med Sci Monit, 2020 Sep 08; 26. PMID: 32893263    Free PMC article.
Hyperprogression: A novel response pattern under immunotherapy.
Xue-Jiao Han, Aqu Alu, +2 authors, Xia-Wei Wei.
Clin Transl Med, 2020 Oct 01; 10(5). PMID: 32997401    Free PMC article.
Review.
Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course.
Julian Burla, Sena Bluemel, +7 authors, Michael Scharl.
Inflamm Intest Dis, 2020 Oct 02; 5(3). PMID: 32999883    Free PMC article.
The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives.
Danilo Rocco, Luigi D Gravara, Cesare Gridelli.
Curr Clin Pharmacol, 2019 Aug 11; 15(1). PMID: 31400270    Free PMC article.
Review.
Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Xing Li, Lei Wang, +4 authors, Chunxia Su.
Thorac Cancer, 2020 Aug 12; 11(10). PMID: 32779372    Free PMC article.
Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review.
Qinge Shan, Haiyong Wang, +2 authors, Zhehai Wang.
Thorac Cancer, 2020 Aug 25; 11(10). PMID: 32833320    Free PMC article.
Review.
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents.
Mariona Riudavets, Joaquin Mosquera, +9 authors, Margarita Majem.
Front Oncol, 2020 Oct 06; 10. PMID: 33014837    Free PMC article.
ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC.
Yao Chen, Xiaobin Li, +4 authors, Yina Wang.
Front Oncol, 2020 Oct 06; 10. PMID: 33014846    Free PMC article.
[Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
Qiaoxi Qin, Jiajin Wang, Hong Wang.
Zhongguo Fei Ai Za Zhi, 2020 Aug 06; 23(9). PMID: 32752580    Free PMC article.
Systematic Review.
Duration of nivolumab for pretreated, advanced non-small-cell lung cancer.
Margaux Geier, Renaud Descourt, +12 authors, Gilles Robinet.
Cancer Med, 2020 May 16; 9(19). PMID: 32412157    Free PMC article.
Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
Zhijie Wang, Jianming Ying, +13 authors, Jie Wang.
JAMA Netw Open, 2020 Oct 06; 3(10). PMID: 33017026    Free PMC article.
Non-invasive decision support for NSCLC treatment using PET/CT radiomics.
Wei Mu, Lei Jiang, +10 authors, Matthew B Schabath.
Nat Commun, 2020 Oct 18; 11(1). PMID: 33067442    Free PMC article.
TAS0314, a novel multi-epitope long peptide vaccine, showed synergistic antitumor immunity with PD-1/PD-L1 blockade in HLA-A*2402 mice.
Yuki Tanaka, Hiroshi Wada, +9 authors, Teruhiro Utsugi.
Sci Rep, 2020 Oct 16; 10(1). PMID: 33057061    Free PMC article.
Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients.
Yuki Katayama, Tadaaki Yamada, +15 authors, Koichi Takayama.
Sci Rep, 2020 Oct 17; 10(1). PMID: 33060826    Free PMC article.
Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib.
Edgardo S Santos, Lowell Hart.
Onco Targets Ther, 2020 Oct 17; 13. PMID: 33061419    Free PMC article.
Review.
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer.
Chaoyue Su, Hui Wang, +7 authors, Jianye Zhang.
Front Oncol, 2020 Oct 20; 10. PMID: 33072580    Free PMC article.
Review.
Clinical Efficacy of Immune Checkpoint Inhibitors in Older Non-small-Cell Lung Cancer Patients: A Meta-Analysis.
You-Meng Sun, Ying Wang, +3 authors, Hai-Yan Meng.
Front Oncol, 2020 Oct 20; 10. PMID: 33072584    Free PMC article.
Systematic Review.
Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review.
Jin-Yuan Shih, Akira Inoue, +2 authors, Sang-We Kim.
Cancers (Basel), 2020 Sep 23; 12(9). PMID: 32957736    Free PMC article.
Review.
Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma.
Alexandra Drakaki, Preet K Dhillon, +8 authors, Ralf Gutzmer.
Oncoimmunology, 2020 Oct 27; 9(1). PMID: 33101774    Free PMC article.
Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1.
Evgeny N Imyanitov, Alexandr O Ivantsov, Ilya V Tsimafeyeu.
Front Oncol, 2020 Oct 27; 10. PMID: 33102215    Free PMC article.
Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer.
Xiaoyang Zhai, Xuquan Jing, +4 authors, Hui Zhu.
Front Oncol, 2020 Oct 27; 10. PMID: 33102221    Free PMC article.
Investigating the Role of the N-Terminal Loop of PD-1 in Binding Process Between PD-1 and Nivolumab via Molecular Dynamics Simulation.
Wenping Liu, Haoyu Jin, +3 authors, Guangjian Liu.
Front Mol Biosci, 2020 Oct 27; 7. PMID: 33102523    Free PMC article.
Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review.
Grzegorz Sławiński, Anna Wrona, +2 authors, Ewa Lewicka.
Int J Mol Sci, 2020 Oct 03; 21(19). PMID: 33003425    Free PMC article.
Review.
Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective.
Wen-Jia Shi, Wei Zhao.
Chin Med J (Engl), 2020 Sep 23; 133(20). PMID: 32960841    Free PMC article.
Review.
Lung cancer treatment in the era of immunotherapy.
Yang Xu, Liang-An Chen.
Chin Med J (Engl), 2020 Sep 25; 133(20). PMID: 32969863    Free PMC article.
Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer.
Fang-Fei Qian, Bao-Hui Han.
Chin Med J (Engl), 2020 Sep 25; 133(20). PMID: 32969861    Free PMC article.
Review.
The relationship between pneumonitis and programmed cell death-1/programmed cell death ligand 1 inhibitors among cancer patients: A systematic review and meta-analysis.
Dongmei Xu, Hongmei Liu, +7 authors, Yuan Tian.
Medicine (Baltimore), 2020 Oct 09; 99(41). PMID: 33031304    Free PMC article.
Systematic Review.
The incidence risk of programmed cell death-1/programmed cell death ligand 1 inhibitor-related alopecia for cancer patients: A systematic review and meta-analysis.
Mingkai Li, Linlin Huang, +7 authors, Fuli Mi.
Medicine (Baltimore), 2020 Oct 22; 99(42). PMID: 33080690    Free PMC article.
Systematic Review.
Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma.
Linwei Fan, Li Li, +3 authors, Jianping Xiong.
Onco Targets Ther, 2020 Oct 30; 13. PMID: 33116590    Free PMC article.
Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy.
Maitane Ocáriz-Díez, Mara Cruellas, +10 authors, Eva M Gálvez.
Front Oncol, 2020 Oct 30; 10. PMID: 33117698    Free PMC article.
Review.
[Progress in Treatment of Advanced Squamous Cell Lung Cancer].
Ming Gao, Qing Zhou.
Zhongguo Fei Ai Za Zhi, 2020 Aug 18; 23(10). PMID: 32798441    Free PMC article.
Review.
Bronchial Fistula: Rare Complication of Treatment with Anlotinib.
Pengbo Deng, Chengping Hu, +6 authors, Qihua Gu.
Zhongguo Fei Ai Za Zhi, 2020 Sep 30; 23(10). PMID: 32987493    Free PMC article.
Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report.
Ning Yang, Pin-Liang Zhang, Zeng-Jun Liu.
Medicine (Baltimore), 2020 Nov 01; 99(44). PMID: 33126358    Free PMC article.
Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence.
Rebecca Pharaon, Isa Mambetsariev, Jeremy Fricke, Ravi Salgia.
J Thorac Dis, 2020 Nov 05; 12(9). PMID: 33145086    Free PMC article.
Review.
Biomarkers in immunotherapy: literature review and future directions.
Rebecca Pharaon, Maria A Koczywas, +2 authors, Erminia Massarelli.
J Thorac Dis, 2020 Nov 05; 12(9). PMID: 33145089    Free PMC article.
Review.
Prognostic nomogram on clinicopathologic features and serum indicators for advanced non-small cell lung cancer patients treated with anti-PD-1 inhibitors.
Rong Chai, Yinxing Fan, +3 authors, Yiping Han.
Ann Transl Med, 2020 Nov 05; 8(17). PMID: 33145297    Free PMC article.
Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.
Yunlong Jia, Lihua Liu, Baoen Shan.
Ann Transl Med, 2020 Nov 05; 8(17). PMID: 33145314    Free PMC article.
Review.
Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study.
Kazuki Takada, Shinkichi Takamori, +14 authors, Masaki Mori.
PLoS One, 2020 Nov 03; 15(11). PMID: 33137158    Free PMC article.
Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.
Wenxian Wang, Zhangzhou Huang, +10 authors, Zhengbo Song.
Front Oncol, 2020 Nov 10; 10. PMID: 33163403    Free PMC article.
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.
Pierre-Olivier Gaudreau, J Jack Lee, John V Heymach, Don L Gibbons.
Clin Lung Cancer, 2020 Apr 18; 21(4). PMID: 32299768    Free PMC article.
The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
K Bishay, P Tandon, +2 authors, J D McCurdy.
Curr Oncol, 2020 Nov 12; 27(5). PMID: 33173388    Free PMC article.
Systematic Review.
Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review.
Rawaa El Sabbagh, Nadim S Azar, Assaad A Eid, Sami T Azar.
Int J Gen Med, 2020 Nov 13; 13. PMID: 33177863    Free PMC article.
Review.
Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study.
Sanna Iivanainen, Tuomo Alanko, +4 authors, Jussi Koivunen.
JMIR Form Res, 2020 Oct 29; 4(10). PMID: 33112242    Free PMC article.
Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance.
Priya Veluswamy, Max Wacker, Maximilian Scherner, Jens Wippermann.
Int J Mol Sci, 2020 Nov 05; 21(21). PMID: 33142805    Free PMC article.
Review.
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Filippo G Dall'Olio, Francesca Abbati, +7 authors, Andrea Ardizzoni.
Ther Adv Med Oncol, 2020 Nov 17; 12. PMID: 33193825    Free PMC article.
Early palliative care of non-small cell lung cancer in the context of immunotherapy.
Małgorzata Pieniążek, Piotr Pawlak, Barbara Radecka.
Oncol Lett, 2020 Nov 17; 20(6). PMID: 33193856    Free PMC article.
Review.
The Resistance Mechanisms of Lung Cancer Immunotherapy.
Fen Wang, Shubin Wang, Qing Zhou.
Front Oncol, 2020 Nov 17; 10. PMID: 33194652    Free PMC article.
Review.
Systematic Assessment of Risk of Fever in Solid Tumor Patients Treated With PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis.
Hongmei Liu, Dongmei Xu, +4 authors, Yuan Tian.
Front Oncol, 2020 Nov 17; 10. PMID: 33194659    Free PMC article.
Systematic Review.
Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors.
Karam Khaddour, Sandra L Gomez-Perez, +2 authors, Yanis Boumber.
Front Oncol, 2020 Nov 17; 10. PMID: 33194687    Free PMC article.
Review.
PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC.
Chiao-En Wu, Ching-Fu Chang, +3 authors, Yu-Chi Chiu.
Anal Cell Pathol (Amst), 2020 Nov 19; 2020. PMID: 33204603    Free PMC article.
TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma.
Jie Liu, Xiao Han, +7 authors, Yanqiu Zhao.
Aging (Albany NY), 2020 Oct 23; 12(20). PMID: 33091876    Free PMC article.
Nivolumab in pre-treated advanced non-small cell lung cancer: long term follow up data from the Dutch expanded access program and routine clinical care.
Robert D Schouten, Lucie Egberink, +4 authors, Paul Baas.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209597    Free PMC article.
Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy.
Zhang-Ru Yang, Mi-Na Liu, +7 authors, Xu-Wei Cai.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209626    Free PMC article.
Review.
Radiotherapy for unresectable locally advanced non-small cell lung cancer: a narrative review of the current landscape and future prospects in the era of immunotherapy.
Tiantian Guo, Liqing Zou, +2 authors, Zhengfei Zhu.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209629    Free PMC article.
Review.
Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge-a narrative review.
Wu-Yan Xia, Wen Feng, +5 authors, Xiao-Long Fu.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209631    Free PMC article.
Review.
FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression.
Pamela Abdayem, David Planchard.
Transl Lung Cancer Res, 2020 Nov 20; 9(5). PMID: 33209637    Free PMC article.
Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations.
Yue Wang, Jingwen Li, +5 authors, Hua Zhong.
Ann Transl Med, 2020 Nov 20; 8(20). PMID: 33209877    Free PMC article.
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
David M Waterhouse, Edward B Garon, +20 authors, David R Spigel.
J Clin Oncol, 2020 Sep 11; 38(33). PMID: 32910710    Free PMC article.
Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
Arafat Tfayli, Majd Al Assaad, +19 authors, Fadlo Khuri.
Cancer Med, 2020 Sep 30; 9(22). PMID: 32991781    Free PMC article.
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee.
Brian Gastman, Piyush K Agarwal, +30 authors, Howard L Kaufman.
J Immunother Cancer, 2020 Nov 18; 8(2). PMID: 33199512    Free PMC article.
Review.
Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer.
Zhibo Zhang, Fan Zhang, +15 authors, Jinliang Wang.
Ther Adv Med Oncol, 2020 Nov 24; 12. PMID: 33224276    Free PMC article.
Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer.
Elisa Gobbini, Aurélie Swalduz, +5 authors, Pierre Saintigny.
Cancers (Basel), 2020 Oct 30; 12(11). PMID: 33114393    Free PMC article.
Review.
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Giuseppe Lamberti, Monia Sisi, +5 authors, Francesco Gelsomino.
Cancers (Basel), 2020 Oct 30; 12(11). PMID: 33114576    Free PMC article.
Review.
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.
Iosune Baraibar, Marta Roman, +23 authors, Ignacio Gil-Bazo.
Cancers (Basel), 2020 Nov 01; 12(11). PMID: 33126649    Free PMC article.
New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives.
Ramon Andrade de Mello, Nathália Moisés Neves, +3 authors, Victor André de Almeida Zia.
J Clin Med, 2020 Nov 07; 9(11). PMID: 33153004    Free PMC article.
Review.
The Landscape of Novel Therapeutics and Challenges in Glioblastoma Multiforme: Contemporary State and Future Directions.
Karam Khaddour, Tanner M Johanns, George Ansstas.
Pharmaceuticals (Basel), 2020 Nov 19; 13(11). PMID: 33202642    Free PMC article.
Review.
The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies.
Habib Sadeghi Rad, Sajad Razavi Bazaz, +4 authors, Arutha Kulasinghe.
Clin Transl Immunology, 2020 Dec 01; 9(11). PMID: 33251010    Free PMC article.
Review.
From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer.
Luigi Formisano, Valerie M Jansen, Roberta Marciano, Roberto Bianco.
Anticancer Agents Med Chem, 2017 Sep 14; 18(9). PMID: 28901258    Free PMC article.
Review.
Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer.
Scott N Gettinger, Anna Wurtz, +9 authors, Roy S Herbst.
J Thorac Oncol, 2018 Mar 27; 13(6). PMID: 29578107    Free PMC article.
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.
Pedro Isaacsson Velho, Emmanuel S Antonarakis.
Expert Rev Clin Pharmacol, 2018 Apr 12; 11(5). PMID: 29641940    Free PMC article.
Review.
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.
Song Ee Park, Jae Myoung Noh, +12 authors, Myung-Ju Ahn.
Cancer Res Treat, 2018 Jun 20; 51(2). PMID: 29914238    Free PMC article.
Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice.
Katsuyuki Hotta, Kiichiro Ninomiya, Eiki Ichihara, Katsuyuki Kiura.
Int J Clin Oncol, 2018 Aug 31; 24(1). PMID: 30159691
Review.
Predictive potential and need for standardization of PD-L1 immunohistochemistry.
Spasenija Savic Prince, Lukas Bubendorf.
Virchows Arch, 2018 Sep 03; 474(4). PMID: 30173280
Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
Kazuki Takada, Gouji Toyokawa, +11 authors, Yoshihiko Maehara.
In Vivo, 2018 Oct 24; 32(6). PMID: 30348714    Free PMC article.
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer.
Junghoon Shin, Jin-Haeng Chung, +11 authors, Jong-Seok Lee.
Cancer Res Treat, 2018 Nov 16; 51(3). PMID: 30428640    Free PMC article.
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018).
M Majem, O Juan, +7 authors, M Provencio.
Clin Transl Oncol, 2018 Nov 18; 21(1). PMID: 30446985    Free PMC article.
The lung microenvironment: an important regulator of tumour growth and metastasis.
Nasser K Altorki, Geoffrey J Markowitz, +5 authors, Vivek Mittal.
Nat Rev Cancer, 2018 Dec 12; 19(1). PMID: 30532012    Free PMC article.
Highly Cited. Review.
Nivolumab therapy for lung cancer with tracheo-parenchymal fistula: A case report.
Masahiro Yamasaki, Wakako Daido, +6 authors, Noboru Hattori.
Medicine (Baltimore), 2018 Dec 19; 97(50). PMID: 30558094    Free PMC article.
Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer.
Qingzhu Jia, Wei Wu, +15 authors, Bo Zhu.
Nat Commun, 2018 Dec 19; 9(1). PMID: 30560866    Free PMC article.
Highly Cited.
Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody.
Tatsunori Kiriu, Masatsugu Yamamoto, +7 authors, Yoshihiro Nishimura.
In Vivo, 2018 Dec 28; 33(1). PMID: 30587626    Free PMC article.
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.
Sung Won Lim, Myung-Ju Ahn.
Korean J Intern Med, 2019 Jan 08; 34(1). PMID: 30612418    Free PMC article.
Review.
The RANK-RANKL axis: an opportunity for drug repurposing in cancer?
S Peters, P Clézardin, +2 authors, C Gedye.
Clin Transl Oncol, 2019 Jan 19; 21(8). PMID: 30656607
Review.
ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective study.
Sanna Iivanainen, Tuomo Alanko, +4 authors, Jussi P Koivunen.
J Cancer Res Clin Oncol, 2019 Jan 23; 145(3). PMID: 30666409    Free PMC article.
Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis.
Luigi Cavanna, Chiara Citterio, Elena Orlandi.
Oncotarget, 2019 Feb 06; 10(2). PMID: 30719215    Free PMC article.
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer.
Manolo D'Arcangelo, Armida D'Incecco, +14 authors, Federico Cappuzzo.
Oncotarget, 2019 Feb 08; 10(5). PMID: 30728907    Free PMC article.
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
Margaret Ottaviano, Sabino De Placido, Paolo Antonio Ascierto.
Virchows Arch, 2019 Feb 13; 474(4). PMID: 30747264
Review.
Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
J Corral, M Majem, +7 authors, M P López Criado.
Clin Transl Oncol, 2019 Feb 17; 21(9). PMID: 30771085
Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects.
Long Long, Chen Zhao, +3 authors, Honglei Chen.
Clin Drug Investig, 2019 Feb 20; 39(4). PMID: 30778885
Review.
Safety and efficacy of atezolizumab in the treatment of cancers: a systematic review and pooled-analysis.
Yan Tie, Hui Yang, +4 authors, Ming Liu.
Drug Des Devel Ther, 2019 Feb 23; 13. PMID: 30787594    Free PMC article.
Systematic Review.
Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer.
Yuichi Ozawa, Yusuke Amano, +8 authors, Takafumi Suda.
Med Oncol, 2019 Mar 03; 36(4). PMID: 30825015
PD-1/PD-L1 blockade in ce